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Background: Preoperative standard fasting is associated with deleterious effects with consequent 
negative clinical outcomes. Preoperative oral carbohydrate loading (POCL) is considered a safe 
alternative to fasting, and recommended by numerous anaesthesia societies worldwide. The 
evidence supporting this intervention is increasing and pooling of data is required to promote 
clinical relevance. 
Objectives: To systematically review the effect of POCL on perioperative complications and well-
being in adult patients undergoing elective surgery. 
Search strategy: Electronic databases, article reference lists and personal files were searched 
from inception up to May 2015. 
Selection criteria: Randomised controlled trials (RCTs) of POCL compared with other 
preoperative regimens in adult patients undergoing elective surgery. The experimental group had 
to receive at least 45 g of carbohydrates with an osmolality of less than 300 mOsm/kg within three 
hours before surgery.  
Data collection and analysis: Details of the eligible studies were extracted by the principal 
investigator and independent reviewer. Authors were contacted to obtain missing information. 
Methodological quality was assessed according to methodology described by The Cochrane 
Collaboration.  
Results: Twenty four RCTs involving 1 903 participants were identified for inclusion. The majority 
of the trials were conducted in developed and emerging countries and were based on otherwise 
healthy adult participants who were not considered to be at increased risk of regurgitation or 
aspiration. The quality of the evidence was moderate to low, hence the high risk of bias. Due to the 
heterogeneity of trials and the small number of included trials per comparison, limited data could 
be pooled for inclusion in a meta-analysis. Twenty-three trials including 1 841 participants reported 
on the primary outcomes. The immune status (in terms of C-reactive protein levels) of patients 
receiving POCL was better preserved compared to those in the standard fasting group (p = 0.006). 
No significant evidence of effect for POCL was demonstrated for any other clinical outcomes. 
Adverse events in terms of regurgitation, aspiration, morbidity and mortality were either not 
reported to occur or were not investigated in the included trials. As reported by 16 trials involving 
1449 participants, the well-being of patients receiving POCL was improved or at least maintained 
in most of the trials.   




Conclusion: POCL is a safe alternative to standard fasting with no associated adverse events. 
There is not enough evidence to draw conclusions with absolute certainty on the clinical outcomes. 
However, there is a trend that POCL improves the well-being of surgical patients. Therefore, the 
potential benefits of POCL need to be balanced against the cost as well as patient preference. 
Emphasis should be on the type of surgery performed as well as the effect of minor versus major 
surgery on outcomes. Keep in mind that POCL is time (up to two hours before surgery), dose (at 
least 45 g carbohydrates) and patient (otherwise healthy elective surgery patients) specific. POCL 
should be perceived as a single element of enhanced recovery and the combination of different 
elements might produce more beneficial results than a single element by itself.  





Agtergrond: Standaard vasperiodes voor chirurgie word gekenmerk deur nadelige effekte wat ’n 
negatiewe kliniese uitkoms veroorsaak. Preoperatiewe orale koolhidraat inname (POCL) is ’n 
veilige alternatief vir vas, en dit word wêreldwyd aanbeveel deur verskeie narkoseverenigings. Die 
literatuur wat hierdie intervensie ondersteun, is besig om toe te neem en die groepering van data is 
nodig om kliniese toepaslikheid te bevorder.  
Doelwitte: Om sistematies die effek van POCL op perioperatiewe komplikasies en welstand in 
volwasse pasiënte wat elektiewe chirurgie ondergaan, te ondersoek.    
Soekstrategie: Elektroniese databasisse, artikels se verwysingslyste en persoonlike dokumente 
tot en met Mei 2015 is bestudeer. 
Seleksiekriteria: Ewekansig gekontrolleerde proewe van POCL in vergelyking met ander 
preoperatiewe praktyke in volwasse pasiënte wat elektiewe chirurgie ondergaan. Die 
eksperimentele groep moes ’n koolhidraatlading van minstens 45 g koolhidrate ontvang met ’n 
osmolaliteit van minder as 300 mOsm/kg binne drie ure voor die aanvang van chirurgie.  
Dataversameling en –analise: Inligting van relevante studies is deur die hoof navorser en 
onafhanklike hersiener onttrek. Outeurs van artikels is gekontak om alle relevante inligting te 
bekom. Die metodologiese kwaliteit van studies is geassesseer soos voorgestel deur The 
Cochrane Collaboration.  
Resultate: Vier-en-twintig ewekansig-gekontrolleerde proewe waarby 1 903 deelnemers betrokke 
was, is ingesluit. Die meeste proewe is uitgevoer in ontwikkelde lande en lande wat besig is om te 
ontwikkel, en is gebaseer op andersins gesonde volwasse deelnemers wat nie ’n verhoogde risiko 
vir regurgitasie en aspirasie getoon het nie. Die kwaliteit van die inligting was middelmatig tot laag, 
daarom die hoë risiko vir sydigheid. Weens die heterogene inligting in die proewe en die klein getal 
proewe per vergelyking wat ingesluit kon word, is daar beperkte inligting wat gegroepeer kon word 
vir insluiting in ’n meta-analise. Drie-en-twintig proewe met 1 841 deelnemers het verslag gedoen 
oor die primêre uitkomstes van hierdie oorsig. Die immuunstatus (in terme van CRP-vlakke) in 
pasiënte wat POCL ontvang het, was beter in vergelyking met die standaard vasgroep (p = 0.006). 
Geen beduidenheid is gevind vir die effek van POCL op enige ander kliniese uitkomste nie. 
Nadelige effekte in terme van regurgitasie, aspirasie, morbiditeit en mortaliteit is of nie aangedui of 
nie ondersoek by enige van die proewe nie. Soos aangedui deur 16 proewe, waarby 1 449 
deelnemers betrokke was, was die welstand van die pasiënte wat POCL ontvang het, verbeter of 
ten minste onderhou in meeste van die proewe.  




Gevolgtrekking: POCL is ’n veilige alternatief vir standaard vasperiodes deurdat dit geen 
addisionele nadelige effekte inhou nie. Daar is egter nie genoeg bewyse in hierdie oorsig om 
gevolgtrekkings met sekerheid te maak oor die kliniese uitkomstes nie. Ongeag daarvan is daar ’n 
neiging dat POCL die welstand van chirurgie-pasiënte verbeter. Dus moet die potensiële voordele 
van POCL gemeet word teen die koste van die intervensie sowel as die pasiënt se voorkeur. Daar 
moet aandag geplaas word op die tipe chirurgie wat uitgevoer word sowel as die effek van klein 
teenoor groot chirurgie op die uitkomstes. Hou in gedagte dat die effek van POCL is tyd- (tot twee 
ure voor chirurgie), dosis- (tenminste 45 g CHO) en pasiënt- (andersins gesonde, elektiewe 
chirurgie-pasiënte) spesifiek. POCL is ’n enkele element van spoedige herstel, en die kombinasie 
van verskillende elemente mag meer voordelige resultate lewer as ’n enkele element. 
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LIST OF DEFINITIONS 
Bias:1 Bias is a systematic error, or deviation from the truth. Bias can lead to underestimation or 
overestimation of the true intervention effect. Bias can vary in magnitude – some are small and 
trivial compared to the observed effect, and some are substantial to the point where an apparent 
finding may be entirely due to blinding. Bias and imprecision are different entities. Bias is a 
systematic error which leads to the wrong answer on average when the same study is multiplied 
several times. Imprecision is a random error, meaning that multiple replications of the same study 
will produce different effect estimates due to sample variation, even if they would give the right 
answer on average.  
Blinding:1 Blinding (or masking) is the process of preventing those involved in a trial from knowing 
to which comparison group a particular study participant belongs. Effective blinding can also 
ensure that the compared groups receive the same amount of attention, ancillary treatment and 
diagnostic interventions.  
Chi-squared (Chi2) test:1 A statistical test based on comparison of a test statistic to a chi-squared 
distribution to test the statistical significance of the heterogeneity. It assesses whether observed 
differences in results are comparable with chance alone. A low p-value (or a large Chi-squared 
statistic relative to its degree of freedom) provides evidence of the heterogeneity of the intervention 
effects (variation in effect estimates beyond chance). Care must be taken in the interpretation of 
the Chi2 test, since it has an insignificant effect on the situation of meta-analyses when studies 
have small sample size or are few in number. This means that while a statistical significant result 
may indicate a problem with heterogeneity, a non-significant result should not be taken as 
evidence of no heterogeneity. Therefore, the p-value of 0.10 rather than the conventional 0.05 is 
sometimes used to determine statistical significance.  
Cluster-randomised trial:1 A trial in which clusters of individuals (e.g. clinics, families, 
geographical areas), rather than individuals themselves, are randomised to different arms. 
Co-intervention:1 The application of additional diagnostic or therapeutic procedures to people 
receiving a particular programme of treatment. 
Concealment of allocation:1 Allocation concealment is the process used to ensure that the 
person deciding to enter a participant into a randomised controlled trial does not know the 
comparison group into which that individual will be allocated. This is distinct from blinding and is 
aimed at preventing selection bias.  




Confidence interval (CI):1 A measure of the uncertainty around the main finding of a statistical 
analysis. Study results are reported with a point estimate together with an associated CI. The CI 
describes the uncertainty inherent in the estimate and describes a range of values within which we 
can be reasonably sure that the true effect actually lies. If the CI range is relatively narrow, the 
effect size is known precisely. If the CI range is wider, the uncertainty is greater, although there 
may still be enough precision to make decisions about the utility of the intervention. If the CI range 
is very wide, it indicates that there is very little knowledge about the effect and that further 
information is needed. A 95% CI is often interpreted as indicating a range within which we can be 
95% certain that the true effect lies. The stricter interpretation CI is based on the hypothetical 
notion of considering the results that would be obtained if the same study were to be repeated 
many times. If a study was repeated infinitely, and on each occasion a 95% CI calculated, then 
95% of these intervals would contain the true effects.  
Confounding:1 A confounder is a factor that can significantly affect validity and leads to incorrect 
conclusions being drawn. Two characteristics are confounded if their influences on the intervention 
effect cannot be disentangled.  
Continuous data:1 Data with a potentially infinite numerical quantity that can take any value in a 
specified range (e.g. weight, height). 
Cross-over trial:1 A type of clinical trial comparing two or more interventions in which the 
participants, upon completion of the course of one treatment, are switched to another. 
Dichotomous data:1 Data of which the outcome is one of only two possible categorical responses 
(e.g. yes or no, present or absent). 
Fixed-effect model:1 A model that calculates a pooled effect estimate using the assumption that 
all observed variation between studies is caused by the play of chance. Studies are assumed to be 
measuring the same overall effect. An alternative model is the random-effects model. 
Forest plot:1 A graphical representation of the individual results of each study included in a meta-
analysis together with the combined meta-analysis result. The plot also allows readers to see the 
heterogeneity among the results of the studies. The results of individual studies are shown as 
squares centred on each study’s point estimate. The overall estimate from the meta-analysis and 
its confidence interval are shown at the bottom, represented as a diamond. The centre of the 
diamond represents the pooled point estimate, and its horizontal tips represent the confidence 
interval. 
Funnel plot:1 A funnel plot is a simple scatter plot of the intervention effect estimates from 
individual studies against some measure of each study’s size of precision. The effect estimate is 
plotted on the horizontal line, and the measure of the study size on the vertical axis. The name 




‘funnel plot’ plot arises from the fact that the precision of the estimated intervention effect increases 
as the size of the study increases. Effect estimates from small studies will scatter more widely at 
the bottom of the graph whereas the spread narrows among larger studies. In the absence of bias 
the plot should resemble a symmetrical (inverted) funnel. 
Grey literature:1 Material that is not published in easily accessible journals or databases. 
Heterogeneity:1 Used in a general sense to describe the variation in or diversity among studies 
included in a systematic review. Clinical heterogeneity refers to variability in the participants, 
interventions and/or outcomes. Methodological heterogeneity refers to variability in study design 
and risk of bias. Statistical heterogeneity is the variability in the intervention effects, and occurs 
when the observed intervention effects differ more from each other than expected from random 
error alone.  
I2:1 A measure used to quantify heterogeneity. It describes the percentage of the variability in effect 
estimates that is due to heterogeneity rather than sampling error (chance). A value greater than 
50% may be considered to represent substantial heterogeneity. 
Incomplete outcome data:1 Any data that is missing from the study can lead to risk of bias. 
Missing outcome data can be due to attrition (participants lost to follow-up, treatment withdrawals 
or trial group changes) or exclusions from the analysis.  
Intention-to-treat analysis (ITT):1 A strategy for analysing data from a randomised controlled trial. 
All participants are included in the arm to which they were allocated, whether or not they received 
(or completed) the intervention given to that arm. Intention-to-treat analysis prevents bias caused 
by the loss of participants, which may disrupt the baseline equivalence established by 
randomisation and which may reflect non-adherence to the protocol. The term is often misused in 
trial publications when some participants were excluded. 
Likert scale:2 A psychometric scale commonly used in questionnaires that is widely used in survey 
research. Respondents specify their level of agreement or disagreement on a symmetric agree–
disagree scale for a series of statements. The scale captures the intensity of feelings. For example, 
a five-point Likert scale could include “strongly disagree, disagree, neither disagree or agree, 
agree, and strongly agree”. 
Mean:1 An average value, calculated by adding all the observations and dividing by the number of 
observations (also called arithmetic mean.) 
Mean difference:1 The mean difference is a standard statistic which measures the absolute 
difference between the mean value in two groups in a trial. It estimates the amount by which the 
experimental intervention changes the outcome on average compared with the control. It can be 




used as a summary statistic in a meta-analysis when outcome measurements in all studies are 
made of the same scale.  
Median:1 The value of the observation that occurs half-way when the observations are ranked in 
order. 
Meta-analysis:1 The use of statistical techniques in a systematic review to integrate the results of 
included studies. It can be used to combine the numerical results of all or some of the studies 
included in a systematic review. This yields an overall statistic, together with its confidence interval, 
that summarises the effectiveness of the experimental intervention compared with the control 
intervention. 
Methodological quality:1 The extent to which the design and conduct of a study are likely to have 
prevented bias. Variation in quality can explain variation in the results of studies included in a 
systematic review. More rigorously designed (better quality) trials are more likely to yield results 
that are closer to the truth. (Also called methodological quality but better thought of as relating to 
bias prevention.) 
Narrative review:1 A review article in the medical literature that summarises a number of different 
studies and may draw conclusions about a particular intervention. Narrative review articles are not 
systematic. (Also called overviews.) 
Odds ratio:1 The ratio of the odds of an event in one group to the odds of an event in another 
group. In studies of treatment effect, the odds in the treatment group are usually divided by the 
odds in the control group. An odds ratio of one indicates no difference between comparison 
groups. For undesirable outcomes an odds ratio that is less than one indicates that the intervention 
was effective in reducing the risk of that outcome. When the risk is small, odds ratios are very 
similar to risk ratios. 
PRISMA flow diagram:1 Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA); is the evidence-based minimum set of items for reporting in systematic reviews and 
meta-analyses; it consists of a four-phase flow diagram that is useful for the critical appraisal of 
systematic reviews. 
Quasi-random allocation:1 Methods of allocating people to a trial that are not random, but were 
intended to produce similar groups when used to allocate participants. Quasi-random methods 
include: allocation by the person's date of birth, by the day of the week or month of the year, by a 
person's medical record number, or just allocating every alternate person. In practice, these 
methods of allocation are relatively easy to manipulate, introducing selection bias. 
 




Random-effects Model:1 A statistical model in which both within-study sampling error (variance) 
and between studies variation are included in the assessment of the uncertainty (confidence 
interval) of the results of a meta-analysis. See also fixed-effect model. When there is heterogeneity 
among the results of the included studies beyond chance, random-effects models will give wider 
confidence intervals than fixed-effect models. 
Randomisation:1 The process of randomly allocating participants into one of the arms of a 
controlled trial. There are two components to randomisation: the generation of a random sequence, 
and its implementation, ideally in a way so that those entering participants into a study are not 
aware of the sequence (concealment of allocation). 
Randomised controlled trial:1 An experiment in which two or more interventions, possibly 
including a control intervention or no intervention, are compared by being randomly allocated to 
participants. 
RevMan (Review Manager):1 Software developed for The Cochrane Collaboration to assist 
reviewers in preparing Cochrane Reviews and systematic reviews in general. 
Risk ratio:1 The ratio of risks in two groups. In intervention studies, it is the ratio of the risk in the 
intervention group to the risk in the control group. A risk ratio of one indicates no difference 
between comparison groups. For undesirable outcomes, a risk ratio that is less than one indicates 
that the intervention was effective in reducing the risk of that outcome. (Also called relative risk.) 
Sensitivity analysis:1 An analysis used to determine how sensitive the results of a study or 
systematic review are to changes in how it was done. Sensitivity analyses are used to assess how 
robust the results are to uncertain decisions or assumptions about the data and the methods that 
were used. 
Standardised mean difference:1 The difference between two estimated means divided by an 
estimate of the standard deviation. It is used to combine results from studies using different ways 
of measuring the same concept. By expressing the effects as a standardised value, the results can 
be combined since they have no units. Standardised mean differences are sometimes referred to 
as a d-index.  
Sub-group analysis:1 An analysis in which the intervention effect is evaluated in a defined subset 
of the participants in a trial, or in complementary subsets, such as by sex or in age categories. 
Systematic review:1 A review of a clearly formulated question that uses systematic and explicit 
methods to identify, select, and critically appraise relevant research, and to collect and analyse 
data from the studies that are included in the review. Statistical methods (meta-analysis) may or 
may not be used to analyse and summarise the results of the included studies. 




Visual analogue scale (VAS):3 Measurement instrument that tries to measure a characteristic or 
attitude that is believed to range across a continuum of values and cannot easily be directly 
measured. Operationally a VAS is usually a horizontal line, 100 mm in length, anchored by word 
descriptors at each end. The VAS score is determined by measuring in millimetres from the left 
hand end of the line to the point that the patient marks. As such a VAS assessment is subjective of 
nature; these scales are of most value when looking at change within individuals, and are of less 
value for comparing across a group of individuals at one time point. It could be argued that a VAS 
is trying to produce interval/ratio data out of subjective values that are at best ordinal.  
Verbal descripive scale (VDS):4 Measurement instrument that tries to measure a characteristic or 
attitude using a scale of descriptive words. Also called a verbal descriptor scale.  




LIST OF ABBREVIATIONS 
ASA score American Society of Anesthesiologists physical status classification system 
ASPEN American Society of Parenteral and Enteral Nutrition 
B.C.  Before Christ 
CHO carbohydrate 
CRP C-reactive protein 
DIGAMI diabetes insulin-glucose in acute myocardial infarction 
EBM evidence-based medicine 
EBN evidence-based nutrition 
EIAS ERAS Interactive Audit System 
EIP ERAS Implementation Programme 
ERAS Enhanced Recovery After Surgery 
ESPEN European Society of Parenteral and Enteral Nutrition 
GRADE grade of recommendation, assessment, development and evaluation 
HEC hyperinsulinaemic euglycaemic clamp 
HOMA-IR homeostatic model assessment – insulin resistance 
ICU intensive care unit 
IV intravenous 
ITT insulin tolerance test 
MD mean difference 
MMC migrating motor complex 
n number of study participants or trials 
NICE-SUGAR normoglycemia in intensive care evaluation – survival using glucose algorithm 
regulation 
NPO nil per os/nulla per os/non per os/nothing by mouth 
NR  not reported 
NS non significant 
ONS oral nutritional supplement 
p-value level of significance 
PCOL preoperative oral carbohydrate loading 
pH figure expressing acidity and alkalinity 
postop postoperative 
preop preoperative 
PRISMA preferred reporting items for systematic reviews and meta-analysis 
QUICKI quantitative insulin sensitivity check index 
RCT randomised controlled trial 
SD standard deviation 
STAI state-trait anxiety inventory 
VAS visual analogue scale 
VDS visual descriptive scale 


















CHAPTER 1: LITERATURE REVIEW  





In the twenty-first century, elective surgery is one of the foremost treatments in modern medicine to 
treat medical disorders with over 312 million major surgical treatments performed globally each 
year.5-7 Traditionally, surgery is performed in the overnight fasted state; meaning that millions of 
the population are unnecessarily starved preoperatively. Nil per os, nulla per os or non per os 
(NPO) is Latin for nothing by mouth, meaning that no intake of fluids or solids is allowed from 
midnight to the time of surgery.8 Even though preoperative fasting is mandatory before 
anaesthesia, patients are often fasted in excess of eight to 16 hours from their last intake in the 
evening until the induction of anaesthesia the following day.9,10 Fasting from midnight is one of the 
most well-known medical routines during the past century. The routine is simple to write, easy for 
nursing staff to follow, basic for patients to understand, and if a cancellation occurs there is no 
problem with operating another patient earlier than scheduled.6 The routine was established by 
tradition and traditions are difficult to break. The dogma resulted from the extrapolation of 
pulmonary aspiration risk in full stomach emergency cases to healthy elective cases.  It appears 
that the practice of prolonged fasting before anaesthesia is a fixed tradition that depends more on 
clinical experience than scientific evidence.11,12  
Prolonged fasting before surgery has a number of deleterious consequences due to the trigger of 
the metabolic response causing increased insulin resistance, loss of lean body mass and 
amplifying the acute-phase response.13 Surgery, with its deliberate insult to the body, also causes 
a change in metabolism to catabolism, including a rapid neuroendocrine response, setting off 
stress hormones and activation of cytokines and immune reactions.14 Changing the metabolic rate 
from a fasted to a fed state before surgery has clinical benefit. As realised many years ago, certain 
elements can be influenced during the perioperative care of a patient that will have a beneficial 
effect on the outcomes.  
The clinical goal for any patient receiving elective surgery is to recover to the preoperative function; 
i.e. return of bowel function, pain control, mobilisation, and no complications associated with early 
discharge.15 Optimal glycaemic control is essential to reduce morbidity and mortality; however, 
glucose homeostasis is affected by different mechanisms during the perioperative period.15,16,17 
Improved glycaemic control by insulin treatment has reduced mortality and morbidity in surgery 
patients; 18,19 however, intensive insulin therapy is associated with difficulties such as medical 
inaccuracies causing significant hypoglycaemia with consequent death.20,21 Therefore, the need 
arose to change practice to optimise glucose control and prevent complications during the 
perioperative period.  




1.2 STANDARD FASTING 
1.2.1 History behind standard fasting 
The history of standard fasting dates back to 1847 when the first book on anaesthesia was 
published, which did not even mention fasting before surgery.22 During the following century, there 
were conflicting results and interpretations with regards to fasting before anaesthesia. Before the 
1960s, the consensus was that an absolute fast before anaesthesia was not necessary. However, 
from the 1960s, the universal adoption of standard fasting for healthy patients with no risk factors 
undergoing elective surgery appears to have begun. A clear distinction between the gastric 
emptying of solids and fluids were already made in 1833.23 Some authors mentioned a light meal 
while others gave detailed descriptions of particular items of food they recommended: milk could 
be part of a light meal while clear fluids included tea, China tea, beef-tea and fruit juice. The 
guidelines applied to healthy patients undergoing elective procedures, except for gastrointestinal 
surgery where no solid food and occasionally no fluid was permitted on the day of surgery.6 See 
Table 1.1 for a detailed description on the history of fasting.23 – 46   
Table 1.1: The history behind fasting before surgery  
Year Findings with regards to fasting before anaesthesia 
1833 The first distinction between the gastric emptying of liquids and solids dates back to William Beaumont, 
American military surgeon, who treated a hunter for an abdominal gunshot wound.
23-26
 The wound left a 
permanent gastric fistula through which the emptying of gastric contents could be observed. Digestion of 
water and most other fluids were not affected by gastric juices and had a quick emptying time whereas easily 
digested solids (i.e. meat, potoatoes, bread) emptied within 5 hours.
23 
1848 The first reported death under anaesthesia was reported when a 15 year old girl Hannah Greener died with a 
full stomach after receiving a chloroform anaesthetic for the removal of a toenail.
27,28
 The exact cause of her 
death is unknown since it could have been aspiration of gastric content (since her stomach was full) or the 




1853 During surgery for a gunshot wound to the thigh a soldier vomited, and the autopsy confirmed that the 
vomited matter appeared in the trachea. Even though the case happened in 1853 it was only reported in 
1862 as a new cause of death under chloroform at a medical meeting in Edinburg.
30
  
1883 Sir Joseph Lister, British surgeon, also emphasised the distinction of gastric emptying between liquids and 
solids. He published the following broad fasting guidelines: ‘While it is desirable that there should be no solid 
matter in the stomach when chloroform is administered, it will be found very salutary to give a cup of tea or 
beef-tea about two hours previously.
31
  
1901 Hewitt stated that a meal can be consumed up to 4 hours before surgery but warned that milk must be 
avoided since it becomes a solid in the stomach.
32  
1914 Gwathmey emphasised that there is no reason to fast for extensive periods, and recommended a fast of 2 to 
3 hours after the intake of thin porridge.
33
  
1920 Buxton recommended that patients scheduled for morning surgery should be allowed to  have a small cup of 
China tea up to 3 hours before induction while those scheduled for afternoon surgery should have a light 




1946 Mendelson, New York obstetrician, reported 66 cases (out of 44016 pregnancies) of aspiration during general 
anaesthesia from over a decade.
35
 He recommended that since gastric emptying is delayed during labour, 
pulmonary aspiration could be reduced by implementing fasting guidelines to ensure emptying of gastric 
contents before anaesthesia. 
1947 In the first edition of A Synopsis of Anaesthesia clear fluids was not even mentioned. Lee recommended that 
apart from candies no food should be taken up to 6 hours before surgery.
36
  
1951 Morton and Wylie, Association of Anaesthetists of Great Britain and Ireland, reported 43 fatalities due to 




Year Findings with regards to fasting before anaesthesia 
regurgitation or vomiting of gastric contents for the period 1950 to 1951.
37
 Interesting to note is that the 
deaths occurred in high risk patients and patients with full stomachs, the anaesthetists were inexperienced 
and the total number of anaesthetics administered is not known. 
1964 In the fifth edition of A Synopsis of Anaesthesia it is recommended that fluids and solids should be withheld 
for up to 6 hours before surgery. Lee contradicts himself by stating that it is a good idea to order nothing on 
the day of surgery, but  stresses that unnecessary starvation and dehydration should be eluded.
38
  
1970 Cohen and Dillon recommended that preoperative patients should receive a list of guidelines stating that they 
should not eat or drink anything from midnight of the day before surgery, and emphasising the extreme 
danger of receiving anaesthesia on a full stomach.
39
 However, on the same list of preoperative instructions 
they recommend that children can receive sweetened fluids per os until 2 hours before anaesthesia. 
1972 Wylie and Churchill-Davidson made a clear distinction between the rapid gastric emptying of clear liquids and 




1974 Roberts and Shirley made a statement that made the medical profession belief that otherwise healthy 
patients with no aspiration risk are also at high risk of aspiration before induction of anaesthesia. Preliminary 
work on Rhesus monkey indicated that individuals with 25 ml gastric content of pH < 2.5 is at high risk of 
aspiration.
41 
The preliminary data on animals had extensive implications, and it was not until 1980 that they 
revealed that the monkeys did not regurgitate or vomited but acid was instilled directly into the bronchus with 
a syringe. From this it is evident that the investigators used the volume in the fasting stomach as a surrogate 
marker for the risk of aspiration, and did not take into account that the total volume in the stomach will not 
reach the lungs during aspiration. Now it is known that 0.8ml/kg gastric contents at pH 1.0 injected directly 
into the trachea of anaesthetized monkeys produced severe pneumonitis (equivalent to 50 ml in adult 
humans).
42
 Interestingly, clinical data demonstrated that 40 – 80% of patients who fasted for at least 8 hours 
before surgery had more than 25 ml gastric contents in their stomach with a pH < 2.5.
 43,44
   
1977 Hester and Heath made the incidental finding that fasting for more than 4 hours did not have a clinical 
advantage on the gastric volume or pH of a patient before surgery.
45 
1983 Miller et al concluded that a light breakfast within the recommended 4 hours before surgery made no 
significant difference to volume or pH of gastric contents compared with a standard fast of no intake.
46
 
Therefore, if a 4 hour fast was safe for solids, it was likely that a shorter interval would be safe for fluids. 
1.2.2 Physiology of Gastric Emptying 
The gastric capacity of the adult stomach is approximately 1500 ml and can accommodate up to 
1000 ml before intra-gastric pressure increases.47 The stomach can be divided into two functional 
parts, i.e. the proximal and the distal part.48 The proximal part consists of the fundus, cardia and 
the upper part of the corpus and acts as a reservoir for ingested food regulating the intra-gastric 
pressure and the speed of gastric emptying. The distal part of the stomach includes the lower part 
of the corpus, antrum and pylorus; the contractions of the distal part of the stomach mix the larger 
solid food particles with gastric fluid. One important factor that determines gastric emptying is the 
blood glucose level, which at physiological levels of ≥ 8 mmol/l slows gastric emptying.49,50 
Therefore, the blood glucose levels should always be maintained at physiological levels (fasting 
plasma glucose of 4.0 – 5.6 mmol/l  and/or 2 hours post prandial value < 7.8 mmol/l) before other 
influences on gastric emptying are considered.51,52,53  
There is a striking difference between the gastric emptying of solids and fluids from the stomach. 
Modern physiological gastric emptying studies use a dual isotope labelling technique in which 
solids and fluids are tagged with different radioactive isotopes.54 Fluids empty in a mono-
exponential phase whereas solids empty biphasically in a lag-phase as well as a linear emptying 
phase (Figure 1.1).55 Ingested fluids are rapidly distributed throughout the entire stomach, and 
empty at an exponential rate that is primarily a function of the pressure gradient between the 




stomach and duodenum, and the volume, caloric density, pH and osmolality of the gastric fluid. In 
otherwise healthy patients, gastric fluid content is not increased in the immediate preoperative 
period despite the theoretical negative impact of anxiety on gastric emptying.56,57 Gastric emptying 
of water and non-caloric fluids follow an extremely fast exponential curve with a mean half-
emptying time of 20 minutes.58 Initially, caloric-containing fluids empty at a slower rate, but after 90 
minutes this difference is negligible.48,59 In contrast, the gastric emptying of solids shows a biphasic 
pattern. The lag phase starts after ingestion of a solid meal, a midgastric transverse band 
separates the proximal and distal parts of the stomach; this is suggested to represent a 
physiological division important for the intra-gastric distribution of solid contents.  During this 
phase, solids are redistributed from the fundus and broken down to smaller particles (1–2 mm), 
which then can pass through the pylorus during the linear emptying phase.60  
Gastric emptying of solid food starts approximately 60 minutes after a meal, and within 120 
minutes approximately 50% of the solid food ingested is passed to the duodenum.55 Gastric 
emptying for solids depends on the type and quantity of food and the size of the food particles. The 
pylorus prevents passage of particles > 2 mm in size, so digestible solids are first broken down to 
chyme, a particulate fluid. Indigestible solids, such as cellulose-containing vegetables, may not 
break down to < 2 mm particles and these larger particles empty by a different mechanism after 
the stomach has emptied liquids and digestible food (interdigestive myoelectric complex).61,62 
Caloric particles are delivered more slowly to the duodenum than non-caloric particles due to a 
negative feedback mechanism mediated by duodenal receptors – this ensures that a constant rate 
of nutrient delivery to the small intestine is maintained through the action of the small intestine 
peptide hormone cholecystokinin.63 Another negative feedback system on upper intestinal motility 
has also been seen where the intestine-derived peptide hormones, glucagon-like peptide-I and 
peptide YY, exert this ‘ileal brake’ mechanism.64 After the intake of food, the fed state reaches a 
maximum at approximately 30 minutes, and takes place all over the gastrointestinal tract and 
occurs for about four hours after a standard 600 kcal meal.65  
After cessation of the fed state, a cyclic pattern of motor activity, secretion and blood flow migrates 
from the distal stomach towards the ileum.66 This pattern is named the migrating motor complex 
(MMC). During the fasting state the MMC in the stomach mainly features periods of pressure 
waves that repeat at highly variable intervals but are usually recurrent every 80 to 120 minutes and 
are characterised by a frequency of three contractions per minute.66 The MMC cycle is divided into 
three separate phases where phase I is characterised by inactivity, phase II by random irregular 
contractions, and phase III by continuous phasic contractions lasting for up to 5 minutes.  





 Figure 1.1: Gastric emptying of clear fluids and solids
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1.2.3 Risk for Aspiration 
Pulmonary aspiration is defined as the entry of particles or liquid into the trachea-bronchial tree, as 
a consequence of passive regurgitation or active vomiting of gastric contents from patients without 
or attenuated laryngeal protection reflexes.67 Aspiration is one of the most feared complications for 
anaesthesiologists – even though it is ranked at only the fifth-most common adverse events that 
can occur during anaesthesia.68 The first death attributed to aspiration allegedly occurred in 475 
BC, when the Greek poet Anacreon died from the inhalation of a grape seed.69 Hippocrates 
realised the dangers of aspiration and in 400 BC, warned that “for drinking to provoke a silent 
cough, or for swallowing to be forced, is bad”.70 The investigation of aspiration dates from the 
1700s when it was stated in a court of law that “it is in the mouth of everybody that a little brandy 
will kill a cat. I have made the experiment; in all those cases where it kills the cat, it kills the cat by 
getting into her lungs, not her stomach”.71 Mendelson was the first to adequately describe the 
aetiology of aspiration in 1946, and because of his pioneering report, aspiration has been referred 
to as Mendelson’s syndrome.35  A review published in 1966 highlighted that the aspiration of 
gastric content during anaesthesia is not a frequent event, but when it occurs it is catastrophic with 
a high mortality risk.72 Fasting before anaesthesia is considered essential to patient safety in order 
to reduce the risk of regurgitation of gastric contents. During anaesthesia there is a reduction in the 
reflexes that function to protect the lungs. If regurgitation occurs with reflexes absent, then 
aspiration is likely to occur with the risk of the subsequent development of pulmonary 
complications.73,74 The extent to which the reflexes are supressed depends on the level of 
anaesthesia.74 This all is physiologically true, but according to evidence-based medicine, the 
occurrence of aspiration due to regurgitation under anaesthetics is infrequent.6,8 The incidence of 
aspiration in elective surgery is one per 2000 to 3000 patients with a negligible morbidity and 




mortality.74-78 A 10-year review of morbidity attributable to anaesthesia in the general surgery 
population in South Africa found two deaths after regurgitation, vomiting and inhalation in 240 483 
patients; one following a Caesarean section and one patient had an intestinal obstruction.79  
The nature and amount of gastric aspirate will determine the type of injury and consequently, the 
clinical outcomes.67 Large particles can obstruct the trachea and major or minor bronchi whereas 
smaller particles lodge in the segmental bronchi or bronchioles and may produce a foreign body 
reaction. Aspiration of solid particles is associated with a higher incidence of mortality compared 
with aspiration of liquids.80 However, the aspiration of liquids during anaesthesia is more frequent 
than the aspiration of solids.67 The severity of the aspiration depends on the chemical composition 
of the gastric aspirate. The volume and acidity of gastric content are a result of gastric secretions 
(approximately 0.6 ml/kg/h), swallowing of saliva (1 ml/kg/h), ingestion of solids and/or liquids, and 
the rate of gastric emptying.81 The values of gastric volume and pH at which patients become at 
increased risk of aspiration are unclear. Arbitrarily critical values were set at a pH value of < 2.5 
and a volume of > 0.4 ml/kg body weight or approximately 25 ml.41 The accuracy of these values in 
humans has been questioned since this was based on unpublished data on animals.42,82 Ethically, 
it is not possible to establish the precise values of gastric volume and pH that increase the risk of 
aspiration. Therefore, intraoperative gastric content parameters are used as surrogate outcome 
measures to evaluate the effect of different preoperative fasting regimes. For passive regurgitation 
and pulmonary aspiration to occur during anaesthesia, a certain gastric volume needs to be 
present. Studies indicated that more than 200 ml gastric fluid is needed for an adult patient to be at 
risk.83  However, lower gastric aspirate volumes, in the range of 10 to 30 ml, are found in elective 
surgery patients not at risk of aspiration.84-87 The extent of pulmonary damage increases 
proportionally as the acidity and volume increases with bile damaging the lungs more severely than 
gastric acid.88,89  
There are three different complications as a result of pulmonary aspiration: acid-associated 
aspiration pneumonitis, bacterial infection associated aspiration pneumonia, or particle-associated 
aspiration (Table 1.2).67 Damage to the lung parenchyma after aspiration has a biphasic 
pathogenesis: phase one is marked by a physiochemical process that is characterised by direct 
toxic damage to the respiratory epithelium from the acid, and as a consequence the lung 
compliance decreases and a discrepancy of ventilation and perfusion occurs; phase 2 (about two 
to three hours later) manifests as immigration and activation of neutrophil granulocytes, and 
presents as an acute inflammatory reaction.90,91 Although there are similarities between aspiration 
pneumonitis and aspiration pneumonia, they are different clinical entities. Aspiration pneumonitis is 
the inhalation of sterile gastric contents while aspiration pneumonia is the inhalation of bacteria 
contaminated contents.67 However, an acid-associated aspiration pneumonitis favours the 
secondary development of aspiration pneumonia by infection with bacteria due to the damaged 
respiratory epithelium.92,93 Particle-associated aspiration is the consequence of the inhalation of 




particulate matter, resulting in an acute obstruction causing sudden arterial hypoxemia and the 
development of atelectasis distal to the foreign content.67  












Material Ingested Aspiration of sterile acidic 
gastric contents 
Aspiration of pathogenic 
bacterial contents 
Aspiration of particulate 
matter 
Pathophysiology Acute lung injury Acute pulmonary 
inflammatory response 
Acute obstruction of 
smaller or larger airways 
with arterial hypoxemia 
and the development of 
atelectases 
Clinical Presentation Asymptomatically or 
symptoms ranging from a 
non-productive cough to 
tachypnoea, 
bronchospasm, productive 
cough, and respiratory 
distress a few hours after 
aspiration. 
Tachypnoea, cough and 
signs of pneumonia. 
Aspiration usually 
witnessed as acute 
choking and coughing 
that can be fatal. 
There are several factors that have been identified to increase the risk for aspiration (Table 
1.3).67,76,80 Delayed gastric emptying is found in numerous situations and is the most profound 
reason for aspiration. Diabetes mellitus and increased blood glucose levels decrease gastric 
emptying – much more for solids than for fluids.48 Several other diseases and symptoms, i.e. 
increased intracranial pressure, hiatus hernia, abdominal obstruction, recurrent regurgitation, and 
dyspepsia, are also known to decrease gastric emptying.94 Pain, opioids and sedatives are well-
known reasons for delayed gastric emptying.77 Gastric emptying may also be delayed in patients 
who have previously undergone upper abdominal surgery.80 There is a theoretical negative impact 
of anxiety on gastric emptying.56,57 Gastric emptying is slower in males than in females.81 Pregnant 
females seem to have a normal gastric emptying rate, except for the first trimester, where 
hormonal changes results in delayed gastric emptying.95 However, when in labour gastric emptying 
will decrease and stay slow for almost 120 minutes after labour.96 To what extent smoking affects 
gastric emptying is still controversial, but there seems to be good reason for avoiding smoking 
immediately before anaesthesia.97,98 High doses of alcohol and recreational abuse of cannabinoids 
also inhibits gastric emptying.99,100 Gastrointestinal stasis (tumour or obstruction) will definitely 
delay gastric emptying and increase the risk for aspiration. Even if the stomach is empty, vomitus 
may come from the small intestine.80 Obesity does not delay gastric emptying (although intra-
abdominal pressure is expected to be higher) but it is associated with other pathologies (i.e. hiatus 
hernia, diabetes mellitus) that increase the risk for aspiration.77 Patients over 80 years have a 
tenfold increased risk in aspiration than the patients under 30 years.75 Any factor decreasing the 
lower oesophageal sphincter pressure (i.e. peristalsis, vomiting, pregnancy and achalasia) will 




increase the risk for aspiration. Surgery may be a risk for aspiration even if there is no other 
predisposing factor. Upper abdominal surgery can be considered a risk for aspiration since surgical 
manipulation may push gastric contents up into the mouth.80 Patients receiving laparoscopic 
surgery may be at risk due to the head-down position.80 Theoretically, a cholecystectomy may be a 
risk for aspiration since gastric secretion is increased and these patients may vomit bile.88 
However, the surgical group with the highest risk for aspiration are the patients receiving 
tracheostomies – probably because the airway is not protected during the change of cannule.75 
The lithotomy or head-down position may encourage regurgitation. Patients with difficult airways 
are prone to pulmonary aspiration, independent of their gastric content.77 Anaesthetic gas that is 
insufflated into the stomach may increase the risk for regurgitation especially when high pulmonary 
inflation pressures are required.80 The incidence of regurgitation increases as the duration of the 
surgery increases.101 Removing an airway before a patient regains consciousness may evoke 
regurgitation and aspiration since both gastrointestinal motor responses (such as gagging or 
recurrent swallowing) and airway reflexes (such as gagging, hiccoughs or laryngospasm) return.78 
Inadequate anaesthesia may also evoke gastrointestinal motor responses and airway reflexes 
resulting in distension of the stomach, regurgitation and vomiting with increased risk for 
aspiration.78 Any airway inserted in the oesophagus inlet will decrease the lower oesophageal 
sphincter tone and may increase the risk for regurgitation and aspiration.102 Incorrect placement of 
an airway in the laryngeal inlet will trigger airway reflexes and increase risk for aspiration.80 The 
choice of anaesthetic technique and airway management seems to be as important when it comes 
to reducing the change of pulmonary aspiration.55 The ultimate aim of preoperative fasting is to 
reduce an event sequence, which begins with regurgitation and aspiration and may result in 
pulmonary damage causing pneumonia and even death.74 
  








Increased gastric content  Delayed gastric emptying 
 Gastric hypersecretion 
 Drugs 
 Overfeeding 
 Lack of fasting 
 Males 
Increased tendency to regurgitate  Gastro-oesophageal reflux 
 Oesophageal obstruction 
 Hiatus hernia 
 Obesity 
 Pregnancy 
 Extreme age 
 Achalasia 
 Zenker’s diverticulum 
 Diabetic autonomic neuropathy 
Laryngeal incompetence  Head injury 
 Cerebral infarction/haemorrhage 
 Neuromuscular disorders 
 Muscular dystrophies 
Surgery Factors 
Procedure  Upper abdominal surgery 
 Emergency surgery 
 Laparoscopic surgery 
 Night time surgery 
Position  Lithotomy  
Anaesthesia Factors 
Airway  Difficult intubation 
 Gas insufflation 
 Prehospital intubation 
Maintenance  Inadequate anaesthesia 
Device  Supraglottic airway 
1.2.4 Modern Fasting Guidelines 
The evidence for rigid fasting practices in elective surgery patients has been challenged and 
shown to be redundant for most study populations. The first randomised controlled trial evaluating 
drinking water versus standard fasting started in 1985, and concluded that the patients drinking 
water had significantly decreased gastric volumes and the pH was no different from the fasting 
group.84 Between 1985 and 1993, several trials were conducted in different countries comparing 
the intake of water or clear fluids to standard fasting before induction of anaesthesia.84,85,87,103-110 
The trials had shortfalls and the ingested volumes varied between trials with some investigators 
allowing patients to decide how much fluid they want to drink preoperatively. However, a statistical 
significant reduction in gastric volume was found in the oral intake group 84,103,106 and there was no 
correlation between ingested volume or ingestion interval with gastric volume at induction of 
anaesthesia. The first review on the topic was published in 1995 and concluded that the intake of 
oral fluids until two hours before general anaesthesia is safe.86 A Cochrane Review on the same 
topic concluded that allowing patients to drink water preoperatively results in significantly lower 
gastric volumes, and there is no evidence to suggest that a shortened fluid fast results in an 




increased risk for regurgitation, aspiration or related morbidity when compared with standard 
fasting.74 An editorial in The British Journal of Anaesthesia in 1993 recommended that the NPO 
after midnight should be abandoned and that clear fluids should be allowed until three hours before 
surgery.112 In 1994, the Norwegian Society of Anaesthesiologists implemented evidence-based 
fasting guidelines recommending clear fluids until two hours before induction of anaesthesia.113 
The American Society of Anesthesiologists published their guidelines in 1999, also recommending 
the intake of clear fluids.114 The liberal fasting guidelines are based on the following:8  
 aspiration is not common in modern medicine (since regurgitation is not always associated 
with aspiration), 
 prolonged fasting can be associated with adverse events,  
 there is no significant relationship between fasting duration and gastric content,  
 fluids and solids pass differently through the stomach.  
Many anaesthesia societies followed suite and changed their guidelines to the intake of clear fluids 
such as water, tea, coffee and light apple juice up until 2 to 3 hours before anaesthesia.55,115-118 
However, such fluids contain only limited amounts of energy and cannot be expected to cause any 
major changes in the metabolism.5,73 Therefore, the patient will undergo surgery in a metabolic 
fasted state. Literature shows that this may not be the ideal metabolic state before surgical stress, 
and that carbohydrate (CHO) feeding shortly before the surgery may be a better way to prepare for 
the stress of elective surgery.5 A review published in 2011 on the role of CHO beverages in 
preoperative nutrition for elective colorectal surgery, concluded that the use of these beverages is 
both safe and effective, and that there is no increased risk for regurgitation and aspiration.119 
Another review published in 2012 that focused on POCL for elective surgery confirmed no 
aspiration was observed in any of the included trials.120 A meta-analysis of 21 trials on POCL in 
elective surgery published in 2013 reported that there were no reported pulmonary complications in 
the group consuming oral CHO beverages.121 Furthermore, a review on the role of POCL published 
in 2014 confirmed that the administration of an oral CHO beverage before surgery is safe since the 
volume and pH of gastric contents were nearly identical between a standard fast and a two-hour 
fast, the clear fluids emptied within 90 minutes; and therefore concluded that there is no increased 
risk for aspiration in patients who received a CHO beverage before surgery.16 This is in line with a 
Cochrane Review published in 2014 showing that POCL does not increase postoperative 
complications.122 The modern fasting guidelines from various international societies are presented 
in Table 1.4.55,123-126   








Type of fluid CHO fluid Volume of fluid 





2 hours Clear fluids (including, but not limited to 
water fruit juices without pulp, carbonated 
beverages, clear tea, black coffee) 
No comment Volume is less important 






2 hours Clear fluids No comment No comment 





2 hours Clear fluids (including water, pulp-free 
juice, tea or coffee without milk) 
Consider the use of oral 
carbohydrate drinks 
No comment 
Scandinavian Society of 
Anaesthesiology and 




2 hours Clear fluids (non-particulate fluids without 
fat, for example, water, clear fruit juice, tea 
or coffee) 
Include the pre-operative 
carbohydrate drink intended 
for pre-operative nutrition 
(Preop® Nutricia) 
No comment 





2 hours Clear fluids (fluid which is non-particulate 
and through which newsprint is visible) 
No comment No comment 
 
*CHO = carbohydrate 
 
Stellenbosch University  https://scholar.sun.ac.za




Milk and milk-containing drinks should be treated as solids since it is believed that milk in large 
volumes acts like a solid due to curdling in the stomach – unfortunately this belief is mostly based 
on animal studies and there is uncertainty around the safe amount that can be consumed without 
delaying gastric emptying.123,125 All the above-mentioned societies recommend a minimum fast of 
six hours for a light meal (typically consisting of toast and clear fluids).55,123-126 Meals that include 
fatty food and meat may prolong gastric emptying time and additional fasting time of more than 
eight hours may be needed.123 Chewing gum, sucking a boiled sweet or smoking immediately 
before anaesthesia should be discouraged due to the effect on gastric emptying, but should not be 
a reason to cancel or delay surgery.125 
Studies of preoperative fasting have not evaluated high risk anaesthetic patients adequately to 
provide definite evidence on whether or not they can adhere to the two-hour cutoff for clear fluids. 
There is controversy in patients with obesity, gastro-oesophageal reflux, diabetes mellitus and 
pregnant women not in labour due to the unknown effect of POCL on the effect of glycaemia and 
gastric emptying.125 The timing of emergency surgery should balance the risk of delaying surgery 
versus risk of aspiration of gastric contents.6 Fasting in non-elective obstetric patients is a bit more 
complex since surgery during labour is usually an emergency and can range from minimal to life 
saving surgery. Logic dictates that women in labour should be fasted – however, literature shows 
that maternal death due to aspiration is extremely rare and women in labour should be allowed to 
drink clear fluids as desired.125 Solid food should be discouraged during labour since it confers no 
benefit to obstetric outcomes. Preoperative fasting in elective obstetric patients is the same as for 
healthy patients: clear fluids can be consumed until two hours before surgery.125  
There is consensus that the prophylactic use of prokinetic agents (e.g. metoclopramide, cisapride), 
H2-receptor antagonists (cimetidine, ranitidine, famotidine), proton pump inhibitors (omeprazole, 
lansoprazole), antacids (sodium citrate, sodium bicarbonate, magnesium trisilicate), antiemetics 
(droperidol, ondansetron) and anticholinergics (atropine, scopolamine, glycopyrolyte) in patients 
who are not at risk of aspiration is not recommended since there is insufficient evidence of clinical 
benefit.123,125 Therefore, the routine use of preoperative multiple agents in patients who have no 
increased risk for aspiration is also not recommended.123 
1.3 CARBOHYDRATE METABOLISM 
1.3.1 Physiology of carbohydrate metabolism 
Dietary CHO provide 50 to 55% of our total energy on a daily basis.127 CHO are digested to 
glucose by the action of amylases and isoamylases in the gut and disaccharides in the 
enterocytes, and absorbed in the portal circulation. The glucose pool is located primarily in the 
plasma which contains glucose for freely available energy.127,128 Plasma glucose concentration is 
the most closely regulated nutrient pool since glucose is the only fuel that the brain can metabolise 
(except in starvation).128 Metabolism gives priority to the brain that if the glucose pool decreases 
below a certain concentration only the brain has access to glucose to ensure sufficient energy 












supply.128 If the plasma glucose concentration is within the normal range, most tissue uses glucose 
as their primary source of energy. Additional glucose is synthesised to glycogen (glycogenesis); 
however, glycogen stores are limited and additional excess glucose will be converted to fat 
(lipogenesis). If the plasma glucose concentration decreases, the body will metabolise glycogen 
back to glucose (glycogenolysis) or glucose can also be synthesised from an amino acid precursor 
(gluconeogenesis). If plasma glucose concentration increases and the renal threshold for glucose 
reabsorption is exceeded, excess glucose will be excreted into the urine (glucosuria). Figure 1.2 



























Amino acid pool 
Excess glucose 
excreted in urine 
Brain metabolism Metabolism in most tissue 
Fatty acid pool 
Fat stores 




The glucose metabolism is primarily regulated by the endocrine system with the ratio of insulin to 
glucagon regulating the hour-to-hour metabolism.127,128 Insulin and glucagon act as antagonists to 
keep plasma glucose concentrations within the normal range.  Both insulin and glucagon have 
short half-lives, and must therefore be continuously secreted to have a constant effect. Insulin 
promotes anabolism with the target cell response being increased glucose metabolism.  
Tissues can be classified as insulin-sensitive or insulin-insensitive.127 Insulin-sensitive tissues, like 
adipose tissue and skeletal muscle, use insulin to promote glucose uptake by stimulating the 
translocation of GLUT-4 transporters to the plasma membrane; these tissue use glucose during 
meals, and fat between meals for energy. Insulin-insensitive tissues, like the brain and epithelia of 
the kidney and gastrointestinal tract, are not dependent on insulin for glucose uptake; glucose 
transport and oxidation remains constant during the day due to specific GLUT-1 and GLUT-3 
transporters as well as a specific enzyme named hexokinase. Interestingly, the brain uses about 
1 mg/kg/min glucose throughout the day (about 1.5 g/kg/day).127 
Glucagon is antagonistic to insulin with the goal to prevent hypoglycaemia.128 The primary stimulus 
for glucagon release is plasma glucose concentration - when plasma glucose concentrations drop 
after a meal and fall below 5.6 mmol/l, glucagon secretion increases dramatically; when plasma 
glucose concentration increases above 5.6 mmol/l, insulin secretion increases and glucagon 
secretion is inhibited and stays at a constant low level.128 The ratio of insulin to glucagon 
determines the direction of metabolism rather than the absolute amount of hormones.128 During a 
fasted state, 75% of glucose comes from glycogenolysis and 25% from gluconeogenesis. Plasma 
glucose concentration is maintained during fasting at 4.4 – 6.7 mmol/l.127 See Table 1.5 for a 
comparison of insulin and glucagon as potent regulators of a glucose metabolism.128  
Table 1.5: Insulin and glucagon as regulators of glucose metabolism
128
 
Hormone Insulin Glucagon 
Classification Anabolic hormone Catabolic hormone 
Secreted by pancreatic islets Beta-cells Alpha-cells 
Primary goal ↓ plasma glucose concentration ↑ plasma glucose concentration 
Primary stimulus hyperglycaemia hypoglycaemia 
Metabolic state dominant Fed state Fasted state 




Metabolic action ↑ glucose synthesis 
↑ protein synthesis 




Anabolic hormones (i.e. insulin) remain relatively low between meals to regulate hepatic glucose 
production while catabolic hormones (i.e. glucagon, adrenaline, cortisol and growth hormone) 




increase between meals or during stress to decrease glucose uptake in insulin-sensitive tissues 
and hepatic glucose production is stimulated. Therefore, glucose production is regulated by the 
balance between anabolic and catabolic hormones. See table 1.6 for the effect of different 
hormones on glucose metabolism.127  
Table 1.6: Effect of hormones on glucose metabolism
127













Glucose uptake (in insulin 
sensitive tissues) 
↑↑ ↓↓ ↓ ↓ ↓ 
Glycogenesis ↑ ↓ ↓ ↑ ↓ 
Glucose Oxidation ↑ ↓ ↓ ↓ ↓ 
Glycogenolysis ↓↓ ↑↑ ↑↑   
Gluconeogenesis ↓ ↑ ↑ ↑↑ ↑ 
1.3.2 Effect of fasting on carbohydrate metabolism 
Food intake is an intermittent process while energy expenditure is a continuous process. Glucose 
stores in the body are limited to approximately 500 to 800 g and are rapidly exhausted.127,129 The 
energy value of one gram of glucose is approximately 4 kcal, one gram of protein also yields about 
4 kcal while one gram of muscle has an energy value of 1 kcal (due to being 75% water), and one 
gram of pure triglycerides yields 9 kcal.129 Reaction to fasting is dependent on energy reserves, 
duration of fasting and any additional stressful influences. The metabolism can be divided into the 
fed and fasted states, and the fasted state can be divided into short-term (less than 72 hours) and 
long-term (more than 72 hours) fasting.129 
The fed state (absorptive state or anabolic state) is the period after a meal when the products of 
digestion are being absorbed, utilised and stored; the fasted state (postabsorptive state or 
catabolic state) is the period where the nutrients of the meal are no longer in the bloodstream and 
as time passes, reserves will be utilised.128 The fed state is recognised by increased insulin and 
decreased glucagon while the fasted state is recognised by decreased insulin and increased 
glucagon.129 The change in plasma glucose concentration is the signal for the body to change from 
the fed to the fasted state. The challenge of the fasted state is to keep the plasma glucose 
concentration within the physiological range so that the brain and the rest of the body have 
adequate energy.128 During the fasted state, the liver glycogen is the primary source of glucose 
production, and can provide enough glucose through glycogenolysis to meet 12 to 24 hours’ 
energy needs. Skeletal muscle glycogen cannot be metabolised to glucose through direct 
conversion since muscle cells lack the enzyme that makes glucose from glucose-6-phosphate. 




Therefore, glucose-6-phospate is metabolised to pyruvate (aerobic conditions) or lactate 
(anaerobic conditions), and transported to the liver to make glucose.128  
During the fasted state, glucose needs are initially met by glycogenolysis but later from 
gluconeogenesis. Additional glucose can be made from amino acids, particularly those in muscles. 
Enzymes remove the amino groups from the amino acids by deamination, and convert the amino 
group to urea, which is excreted, leading to a loss of up to 75 g protein per day (300 g of 
muscle).128,129 Some deaminated amino acids act as an intermediate to produce energy while other 
amino acids are converted to pyruvate, which is transported to the liver and made into glucose.128 
During the fasted state, adipose tissue breaks down its stores of triglycerides into glycerol and fatty 
acids by lipolysis.129 Glycerol goes to the liver where it is converted to glucose while fatty acids are 
released into the plasma where they are used as a source of energy for many tissues. If there is 
excess fatty acid breakdown, β-oxidation creates ketones, which are transported from the liver to 
the nervous system and muscle for energy. Besides glucose, ketones are the only source of 
energy that the brain can use. Therefore, ketones become a significant source of energy during 
prolonged starvation. The adaption of the brain to use ketones instead of glucose leads to a two-
third reduction in gluconeogenesis (saving 25 g of protein equivalent to 100 g of muscle per 
day).129 Unfortunately, ketones are moderately strong acids and excessive production leads to an 
acidosis state (known as ketoacidosis).128 During short term fasting, the metabolic rate increases 
initially but begins to decrease after two days.129 Table 1.7 gives a summary of the effect of the fed 
versus the fasted states on the metabolism.129 














Short Term Fasting Long Term Fasting 
↑ Glycogenesis ↑↑ Glycogenolysis Depleted glycogen stores 
↑ Glucose oxidation Glucose oxidation ↓↓ Glucose oxidation 
↓ Lipolysis ↑ Lipolysis ↑↑↑ Lipolysis 
↓ Lipid oxidation Ketogenesis in liver ↑↑↑ Ketogenesis in liver 
↑ Protein synthesis ↑↑↑ Protein catabolism ↑ Protein catabolism 
↑↑ Energy expenditure ↑ Energy expenditure ↓ Energy expenditure 
1.3.3 Effect of surgery on carbohydrate metabolism 
The stress response is the name given to the hormonal and metabolic changes that follow injury or 
trauma.130 Elective surgery is a treatment that deliberately causes an injury to the body to repair 
organs or remove disease.15 The metabolic effect from surgery is characterised by a state of 
hypermetabolism.17 Surgical trauma induces a catabolic response by the release of stress 
hormones and inflammatory mediators with a compensatory increase in insulin release and a 




reduction in the effects of insulin resulting in insulin resistance with hyperglycaemia.12,17 A state of 
metabolism resembling non-insulin dependent diabetes mellitus develops when glucose production 
is increased and there is a reduction in glucose uptake in the periphery (see Table 1.8 for the 
metabolic similarities between postoperative patients and patients with diabetes mellitus type 2).15 
Insulin resistance occurs within hours after the initiation of surgery, with a definite insulin resistance 
after surgery.17 Postoperative insulin resistance, which peaks on the first postoperative day, 
progresses after surgery in a dose-dependent mode directly related to the extent of the surgical 
procedure and may persist for up to three weeks after major abdominal surgery.131-133  Several 
factors have an effect on insulin resistance after surgery: surgical technique, pain control, 
postoperative muscle activity, and the duration of preoperative fasting.134-138 The surgical technique 
used makes a difference since laparoscopic techniques cause minimal insulin resistance, while the 
same procedure done using open techniques results in a rise in insulin resistance.132 Interestingly, 
insulin resistance may start before surgery due to prolonged fasting and exacerbate the metabolic 
response to stress.13 Postoperative insulin resistance occurs mainly in the periphery while the 
splanchnic tissue play an insignificant role.117 Fasting-induced insulin resistance is caused by 
impaired GLUT-4 translocation from the microsomal membrane to the plasma membrane in 
skeletal muscle, blocking glucose uptake into the muscle and thereby not encouraging insulin 
release.118 Insulin resistance causes less effective glucose transport into muscle cells as well as 
less glycogen storing, and loss of protein from muscle causing loss of lean body mass. Therefore, 
there will be less energy and less structural protein, resulting in lower muscle function and less 
mobilising capacity. Insulin resistance is a significant element for outcomes in surgical trauma due 
to the development of complications.139 Insulin resistance following surgery is an independent 
element forecasting the length of stay in the hospital.132 
Table 1.8: Metabolism in postoperative patients versus patients with diabetes mellitus
15
 
Metabolism  Postoperative Diabetes Mellitus Type 2 
Hyperglycaemia ↑↑ ↑↑ 
Insulin sensitivity ↓ ↓↓ 
Glucose production ↑ ↑↑ 
Peripheral glucose uptake ↓↓ ↓↓ 
GLUT-4 translocation ↓ ↓ 
Glycogen formation ↓ ↓ 
Stress starvation occurs when an individual is not only starved but subjected to the metabolic 
response of stress.129 During this situation, normal adaptive responses of simple starvation to 
conserve body protein are overruled by the effects of injury. The metabolic rate increases, ketosis 
is minimal, and protein metabolism increases to meet the demands of tissue repair and 
gluconeogenesis – therefore, this state is recognised by hyperglycaemia and glucose 




intolerance.129 The metabolic goal during a stress response is to supply suitable substrates for 
tissues to meet energy requirements.140 Stress initiates a strong increase in endogenous glucose 
production and turnover – up to 150% above normal levels. Glucose is a vital substrate since 
glycolysis does not require oxygen to produce energy. Therefore, it can be utilised in hypoxic and 
inflammatory tissues and in healing wounds where mitochondria are not developed or where 
capillaries are absent and fat cannot reach the cells.  Glycogen can only supply glucose for 12 to 
24 hours during the normal fasting state, and stores are exhausted in less time during a stress 
response. Therefore, new glucose is formed from amino acids and lactate during gluconeogenesis. 
This production cannot be fully suppressed by exogenous glucose or by insulin like during the 
fasted state – suggesting that gluconeogenesis is an obligatory process initiated by catabolic 
hormones and cytokines. Glucose is also formed from glycerol, released from adipose tissue 
during lipolysis. Amino acids are predominantly derived from muscle and are, together with 
glycerol, the main substrates for glucose production in the liver. The degree of protein catabolism 
during a stress response is large – reaching 260 g per day (corresponding to more than 1 kg of 
muscle). Amino acids released from muscles are also used for the synthesis of acute phase 
proteins. Net muscle protein gain can only be established during the anabolic phase of disease, 
provided adequate nutrition is administered, and protein turnover decreases.  The oxidation of fat 
supplies almost 90% of the energy necessary for increased gluconeogenesis. Although an 
increased rate of lipolysis is part of the metabolic response to stress, the fatty acid release can 
exceed energy requirements. The excess fatty acids are re-esterified to triglycerides causing fatty 
infiltration of the liver and muscle tissues (especially when the high doses of glucose are 
administered continuously exceeding the glucose oxidation rate of 4 to 5 mg/kg/min). High insulin 
levels during the stress response cause ketogenesis to be stimulated to a lesser degree than 
during the fasting state alone. The stress response is essential for survival in the short term but it 
can be destructive when extreme or sustained (see Table 1.9 for the fed versus fasted state versus 
stress response on metabolism).140  
  




Table 1.9: Fed versus fasted state versus stress response on metabolism
140
 
Metabolism Fed State Fasted State Stress Response 
Gluconeogenesis ↓ ↑ ↑↑↑ 
Glycolysis ↑ ↓ ↑↑↑ 
Glucose oxidation ↑↑↑ ↓ ↓ 
Glucose cycling ↑ ↓ ↑↑↑ 
Proteolysis ↓ ↓ ↑↑↑ 
Protein synthesis ↑ ↓ ↑↑ 
Amino acid oxidation ↑ ↓ ↑↑↑ 
Lipolysis ↓↓ ↑↑↑ ↑↑ 
Lipid oxidation ↓ ↑↑↑ ↑ 
Ketogenesis ↓↓ ↑↑↑ ↑ 
Fatty acids - ↓ ↑↑ 
Insulin resistance is a state in which there is decreased responsiveness of skeletal muscle, 
adipose tissue and the liver to biological actions of insulin. The development of postoperative 
insulin resistance is associated with prolonged hospital stay, greater postoperative morbidity and 
mortality.141 Most of the common complications developing during surgery are similar to those 
observed in diabetes mellitus type 2.15 However, the complications develop within days of surgery 
whereas in diabetes mellitus they develop after a longer period. Interestingly, some of the cells 
involved in these complications are not dependent directly on insulin for their glucose uptake. 
Examples include immune cells involved in infection, neural cells for neuropathies, and endothelial 
cells for cardiovascular complications. These cells have no glucose storage capacity, so glycolysis 
is the only pathway for glucose once inside the cell. When there is an excess inflow of glucose into 
these cells they eventually start producing oxygen free radicals, consequently changing the gene 
expression in numerous cells causing further enhancement of inflammation, which results in further 
insulin resistance in an already vicious cycle.142 
1.3.4 Glucose control 
Depending on the definition of hyperglycaemia, the prevalence of hyperglycaemia can be as high 
as 97.5% when hyperglycaemia is defined as a blood glucose level above 6.1 mmol/l in tight 
glucose control settings.19 Hyperglycaemia is common in critically ill patients – almost 60% of 
critically ill patients have increased glucose levels with just more than 20% of this population 
diagnosed with diabetes mellitus.143 Although a number of metabolic interactions result in stress 
hyperglycaemia, such as neurohormonal alterations with cytokine release, the primary 
mechanisms behind stress hyperglycaemia are insulin resistance and gluconeogenesis.144 Glucose 
control should be maintained at normal levels while feeding the severely stressed surgical patient 
since it is essential to reduce morbidity and mortality.16,17,145 Metabolic changes during surgery can 
be reversed by the use of exogenous insulin.146  




The first study on glucose control in critically ill patients was only published in 1995 since medical 
personnel did not feel that glucose control was important in the management of this population.147 
Hyperglycaemia was considered an adaptive response to critical illness and not treated until 
glucose levels exceeded the renal threshold of 12 mmol/l.148 The Diabetes Insulin-Glucose in Acute 
Myocardial Infarction (DIGAMI) study was one of the first studies on tight glucose control, and 
mortality was reduced by 26% in one year.149 However, the outcome was questioned since it was 
unclear whether tight glucose control or improved diabetes management after discharge lead to 
the decreased mortality. The DIGAMI 2 study found no effect on morbidity or mortality after two 
years of follow up, probably due to an inability to achieve tight glucose control.150 The landmark 
Leuvin 1 study showed that patients in a surgical intensive care unit (ICU) benefited from intensive 
insulin treatment to normalise glucose levels at 4.5–6.0 mmol/dL.18 In this study, patients were fed 
and showed that insulin action seems not only to be a key to successful immediate postoperative 
feeding but also to avoid further catabolic complications. A range of complications were lowered 
including infections, renal failure, polyneuropathy, and the need for ventilation. However, when the 
same authors applied the same protocol to medical ICU patients in the Leuvin 2 study, the results 
were different with mortality in the medical ICU population much smaller (6%) than in the surgical 
ICU population (42%).151 From these two studies it seems that the beneficial effect of tight glucose 
control is more pronounced in severely ill surgical patients requiring prolonged ICU care. The 
Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) study applied the same 
protocol to septic patients and achieved lower blood glucose levels with no decrease in mortality.152 
Unfortunately, the VISEP study was stopped due to high rates of hypoglycaemia. The 
Normoglycemia in Intesive Care Evaluation – Survival Using Glucose Algorithm Regulation (NICE-
SUGAR) study showed that morbidity and mortality were increased when using an intensive insulin 
protocol maintaining glucose levels at 4.5 – 5.6 mmol/l versus physiologic levels below 10 mmol/l 
in a medical ICU with a heterogeneous group of patients that are severely stressed.20 Despite the 
numerous methodological differences, the difference between results in various trials of glucose 
control can be attributed to the fact that in surgical patients, controlling plasma glucose 
concentrations by treating insulin resistance is beneficial in the sense that it avoids the 
development of complications, whereas in severely stressed septic medical patient, insulin is used 
to treat insulin resistance with the complications already present.15 There is no definite blood 
glucose control target: although hyperglycaemia is associated with adverse events; the greatest 
risk of tight glucose control is hypoglycaemia. Table 1.10 indicates different blood glucose targets 








Table 1.10: Target blood glucose recommendations 
Study Recommendation Study Population 
Van den Berge et al, 2001
18
 4.5 – 6.0 mmol/l Surgical critically ill patients 
Preiser et al,  
2007
153 
7.7 – 9.9 mmol/l Medical and surgical critically ill patients 




7.7 – 9.9 mmol/l Medical and surgical critically ill patients 




7.7 – 9.9 mmol/l Heterogeneous group of critically ill patients 














7.7 – 9.9 mmol/l Heterogeneous group of patient 
*ASPEN = American Society of Parenteral and Enteral Nutrition; NICE-SUGAR = Normoglycemia in Intesive Care 
Evaluation – Survival Using Glucose Algorithm Regulation; ADA = American Dietetic Association 
Hyperglycaemia results in a number of undesirable physiological consequences that lead to poor 
clinical outcomes in the critically ill population (Figure 1.3).144 These complications are the results 
of the vicious inflammation cycle, increased oxidative stress and altered nutrient utilisation. 
Hyperglycaemia increases the inflammatory state by increasing transcription of proinflammatory 
cytokines.158,159 Increased oxidation stress is due to increased reactive oxygen species and 
depleted glutathione.158,160 Hyperglycaemia and the consequent increase in inflammatory markers 
and oxidative species results in increased infectious complications due to decreased phagocytosis 
and glycosylation of immune globulins. Altered nutrient utilisation during hyperglycaemia causes a 
state of hypermetabolism, which can negate the efforts to improve or maintain nutritional status 
during the perioperative period.144  





Figure 1.3: Physiological effects of hyperglycaemia 
Although there is limited evidence, nutrition support plays an integral part in glucose control. There 
are no large multicentre randomised controlled trials of different nutrition parameters on glucose 
control. Recommendations for nutrition support practice are extracted from limited trials and 
tempered with feedback from clinical experience. Strategies for improving glucose control include:  
 avoiding prolonged fasting before surgery,  
 providing preoperative CHO beverages,  
 avoiding overfeeding,  
 ensuring continuous enteral feeding,  
 providing a mixed fuel source for parenteral nutrition,  
 considering hypocaloric feeding for obese patients,  
 providing hypocaloric feeding initially for patients in the acute phase response or those at 
increased risk of hyperglycaemia,   
 using of insulin to maintain glucose control is likely to be a better approach when compared 
to CHO restriction that causes starvation.144,145 
1.4 CARBOHYDRATE LOADING CONCEPT 
1.4.1 Route of carbohydrate loading 
Traditionally, in the morning after waking up, most people have a breakfast consisting of a mixed 
meal, which causes insulin release and change in the metabolism from the fasted to the fed state. 
The most obvious way to change the metabolism from the fasted to the fed state is to give a CHO 
increase infectious complications 
poor wound healing (altered collagen synthesis) 
initiate a catabolic state 
delays nutritional repletion (altered nutrient utilisation) 
hypertriglyceridemia (decrease lipoprotein lipase activity) 
fluid and electrolyte abnormalities 
increase serum osmolality 
aggrevate symptoms of gastroparesis 
attenuates promotility action of erythromycin 




load. The hypothesis of being in the fed and not the fasted state at the onset of surgery was first 
verified using an overnight intravenous (IV) infusion of glucose to achieve an endogenous insulin 
response.161 The insulin response to glucose infusion is dose dependent and it was necessary to 
give a very high dose (5 mg/kg/min) and concentration (20%) of glucose infusion so that the 
quantity of glucose given was about 300 g in 1500 ml. A high dose of glucose infusion increases 
endogenous insulin release to serum insulin levels seen after the consumption of a standard mixed 
meal (60–70 μU/ml) and consequently, the patient enters the theatre in a state of normoglycaemia 
and hyperinsulinaemia, representing a fed metabolic state. This intervention has the desired 
metabolic effect, but in practice, the use of IV glucose and insulin infusions necessitate access to 
large veins, frequent control of glucose levels, and adjustment of the glucose infusion rates to 
maintain glucose levels.17 These difficulties could be overcome if CHO could be administered 
through a more physiological route - hence, the oral route of giving CHO was investigated.  
1.4.2 Characteristics of oral carbohydrate loading 
Preoperative CHO loading can only be given orally in clinical practice if two criteria are fulfilled: 
1. the beverage must pass the stomach fast enough to be safe (time specific) 
2. the intake of the beverage should induce an endogenous insulin response to cause the 
desired change in metabolism from the fasted to the fed state (dose specific).5  
Commercially available oral nutritional supplements (ONS) can change the metabolism from the 
fasted to the fed state, but they have a relatively slow rate of gastric emptying due to the fat and 
fibre contents, and are thus theoretically unsafe to use.17 Another alternative could be clear fluids 
or sport beverages, which contain mainly CHO with rapid gastric emptying. However, the 
concentration of CHO is too low (< 8%) to cause an insulin response to switch the metabolism from 
the fasted to the fed state.5 A CHO beverage was pioneered, consisting of about 12% (12 g/100 
ml) CHO with an osmolality less than 300 mOsm/kg, for preoperative use.57 The energy content of 
this beverage is adequate to increase serum insulin levels seen after a standard mixed meal, 
therefore providing enough energy to switch the patient from the fasted to the fed state before the 
onset of surgery. The CHO used must be complex, such as maltodextrins rather than glucose or 
sucrose, to minimise the osmotic load of the beverage to reduce the gastric emptying time.141 Note 
that this specific beverage is also protein, fat and fibre free. Upon testing a dose of 400 ml (50 g 
CHO) of this beverage passed the stomach within 90 minutes.57 The consumption of 400 ml of this 
CHO beverage compared to a placebo showed no significant difference in the gastric contents 
(volume and pH) at the onset of surgery.162 The intake of up to 400 ml of the CHO beverage also 
does not contribute to additional adverse events when compared to a similar intake of water.81,163 
Therefore, the intake of a CHO beverage before elective surgery is as safe as the intake of other 
recommended clear fluids. This formula with about 12% CHO and an osmolality of < 300 mOsm/kg 
is considered the best method of CHO administration before surgery.17 There are various 




beverages available internationally adhering to these principles that are marketed for preoperative 
use (Table 1.11).164  
A new formulation of CHO beverages has been developed containing sources of protein i.e. 
hydrolysed protein, whey protein and glutamine.165-167 The composition of the new formulas looks 
promising since it might reduce insulin resistance, causing decreased loss of lean body mass, and 
enhance surgical recovery.9 Whey protein contains essential amino acids that are rapidly used by 
skeletal muscle during the stress response, it stimulates protein synthesis inducing protein gain, 
and it is a source of cysteine, which is a precursor of glutathione, which acts as an antioxidant.168-
170 Glutamine is a conditionally essential amino acid and contributes to more than 50% of the 
body’s free amino acid pool.171 Glutamine attenuates the development of postoperative insulin 
resistance, increases liver glycogen and enhances the mitochondrial membrane complex activity 
resulting in fewer cases of hyperglycaemia, decreased insulin requirements, decreased negative 
nitrogen balance, increased serum glutathione, and decreased inflammatory markers.165,172-174 
Furthermore, whey protein is rapidly digested and absorbed in the small intestine when compared 
to casein, and supplements containing glutamine are safely emptied from the stomach within two 
to three hours.175,176 The overall findings of the potential benefits of whey protein and glutamine-
enriching carbohydrate beverages for preoperative use, seems relevant. However, further research 
is required to establish the clinical benefit. See Table 1.12 for the carbohydrate containing clear 
beverages available in South Africa.177-182 The energy supply ranges from 50 kcal to 150 kcal per 
100 ml with all of the beverages being fat and lipid free. All beverages contain a source of protein 
except for the preOp® (Nutricia). All beverages contain at least 12 g CHO per 100 ml that will 
change the metabolism from the fasted to the fed state. Only the preOp® (Nutricia) adheres to the 
recommended < 300 mOsm/kg osmolality to ensure rapid gastric emptying. Due to the increased 
osmolality of the other beverages, the different companies manufacturing these beverages should 
give evidence that these beverages clear within the recommended time to make it safe for 
preoperative use.  The vitamin, trace element and electrolyte contents of all the beverages differ 
significantly. From this table it is important to note that not all clear fluid beverages are designed for 
preoperative use.  
 




Table 1.11: International available carbohydrate beverages for preoperative use
164
















Europe, United Kingdom, 
Canada, South Africa 
200 50.4 40 12.5 260 - 285 400 
Maxijul ® 
(Nutricia) 
United Kingdom, Europe 190 47.5 43.25 32 420 150 
Clearfast ® 
(BevMD) 
United States 200 50 44 14.0 270 355 
ONS300 ® 
(Fresenius Kabi) 
Germany 200 50 50 16.6 266 300 
ONS400 ® 
(Fresenius Kabi) 
Germany 200 50 50 12.5 266 400 
Preload ® 
(Vitaflo / Nestlé) 
United Kingdom 200 52 47.5 13.0 135 400 
Arginaid ® H20 
(Nestlé) 
Japan 300 52 52 18 200 250 
Nidex ® 
(Nestlé) 
Brazil 200 50 50 12.5 200 400 
*nutritional information per unit 
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Ensure Plus Juce 
(Abbot)
182 
Energy (kcal) 150 150 50 150 104 150 
Protein (g) 4 
11% of Energy 
Pea protein hydrolysate 
4 
11% of Energy 
Whey protein 
none 4 
11% of Energy 
Whey protein 
3.8 
10% of Energy 
Whey protein 
4.8 
12.8% of Energy 
 
Carbohydates (g) 33.5 







































































Osmolarity (mOsm/l) 680 - 700 680 260 715 – 750  630 660 










Packaging (ml) 200 200 200 200 237 220 
Age Restriction < 2 years < 2 years < 1 year < 3 years < 4 years Unknown 
Preoperative Indication 400 ml night before 
surgery; 200 ml up to 2 
hours before surgery 
Safe to consume 200 ml 
up to 2.5 hours before 
surgery 
800 ml night before 
surgery; 400 ml up 
to 2 hours before 
surgery 
Indicated for 
preoperative use  
474 ml night before 
surgery; 237 ml up to 2 




# Nutritional analysis per 100ml 
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1.4.3 Benefits of oral carbohydrate loading 
The main objective of preoperative CHO loading is to cause an alteration in metabolism that 
usually takes place when a patient consumes a light meal – prompting an endogenous insulin 
release that switches the metabolism from the fasted to the fed state. A 50 g CHO load causes a 
severe rise in total body insulin sensitivity (approximately 50%) with a marked increase in glucose 
absorption and a decrease in glucose production.17 After the consumption of the CHO beverage, 
the metabolism is in a CHO storing state (anabolism), and when the stress of the surgery occurs, 
there are mediators released to act in the opposite direction shutting off glucose absorption in 
muscle and increasing glucose production.17 If the patient is pretreated with a CHO beverage, the 
starting point for these reactions are much more anabolic and hence, the stress results in a lower 
catabolic setting compared with when the patient already has a starting point towards the catabolic 
state by being fasted overnight.  
Numerous studies have shown positive outcomes for POCL with regards to clinical outcomes and 
patient well-being.16,74,119-122,164,183 POCL results in approximately 50% less pronounced insulin 
resistance.184-186 Muscle function is improved by enhanced protein metabolism after surgery by 
losing less muscle mass and improved muscle strength.187,188 Protein breakdown after surgery may 
be reduced through enhanced insulin action by POCL.189 Improved nitrogen balance is also 
observed following POCL.189 The change in metabolism due to POCL results in a shorter length of 
stay.5 The depression of the immune system that takes place in response to surgery is also 
limited.190 Thirst is the primary outcome improved by giving oral CHO preoperatively.17 Other 
preoperative discomforts like hunger, anxiety, nausea and vomiting are also reduced when POCL 
is given.191,192 See figure 1.4 for the potential benefits of preoperative oral CHO treatment. 





Figure 1.4: Potential benefits of preoperative oral carbohydrate treatment 
1.5 ENHANCED RECOVERY AFTER SURGERY 
1.5.1 ERAS history  
Enhanced Recovery After Surgery (ERAS) is a multimodal perioperative care pathway designed to 
achieve early recovery for patients undergoing surgery.193 Although fast-track surgery was the first 
term used to describe this concept, it was misleading and placed too much focus on faster 
discharge rather than focusing on the patient’s recovery. The term ERAS is now an acknowledged 
term in the medical literature.193 ERAS is not just a term for a protocol but a continuous movement 
to develop and improve perioperative care pathways. The ERAS Society has its roots in what was 
called the ERAS Study Group in 2001, comprisingof a group of surgeons. The intention of the 
group was to develop the optimal perioperative care pathway by means of literature review and 
adaption of traditional treatment to optimise patient care since there were a variety of traditions in 
use in different hospitals and there was great discrepancy between the actual practices and what 
was already known to be best evidence based practice.   
The ERAS Study Group developed and published their first guidelines on elective colonic surgery 
in 2005, with the elective rectal/pelvic surgery guidelines following in 2009. The international 
collaboration, together with expanding interest in the ERAS concept, made the ERAS Study Group 
decide to take this experience to the next level by forming the ERAS Society in Stockholm, 
Sweden in 2010. The ERAS Society is a multiprofessional, multidisciplinary collaboration with the 
aim to improve perioperative care through research and education as well as the implementation of 
best evidence-based practice. The colonic and rectal/pelvic surgery guidelines were updated in 
attenuate anabolic metabolism 
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↓ postoperative complications 
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preservation of muscle mass 
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↓ inflammatory markers 
↓ length of stay 
↑ well-being 
↓ fatigue 




2012; the pancreaticoduodenectomy and cystectomy guidelines followed in 2013; gastrectomy 
guidelines were published in 2014, gastrointestinal guidelines published in 2015, and gynaecologic 
guidelines published in 2016. The ERAS Society collaborates with national and international 
medical societies. The network of centres involved in the development of perioperative care 
expanded rapidly with centres of excellence in more than 15 countries in Europe, Australia, and 
North and South America. Africa opened its first centre of excellence in Cape Town, South Africa in 
2015.  
1.5.2 ERAS principles and recommendations 
ERAS represents a paradigm shift in perioperative care in two ways: Firstly, it re-examines 
traditional practices and replaces them with evidence-base best practices; secondly, it is 
comprehensive in its scope covering all areas of the patient’s journey through the hospital. The 
mission of ERAS is to develop perioperative care and to improve recovery through research, 
implementation of evidence-based practices, and audit education. See Figure 1.5 for the patient’s 






Figure 1.5: The patient’s journey through the hospital
193
 
The ERAS Protocol is the evidence-based care protocol developed by the ERAS Society. The 
protocol describes the perioperative care pathway with recommendations for patient care at 
various steps in the perioperative process (Table 1.13).193 The ERAS Protocol has to involve the 
entire team, including surgeons, anaesthetists, intensivists, nurses, dietitians, physiotherapists and 
psychologists when necessary.  The ERAS team forms the basis of the implementation, 
maintenance, sustainability and further development of the ERAS Protocol.  The ERAS 
Implementation Programme (EIP) is a specific training programme designed and customised for 
the ERAS care team to implement the ERAS Protocol. The EIP focuses on building well-
functioning teams from various units involved in surgical care, introducing highly specific changes 
to current routines to conform to best-practice, and providing the tools to monitor and analyse the 
effects of those changes (Figure 1.6).193 The ERAS Interactive Audit System (EIAS) is an online 
software tool used to enter patient data related to the patients’ journey as well as to ensure that all 
members of the team conform to the standard ERAS care procedure. The tool consists of two 
parts: EIAS Data Entry – a module for entering patient data following the patients’ journey through 
the perioperative phase; EIAS Analysis and Report – focused on quality of life for patients by 
INTEGRATED ERAS PROTOCOL 
CLINIC PREOP INTRAOP POSTOP WARD HOME 
PRE / INTRAOPERATIVE ENHANCEMENT POSTOPERATIVE RECOVERY 
CONTINUOUS AUDIT OF OUTCOMES AND COMPLIANCE 




monitoring the rate of complications and length of stay. EIAS becomes a crucial support in the daily 
decision-making process and an important quality assurance tool.  
Table 1.13: Components of the ERAS Protocol 
Preoperative Intraoperative Postoperative 
 Preadmission counselling 
 Fluid and carbohydrate 
loading 
 No prolonged fasting 
 No/selective bowel 
preparation 
 Antibiotic prophylaxis 
 Thromboprophylaxis 
 No premedication 
 Short-acting anaesthetic 
agents 
 Mid-thoracic epidural 
anaesthesia/analgesia 
 No drains 
 Avoidance of salt and water 
overload 
 Maintenance of 
normothermia (body 
warmers / warm intravenous 
fluids) 
 Mid-thoracic epidural 
anaesthesia/analgesia 
 No nasogastric tubes 
 Prevention of nausea and 
vomiting 
 Avoidance of salt and water 
overload 
 Early removal of catheter 
 Early oral nutrition 
 Non-opioid oral 
analgesia/NSAIDs 
 Early mobilisation 
 Stimulation of gut motility 
Audit of compliance and outcomes 




Figure 1.6: Goals of the ERAS Implementation Programme 
The ERAS Society, in collaboration with other medical societies, reviews and updates literature for 
novel guidelines in different surgical procedures including colonic, rectal/pelvic, pancreatic, 
bladder, gastric, gastrointestinal and gynaecologic surgery.194-202 Existing guidelines are 
continuously updated, and the guidelines must also be evaluated to confirm whether the 
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novel guidelines constructed by the expert groups, and after evaluation in a single centre study, it 
was confirmed that the outcomes were improved substantially when the ERAS Protocol was 
followed.194 The intention is to complete the same studies in different surgical procedures as well 
as in multicentre studies using the EIAS. Expert groups are working on a wide range of procedures 
to include in the future (including breast and reconstructive surgery, head and neck cancer, 
thoracic surgery, hepatobiliary surgery and orthopaedic surgery). 
1.5.3 ERAS nutrition guidelines  
Optimal nutrition forms an integral part of the ERAS Protocol (Table 1.14).13 Preoperative 
optimisation is a crucial step in preparation for surgical procedures and should be used to identify 
patients at risk for morbidity and mortality.195 Therefore, preoperative screening and assessment is 
of utmost importance to identify patients at risk of malnutrition. Malnutrition is an independent risk 
factor for poor outcomes, and has been associated with increased morbidity after surgery. These 
malnourished patients should receive supplementation. The oral and enteral route seems to be the 
first choice with parenteral nutrition warranted in cases where enteral nutrition has failed.203 There 
is no conferred benefit of supplementation in patients who are not at risk of malnutrition.203 The 
ERAS Society recommends an intake of solids up to 6 hours before surgery and clear fluids up to 2 
hours before surgery.194-202 POCL should be used routinely. The clinical effectiveness of POCL as 
a routine practice in diabetic patients has yet to be established. However, when CHO treatment is 
given with normal diabetic medication, gastric emptying seems to be normal.204 In patients where 
gastric emptying may be delayed specific safety measures should be used at the induction of 
anaesthesia. Postoperative gum chewing has been shown to be safe and beneficial in reducing 
time to first bowel movement after gastrointestinal surgery.205 Normal food intake is the basis for 
nutrition before and after surgery for most patients according to the ERAS recommendations. 
Addition of ONS can improve overall intake to meet nutrition requirements. Postoperative patients 
can drink immediately after recovery from anaesthesia and progress to eating normal food 
spontaneously as soon as possible. Early feeding reduces the risk of infection and length of stay, 
and is not associated with an increased risk of anastomotic breakdown; however, the risk of 
nausea increases without associated vomiting.206,207 Immunonutrition has been investigated 
extensively in surgery patients but conclusions are difficult to make since the route of 
administration (i.e. enteral versus parenteral) is not comparable, patient populations are 
heterogeneous (i.e. different surgical procedures), at different time periods (i.e. pre- and/or 
postoperative), in different combinations (i.e. single versus combination), in different dosages, and 
compared with control groups that are not always isonitrogenous. Therefore, further trials should 
be conducted in modern perioperative settings and with single immune enhancing products. The 
ERAS recommendations based on nutrition per surgical procedure are presented in Table 1.15.194-
202  
 




Table 1.14: Perioperative nutrition interventions as recommended by the ERAS society 















Screening Limited fasting  




Early intake without restriction 
Assessment Chewing gum 




Immunonutrition   
(formula/dose/timing) 











Table 1.15: ERAS recommendation related to nutrition per surgical procedure 
COLONIC SURGERY
194 
Item Recommendation Evidence Level Recommendation grade 
Preoperative optimisation Patients should be screened for nutritional status and if at risk of under nutrition given 
active nutrition support  
extrapolated strong 





Oral carbohydrate treatment should be used routinely. In diabetic patients treatment can 
be given along with the diabetic medication. 
low (routine) 
very low (diabetic) 
strong (routine) 
weak (diabetic) 
Chewing gum Chewing gum can be recommended. moderate strong 
Early oral intake Patients should be encouraged to take normal food as soon as lucid after surgery. high strong 
Oral nutrition supplements ONS may be used to supplement total intake. low strong 
Immunonutrition IN could be considered in open colonic resection. low weak 
RECTAL/PELVIC SURGERY
195 
Item Recommendation Evidence level Recommendation grade 
Preoperative optimisation Specialised nutrition support should be considered for malnourished patients. extrapolated strong 





Oral carbohydrate loading should be administered to all non-diabetic patients. low to moderate strong  
Chewing gum Approach to optimising gut function should include chewing gum. moderate strong 
Early oral intake An oral ad-libitum diet four hours after surgery. moderate strong 
Oral nutrition supplements In addition to normal food intake, ONS should be offered to maintain adequate intake of 
protein and energy. 
low strong 
Immunonutrition No recommendation. none none 
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Item Recommendation Evidence level Recommendation grade 
Preoperative optimisation Routine use of artificial nutrition is not warranted; malnourished patients should be 
optimised with ONS or enteral nutrition. 
very low weak 
Preoperative fasting Intake of clear fluids up to two hours and solids up to six hours prior to induction of 
anaesthesia. 
low to high strong 
Preoperative treatment 
with carbohydrates 
Oral carbohydrate loading should be administered to all non-diabetic patients. low strong  
Chewing gum Chewing gum is safe and may accelerate gastrointestinal transit. low weak 
Early oral intake Patients should be allowed a normal diet after surgery without restrictions; cautioned to 
begin carefully and increase intake according to tolerance over three to four days; 
enteral tube feeding should be given only on specific indication and parenteral nutrition 
should not be employed routinely. 
moderate strong 
Oral nutrition supplements 
Immunonutrition IN for five to seven days perioperatively should be considered. moderate weak 
BLADDER SURGERY
197 
Item Recommendation Evidence level Recommendation grade 
Optimisation Specialised nutrition support should be considered for malnourished patients. extrapolated strong 





Oral carbohydrate loading should be administered to all non-diabetic patients. extrapolated strong  
Chewing gum Optimisation of gut function should involve gum. moderate strong 
Early oral intake Early oral nutrition should be started four hours after surgery. extrapolated strong 
Oral nutrition supplements No recommendation. none none 
Immunonutrition No recommendation. none none 
GASTRIC SURGERY
198 
Item Recommendation Evidence level Recommendation grade 
Preoperative optimisation Routine use of artificial nutrition is not warranted; malnourished patients should be 
optimised with ONS or enteral nutrition. 
very low strong 
Preoperative fasting Intake of clear fluids up to two hours and solids up to six hours prior to induction of 
anaesthesia. 
low to high strong 
Preoperative treatment 
with carbohydrates 
Oral carbohydrate loading should be administered to all non-diabetic patients. extrapolated strong  
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Chewing gum No recommendation. none none 
Early oral intake Patients undergoing total gastrectomy should be offered drink and food at will from 
postoperative day one; they should be advised to begin cautiously and increase intake 
according to tolerance. Patients clearly malnourished or those unable to meet 60% of 










Oral nutrition supplements 
Immunonutrition The benefit shown for major gastrointestinal cancer surgery in general has not been 
reproduced in dedicated trials on patients undergoing gastrectomy; although benefit 




Item Recommendation Evidence level Recommendation grade 
Preoperative optimisation Optimisation of nutritional status should follow international guidelines. none none 
Preoperative fasting Intake of clear fluids should be allowed until two hours before induction of anaesthesia. 




Preoperative treatment with oral carbohydrates should be routinely administered except 
in patients with documented delayed gastric emptying or slow gastrointestinal motility 
and as well as in patients undergoing emergency surgery.  
 strong  
(routine use) 
weak (diabetic/obese) 
Chewing gum Recommended to improve stimulatory effect. unknown unknown 
Early oral intake Recommended for the anabolism, stimulatory effect and to decrease insulin resistance. unknown unknown 
Oral nutrition supplements No recommendation.  none none 
Immunonutrition No recommendation. none none 
GYNAECOLOGIC/ONCOLOGY SURGERY
201,202 
Item Recommendation Evidence level Recommendation grade 
Preoperative optimisation No recommendation. none none 
Preoperative fasting Clear fluids should be allowed up to two hours and solids up to six hours prior to 




Carbohydrate loading reduces postoperative insulin resistance and should be used 
routinely. 
moderate strong 
Chewing gum The use of chewing gum should be considered. moderate weak 
Early oral intake A regular diet within the first 24 hours after surgery is recommended. high strong 
Oral nutrition supplements No recommendation. none none 
Immunonutrition No recommendation. none none 
* ONS = Oral nutrition supplements; IN = Immunonutrition 
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The problem with trials comparing ERAS with traditional care is that it is very hard to blind the 
studies; hence, the level of the evidence cannot be the highest. There is no uniformity in the 
elements that are actually tested since some investigators may see certain elements as standard 
while others do not. The ERAS guidelines use the Grade of Recommendation, Assessment, 
Development and Evaluation (GRADE) system for rating the level of the evidence and the strength 
of the recommendation.1   
The GRADE system for rating quality of evidence:  
 high quality: further research is unlikely to change the confidence in estimate effect, 
 moderate quality: further research is likely to have an important impact on the confidence in 
estimate of effect,  
 low quality: further research is very likely to have an important impact on the confidence in 
estimate of effect, 
 very low quality: any estimate of effect is very uncertain. 
GRADE system for rating strength of recommendation: 
 strong: when desirable effects of the intervention clearly outweigh the undesirable effects, 
or clearly do not, 
 weak: when trade-offs are less certain – either because of low quality evidence or because 
there is a balance between the desirable and undesirable effects. 
Despite the drawbacks of the methodology, it does become evident that ERAS Protocols have 
major benefit for outcomes. 
1.5.4 Benefits of ERAS 
The mechanism behind the effectiveness of the ERAS Protocol can be attributed to the reduction 
in metabolic stress and maintenance of fluid homeostasis to reduce the length of stay in the 
hospital as well as complications associated with surgery. A recent meta-analysis showed that 
ERAS protocols in major surgery reduced recovery time and length of stay by two to three days 
and complications by 30 to 50%.208 The development of insulin resistance as a consequence of the 
stress of surgery sets off a catabolic response where all parts of the metabolism are disrupted.193 
Protein is being lost from the muscles, causing loss of muscle mass and decreased strength, 
resulting in difficulty in mobilisation. Further hyperglycaemia develops, which is associated with 
increased postoperative complications. By reducing metabolic stress and insulin resistance, protein 
and energy consumed will be utilised in an anabolic fashion, hyperglycaemia can be prevented, 
and lean body mass can be conserved to promote early mobilisation. Figure 1.7 shows the 
influence of ERAS versus traditional care on insulin sensitivity.15 
 





ERAS = enhanced recovery after surgery; iv = intravenous; NPO = nil per os, prep = preparation  




Fluid homeostasis also plays an important role in the recovery process since fluid overload results 
in a delayed return of bowel function as well as postoperative complications. The literature on the 
effect of ERAS on the quality of life is heterogeneous since health-specific quality of life 
instruments for perioperative care are unavailable and investigators use generic quality of life 
instruments or instruments developed for certain specific diagnosis. There is limited evidence on 
the cost benefit of ERAS but the fact that it reduces the incidence of complications and decrease 
length of stay in the hospital, it indirectly lends itself to support the cost benefit.194 Interventions like 
the ERAS concept are prone to show significant Hawthorne or trial effects, meaning that the 
collateral effect on the infrastructure and management culture to implement such a comprehensive 
programme will have beneficial consequences in addition to those caused by the protocol items 
themselves or their synergistic effect.209 Nevertheless, there is a benefit to the use of the ERAS 
concept (Figure 1.8).194-202 However, further multicentre and multinational research is required to 
validate and unify the overall benefits of the comprehensive ERAS protocol. 





Figure 1.8: Potential benefits of the ERAS protocol
194-202
 
1.6 MOTIVATION FOR THE STUDY 
Evidence-based medicine (EBM) is an important focus in health care since it provides the potential 
for healthcare practitioners to close the gap between theory and practice.11 A systematic review is 
a complete collection and objective analysis of all available relevant studies in a specific area to 
answer a specific question; whereas a meta-analysis is the use of statistical methods to summarise 
the results of independent studies.210 Both systematic reviews and meta-analyses are used in EBM 
since they allow for standardised methods of compiling evidence in a systematic approach. 
According to the quality of evidence, systematic reviews of randomised controlled trials are the 
best quality of evidence available with meta-analyses ranked as very strong evidence.211  
The concept of evidence-based nutrition (EBN) can be defined as the application of the best 
available systematically assembled evidence in setting nutrition policy and practice.212 A 
tremendous need arose for the massive volume of research to be compact, accessible, and able to 
be applied by healthcare practitioners. Nutrition is an evolving paradigm in the medical field and is 
in definite need for evidence-based guidelines. Nutrition guidelines can be developed based on a 
systematic review of the relevant scientific literature to ensure that the available scientific evidence 
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is accurately reflected. Guidelines based on evidence have led to improved performance and 
better outcomes.11 From a nutritional point of view, it is our duty to advocate optimal nutrition for all 
and to emphasise the implementation of best clinical practice accordingly to EBN.  
Inappropriate preoperative fasting is a subject that necessitates attention. Virtually all patients for 
elective surgery are admitted a few days in advance, and the medical personnel still write ‘NPO 
from midnight’ on the patient’s chart. This practice was established by tradition, and traditions are 
not easy to break. Bridging the gap between evidence-based medicine and its implementation in 
practice is of utmost importance in refining the quality of care and improving patient safety.11 
Quality of care is seen as the element that can most increase the possibility of positive 
outcomes.213 The importance of this challenge is clear, since the quality of health care provided will 
increase patient well-being and in return, provide increased clinical outcomes, less discomfort and 
cost reductions for the patient and healthcare system.13  
Recent insight taught us that together with surgical techniques, metabolic control is as important to 
achieve optimal patient care – therefore nutrition care should be seen as an integral part of the 
optimal management of the surgical patients.15 Nutrition is no substitute for poor surgery or 
anaesthesia or shortcomings in other aspects of care. Optimisation of the metabolic state prior to 
major surgery, however, leads to improved surgical outcomes. Strategies to minimise 
hyperglycaemia and insulin resistance by aggressive preoperative nutrition and CHO loading may 
promote maintenance of a perioperative anabolic state, improving healing, reducing complications, 
and shortening the time to recovery of bowel function and hospital discharge. The ERAS concept 
establishes a multiprofessional and multidisciplinary approach toward patient care with regards to 
evidence that aims to form a platform to simplify communication, enhance novel treatments, 
update and implement guidelines. One of the main nutrition-related elements of the ERAS 
recommendations is that CHO-containing clear fluids should be allowed up to two hours prior to the 
induction of anaesthesia.193  
POCL has been introduced, but has not, so far, been widely implemented into clinical practice. 
Several systematic reviews have been done on this topic – published between 2010 and 2015, 
which included studies up to 2014.16,74,119-122,164,183 Lately, several studies have been published 
examining the effects of POCL in different elective surgical situations and the results have been 
conflicting with some showing benefit and others no benefit. A systematic review on this topic will 
give the investigator an opportunity to explore the question once more by summarising the latest 
available data up to 2015 with the aim of motivating healthcare practitioners to believe in the 
intervention. The results will help facilitate the implementation of up-to-date guidelines for 
healthcare practitioners to reach the therapeutic goal for the patient of rapid recovery to normal 
function and well-being, the minimum complications and early discharge home. POCL provides a 




simple and practical intervention, reflecting good clinical practice and economics that may improve 
the outcome for many elective surgery patients.  
It is often said that it takes up to 15 years for a proven medical treatment to become common 
practice – this shows how hard it is to move evidence into practice.193 Implementing the ERAS 
concept in a hospital requires commitment since it involves changing the way some things have 
been done in the past. The first clinical centre of excellence in Africa was opened in Cape Town, 
South Africa in 2015 and may aid in the implementation of the concept on the African continent. In 
collaboration with the ERAS recommendations, this systematic review will be used to emphasise 
the importance of the modern fasting guidelines in the clinical setting with regards to biochemistry 
and clinical events, length of stay, adverse events and patient wellbeing.  The focus will be to 
advocate evidence-based nutrition through changing guidelines as part of the ERAS concept by 
decreasing prolonged fasting and implementing POCL into practice.  
  














CHAPTER 2: METHODOLOGY 
  




2.1 STUDY OBJECTIVES 
2.1.1 Purpose of the study 
This systematic review assessed the effects of providing preoperative oral CHO treatment 
compared to standard fasting, placebo treatment, a combination of oral CHO treatment and IV 
fluids, and/or IV CHO administrations in adult patients undergoing elective surgery in terms of 
perioperative complications.  
2.1.2 Specific objectives 
The primary objectives of this review were to examine the effect of preoperative oral CHO 
treatment in adult patients on: 
 biochemistry and clinical events 
 length of stay 
 adverse events  
(Meta-analysis) 
The secondary objectives were to briefly describe the effects of preoperative oral CHO treatment in 
adult patients with regards to other patient-reported psychosomatic perioperative events. 
(Descriptive approach) 
2.2 CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW 
2.2.1 Types of studies 
All RCTs that compared the effect of preoperative oral CHO treatment to standard fasting, placebo 
treatment, a combination of oral CHO treatment and IV fluids, and/or IV CHO administration were 
included. Trials were included regardless of the lack of blinding or placebo treatment. All other less 
robust study designs and publication types (including quasi-controlled trials, abstracts, comments, 
review articles, editorials and letters) and unpublished data were excluded. Cross-over trials were 
also excluded as this methodology is not suitable for evaluating an intervention that must be given 
at a specific point in time. 
2.2.2 Types of participants 
Participants included were male and female human adult patients1 undergoing elective surgery2 
and receiving general and/or spinal or epidural anaesthesia3. This review included trials that 
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 Anaesthesia is the loss of the ability to feel pain; caused by the administration of a drug or other medical interventions. 
General anaesthesia is the induction of a balanced state of unconsciousness, accompanied by the absence of pain 
sensation and the paralysis of skeletal muscle over the entire body; produced by the administration of anesthetic agents 
by inhalation, intravenously, intramuscularly, rectally or via the gastrointestinal tract. Spinal anaesthesia is a regional 
anaesthesia caused by injection of a local anesthetic into the subarachnoid space around the spinal cord. Epidural 
anaesthesia is a regional anaesthesia caused by the injection of a local anesthetic into the extradural space, either 
between the vertebral spines or into the sacral hiatus.
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evaluated the evidence of high-risk anaesthetic patients4; however this review excluded patients 
with diabetes mellitus type 1 and type 25, patients with abnormal blood glucose values prior to 
surgery6, patients with insulin resistance syndrome7, and emergency non-elective cases.   
2.2.3 Types of interventions  
Figure 2.1 shows the types of interventions employed in the studies reviewed. The experimental 
intervention consisted of a CHO-rich beverage for oral consumption containing ≥ 12% (45 g) CHO 
to achieve a rise in insulin levels to change the metabolism from a fasted to a fed state, and a low 
osmolality (< 300 mOsm/kg) to move through the stomach fast enough to ensure that it is perfectly 
safe to use preoperatively. Trials were eligible if the oral CHO treatment was administered within 
the following dosage and time: 400 ml within 90–300 minutes (1.5–5 hours) before the induction of 
anaesthesia (with or without 800 ml the evening before surgery). Co-interventions [≥ 12% (45 g) 
CHO beverages with different macronutrient profiles] were also eligible for inclusion in the 
systematic review. 
The systematic review focused on the safety and effects of giving oral CHO treatment before 
elective surgery compared to inactive controls [standard fasting i.e. no oral intake for 6–8 hours 
before the induction of anaesthesia, and a placebo consisting of a beverage containing < 12% 
(45 g) CHO] and an active control (IV fluids containing ≥ 12% CHO). The inactive control groups 
may have received IV fluid therapy during the five hours before surgery start time as long as the 
total combined dose of CHO given remained <12% (45 g). 
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 High-risk anaesthetic patients include: pregnant (second trimester or later), postpartum, obese, elderly and those 




 Criteria used for diagnosis of diabetes mellitus are as follows: symptoms of diabetes mellitus plus random plasma 
glucose > 11.1 mmol/l (200 mg/dl) OR fasting plasma glucose >7.0 mmol/l (126 mg/dl) OR 2-hour plasma glucose 




 Normal Glucose Values: fasting plasma glucose of 4.0 – 5.6 mmol/l (72 – 100 mg/dl) and 2-hour post prandial value 




 Insulin Resistance Syndrome: fasting plasma glucose between 6.5 – 7.0 mmol/l (100 – 126 mg/dl) and two-hour post-
prandial values of 7.8 – 11.1 mmol/l (140 – 200mg/dl) during the oral glucose tolerance test. 
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Figure 2.1: Type of interventions 
2.2.4 Types of outcome measures 
2.2.4.1 Primary outcomes 
The primary outcomes of this review were to examine the effect of preoperative oral CHO 
treatment in adult patients on:  
 Biochemistry and clinical events (glucose, insulin, insulin resistance, intestinal function, 
protein status, immune response) 
 Length of stay (intensive care unit, hospital) 
 Adverse events (regurgitation, aspiration and any related morbidity or mortality) 
2.2.4.2 Secondary outcomes 
The secondary outcomes were to briefly describe the effect of preoperative oral CHO treatment in 
adult patients with regards to other perioperative events (patient-reported psychosomatic 
outcomes): 
 Discomfort/wellbeing (including thirst, hunger, nausea, vomiting, anxiety, pain) 
 Fatigue (including weakness, tiredness, malaise) 
Oral beverage containing  
≥ 12% (45 g) CHO 
[Oral CHO group] 
PLACEBO 
Oral beverage containing  
< 12% (45 g) CHO ± IV fluids 
INTRAVENOUS CHO 
IV fluids containing  
≥ 12% (45 g) CHO 
 
STANDARD FASTING 
No oral intake ± IV fluids  
Containing < 12% (45 g) CHO 




2.3 SEARCH METHODS FOR IDENTIFICATIONS OF STUDIES 
2.3.1 Data sources 
Several electronic databases were searched from inception up to May 2015 to locate articles for 
inclusion in the systematic review. The electronic search included the following major databases to 
identify potential citations: 
 Pubmed - MEDLINE  
 Cochrane Library, including: 
o Cochrane Database of Systematic Reviews (CDSR; Cochrane Reviews) 
o Cochrane Central Register of Controlled Trials (CENTRAL; Clinical Trials) 
o Database of Abstracts of Reviews of Effects (DARE; Other Reviews) 
 EBSCO Host, including: 
o Academic Search Premier  
o Cumulative Index to Nursing & Allied Health Literature (CINAHL) 
o Africa Wide 
o CAB Abstracts 
 ISI Web of Knowledge – Web of Science 
 Scopus Abstracts  
 ProQuest Medical Library 
 Science Direct  
 Springerlink 
 Google Scholar 
 SABINET 
In addition, reference lists from relevant studies were reviewed and personal files searched to 
identify additional publications. Unpublished trials were searched using “Dissertations Abstracts 
International”, “Database of African Theses and Dissertations” and “Proceedings First”. Databases 
of ongoing trials (such as Current Controlled Trials, Clinical Trials.gov and the World Health 
Organization’s Clinical Trials Registry Platform) were also searched and documented so that when 
this review is updated, these trials can be assessed for possible inclusion (see Chapter 5). 
2.3.2 Keywords for searching 
The above-mentioned databases were searched using specific search strategies identified with the 
assistance of a qualified healthcare librarian with experience in systematic reviews. English 
language restriction was not placed on the searches. The research period was not restricted to 
include all relevant studies. The latest version of the citations was included. 
  




The following keywords and strings were compiled and searched: 
1. preoperative 












14. 1 AND 2 
15. 1 AND 2 AND (3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10) 
16. 1 AND 2 AND (3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10) AND 11 
17. 1 AND 2 AND (3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10) AND 11 AND 12 
18. 1 AND 2 AND (3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10) AND 11 AND 12 AND 13 
19. 1 AND 2 AND 11 
20. 1 AND 2 AND 11 AND 12 
21. 1 AND 2 AND 11 AND 12 AND 13 
[* all terms beginning with this root was searched (e.g. searching with the root load will included 
terms such as loads, loading and loaded).] 
2.4 DATA COLLECTIONS AND ANALYSIS 
2.4.1 Selection of studies 
The selection of studies was divided into three separate phases (Figure 2.2). Phase 1 was 
conducted by the investigator with the assistance of a healthcare librarian to implement the initial 
search for studies, applying the relevant resources and search strings (Table 2.1). The initial 
search used very broad search criteria and was purposefully not very specific to allow the 
maximum number of potentially relevant studies to be identified. After the initial screening process, 
further assessment (phase 2) based on pre-specified inclusion and exclusion criteria (Table 2.2) 
was applied to the titles and abstracts of all the studies for inclusion in the systematic review. The 
titles and abstracts were examined by the investigator and independent reviewer for inclusion of 
eligible studies. If there was insufficient information in the title and abstract, the full text article was 
obtained for clarification. All searches failing to meet the inclusion criteria were excluded. The full 




text articles of all potentially eligible studies were retrieved by the investigator. Studies were 
excluded if no full-text article was available. Multiple reports of the same study were linked 
together, and data were included only if multiple publications of the same study existed or if 
multiple studies presented the same data from the same participant. Phase 3 consisted of the 
investigator and independent reviewer examining the full text articles for compliance of studies with 
the eligible criteria using a pilot-tested eligibility form (Appendix 6.1). Eligibility was assessed so 
that the first ‘no’ response was used as the primary reason for exclusion of the study. The 
reference lists of review articles were reviewed to ensure that all eligible studies were included. 
The reviewer was a registered dietitian trained by the investigator in terms of the methodological 
processes of a systematic review. The investigator was knowledgeable in the area under review, 
but the independent reviewer was not a content expert. The review process was blinded (the 
investigator and reviewer independently reviewed the articles) to ensure that all eligible studies 
were included. Differences of opinions were settled by a discussion between the investigator and 
the reviewer, or arbitration by a third person (one of the review authors).  
  










Applied resources and search strings (librarian + investigator) 
 
 
Examined titles and abstracts (investigator + reviewer) 
Applied inclusion and exclusion criteria (investigator + reviewer) 
*excluded irrelevant studies 
 
 
Retrieved full text of potentially relevant studies (investigator) 
*excluded studies if no full text available 
 
 
Linked together multiple reports of the same study (investigator) 
    
 
Examined full text articles for compliance of studies with eligibility criteria (investigator + reviewer) 
























COMPILED A LIST OF INCLUDED AND EXCLUDED STUDIES 
(Investigator) 
 
DATA EXTRACTION AND ASSESSMENT OF RISK OF BIAS 
(Investigator and reviewer) 
 
META-ANALYSIS/DESCRIPTIVE STATISTICS 
(Investigator and statistician) 
 
SELECTION OF STUDIES 
(Investigator, librarian and reviewer) 
 




Table 2.1: Initial search criteria (Phase 1) 
Study participants Human adults 
Study intervention Oral CHO treatment and related terms 
Study design Randomised controlled trials 
Language All 
Search period All 
 
Table 2.2: Inclusion and exclusion criteria (Phase 2) 
Inclusion criteria Exclusion criteria 
Human studies Animal studies 
Adults (≥ 18 years) Neonates, paediatric patients, adolescents  
Male and female None 
Experimental interventions includes patients receiving 
CHO treatment: 
 Oral consumption 
 CHO content ≥ 12% (12 g/100 ml); ≥ 45 g 
 < 300 mOsm/kg osmolality 
 800 ml the evening before surgery plus another 
400 ml 90–300 minutes before the induction of 
anaesthesia, or only 400 ml 90–300 minutes before 
the induction of anaesthesia 
 Beverages (complying to above mentioned inclusion 
criteria) with different macronutrient profiles 
Criteria not considered in the inclusion criteria 
Control interventions includes patients receiving the 
following: 
 no oral intake for 6–8 hours before the induction of 
anaesthesia with or without additional IV fluids 
containing < 12% CHO (standard fasting) 
 oral CHO beverage containing < 12% CHO with or 
without additional IV fluids (placebo) 
 IV fluids containing ≥ 12% CHO (IV CHO) 
Criteria not considered in the inclusion criteria 
Low and high risk anaesthetic patients  None  
Normal blood glucose values (before surgery): fasting 
plasma glucose of 4.0–5.6 mmol/l (72–100 mg/dl) and 2-
hour post prandial value < 7.8 mmol/l (140 mg/dl) 
Diabetes Mellitus Type 1 and 2 
Abnormal blood glucose values prior to surgery,  
insulin resistance syndrome 
Elective Surgery Cases Emergency cases  
No surgery 
All studies reporting on 1 or more of the following: 
 Glucose 
 Insulin 
 Insulin resistance 
 Hyperglycaemia 
 Intestinal function (flatus/movement) 
 Muscle function 
 Muscle strength 
 Muscle mass 
 Lean body mass 
 Nitrogen balance 
 Total body protein 
 Immune response 
 Length of intensive care unit stay 
 Length of hospital stay 
Outcomes not considered in the objectives 




Inclusion criteria Exclusion criteria 












 Weakness  
 Tiredness 
 Malaise 
English language studies Foreign language studies 
Randomised controlled trials All other study designs and publication types: 
 Cross-over trials 
 Quasi-randomised controlled trials 
 Review articles 
 Unpublished trials 
 Abstracts/editorials/comments/letters 
Full text available of the study  Unavailable full text of the study 
2.4.2 Data extraction and management 
Details of the eligible studies were independently extracted by the investigator and a reviewer. The 
investigator was knowledgeable in the area under review, but the independent reviewer was not a 
content expert. The reviewer was trained regarding the data extraction process. A data extraction 
form was designed following the Cochrane Collaboration’s checklist of items.216 The data extraction 
form was pilot tested; after consensus had been reached between the review authors, the form 
was modified as required (Appendix 6.2). For trials that were published more than once, the data 
extraction utilised all sources to retrieve the maximum amount of data and the information was 
reported directly onto a single data extraction form. The review authors were not blinded to 
information in an article and had access to all the information. Disagreement between the 
investigator and reviewer were resolved by discussion, arbitration by a third party, or by contacting 
the study authors. No disagreements were unresolved.  
2.4.3 Assessment of risk of bias in included studies 
The risk of bias was assessed based on the updated domain-based evaluation, ‘Cochrane risk of 
bias assessment tool’ (Table 2.3).217 Assessment of risk of bias forms (Appendix 6.3) were 
completed for each eligible study to critically assess the different domains. Each of the domains 
had a description and received a judgement of ‘low risk of bias’, ‘high risk of bias or ‘unclear risk of 
bias’. The data was entered into the Review Manager 5.3 (RevMan 5.3) software program, and a 
risk of bias table was completed for each study to generate a risk of bias graph and/or summary 
figure. The overall risk of bias of all included studies were assessed and included in the review as 




part of ‘table of characteristic of included studies’ (see Chapter 3), and the overall outcomes is 
addressed in the results of included studies (see Chapter 3).  
The investigator and one reviewer assessed the risk of bias of all eligible studies independently. 
The reviewer was trained in collecting information for assessments of risk of bias. The risk of bias 
tool was pilot tested by the investigator and reviewer prior to assessment to ensure consistency 
and consensus. Blinded assessment did not take place as this method is time consuming and the 
articles were well-known to the investigator. Disagreement was resolved by consensus and/or 
arbitration by a third person (one of the review authors). The authors of studies with incomplete 
reporting were contacted, and open-ended questions were used to avoid the risk of overly positive 
answers. Data was documented as ‘not reported’ if the authors of the studies did not respond.  
Table 2.3: Domains assessed in the Cochrane Risk of Bias Tool217 
Domain Description Judgement 
Sequence generation Describe the method used to 
generate the allocation sequence in 
sufficient detail to allow an 
assessment of whether it should 
produce comparable groups. 
Was the allocation sequence adequately 
generated? 
Allocation concealment Describe the method used to conceal 
the allocation sequence in sufficient 
detail to determine whether 
intervention allocations could have 
been foreseen in advance of, or 
during, enrolment.  
Was allocation adequately concealed? 
Blinding of participants, personnel 
and outcomes 
Describe all measures used, if any, 
to blind study participants and 
personnel from knowledge of which 
intervention a participant received. 
Provide any information relating to 
whether the intended blinding was 
effective.  
Was knowledge of the allocated 
intervention adequately prevented during 
the study? 
Incomplete outcome data Describe the completeness of 
outcome data for each main 
outcome, including attrition and 
exclusions from the analysis. State 
whether attrition and exclusions were 
reported, the numbers in each 
intervention group (compared with 
total randomised participants), 
reasons for attrition/exclusions where 
reported, and any re-inclusions in 
analyses performed by the review 
authors. 
Were incomplete outcomes data 
adequately addressed? 
Selective outcome reporting State how the possibility of selective 
outcome reporting was examined by 
the review authors, and what was 
found.  
Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Other sources of bias State any important concerns about 
bias not addressed in the other 
domains in the tool. 
Was the study apparently free of other 
problems that could put it at a high risk of 
bais? 
 




2.4.4 Data synthesis/analysis of data 
2.4.4.1 Measure of treatment effects 
Risk ratios were calculated for dichotomous outcomes and mean difference (MD) for continuous 
outcomes. Results are presented with 95% confidence intervals (CI). Continuous outcomes 
reported in terms of medians and ranges are presented in a table (see Chapter 3).  
2.4.4.2 Unit of analysis issues 
The level at which randomisation occurred was taken into account. The following was considered 
in each study: Whether groups of individuals were randomised together to the same intervention 
(cluster-randomised trials) or whether there were multiple observations for the same outcome. 
However, there were no cluster-randomised trials included in this systematic review. Cross-over 
trials were excluded as this methodology is not suitable for evaluating an intervention that must be 
given at a specific point in time. In cases where a multi-arm study contributed multiple comparisons 
in a meta-analysis, treatment groups were either combined or the shared group was split as 
appropriate. This was done to ensure that ‘double counting’ was avoided.  
2.4.4.3 Dealing with missing data 
The original authors of included studies were contacted (via electronic mail by the primary 
investigator) where data was found to be missing. No method of imputing missing data was used. 
The impact that the missing data had on the review will be addressed in the discussion section 
(see Chapter 4). Intention-to-treat analysis was performed to estimate the intervention effect if 
there was no missing data. In the case of missing data, an available case analysis was carried out.  
2.4.4.4 Assessment of heterogeneity 
Statistical heterogeneity was assessed by applying the Chi-squared test (Chi2 test) where a p-
value < 0.10 was considered statistically significant, and also by I2 statistics where a value of 
greater than 50% represents substantial heterogeneity.218 The Chi2 test assesses the statistical 
significance of heterogeneity and the I2 statistics quantifies the percentage of the variability in 
effect estimates that is due to heterogeneity rather than chance.218  
2.4.4.5 Assessment of reporting biases 
Reporting biases in general include publication, time lag, multiple publication, location, citation, 
language and outcome reporting biases. The authors planned to include funnel plots would there 
have been any evidence of publication bias (if there were more than 10 studies included in the 
meta-analysis). As a rule of thumb, tests for funnel plot asymmetry should be used only when there 
are at least 10 studies included in the analysis, because when there are fewer studies the power of 
the test is too low to distinguish chance from real asymmetry. 219 




2.4.4.6 Data synthesis 
The investigator was responsible for the preparation of the data for statistical analysis, and a 
statistician trained in systematic reviews performed the actual data synthesis. RevMan 5.3 was 
used to perform data synthesis. Analyses were done separately for different comparisons. A meta-
analysis was only conducted if there were sufficient data and studies reporting similar comparisons 
for the same outcome measures.  
Where substantial methodological or statistical heterogeneity existed, study results were not 
pooled in a meta-analysis and reported separately. A meta-analysis was used to establish whether 
there was evidence of an effect; it estimated the size of the effect and the uncertainties 
surrounding that size; and investigated whether the effect was consistent across studies. A random 
effects model of meta-analysis was used in the presence of moderate heterogeneity of treatment 
effects and a fixed effect model in the absence of heterogeneity.  
2.4.4.7 Subgroup analysis and investigation of heterogeneity 
Subgroup analysis was only conducted in the presence of statistical heterogeneity. The following 
factors were considered for subgroup analysis: dose and duration of the experimental intervention, 
study quality (blinding or not), studies that used a placebo treatment or not, macronutrient profile of 
the experimental intervention, type of surgery (abdominal surgery or not), type of anaesthesia 
(general, neuraxial or combined), anaesthetic risk (high or low), funding of the study, and between 
the different control interventions. However, due to insufficient data, most of these factors could not 
be assessed in subgroup analyses. RevMan 5.3 was used to perform the subgroup analysis.  
2.4.4.8 Sensitivity analysis 
Providing there were sufficient trials per meta-analysis, a sensitivity analysis to assess the 
influence of potential factors on the findings were performed. We performed a sensitivity analysis in 
cases where there was a clear outlying study (or studies) by excluding them from the meta-
analysis.  
2.5 ETHICS AND LEGAL ASPECTS 
The research protocol for the study was approved (S12/06/152) by the Health Research Ethics 
Committee, Faculty of Medicine and Health Sciences, Stellenbosch University (Appendix 6.4). The 
protocol was also registered at the Prospective Register of Ongoing Systematic Reviews 
(PROSPERO) to receive a unique identifying number (CRD42012002313) to record the existence 
of the protocol and systematic review (Appendix 6.5). 
  















CHAPTER 3: RESULTS 
  




3.2 DESCRIPTION OF STUDIES8 
3.2.1 Results of the search 
The initial search (phase 1) produced 2140 citations, of which 266 were selected by the 
investigator as potentially relevant citations (Table 3.1). These citations were selected by applying 
the relevant resources and search strings (see Chapter 2). Additional citations were added as 
obtained from ongoing trials (n = 9), unpublished trials (n = 2), and article reference lists and 
personal files (n = 30). All citations were corrected for duplicates/multiple citations (n = 162), 
providing a total of 145 citations for further assessment in phase 2 (Appendix 6.6). 
Table 3.1: Summary of databases searched (phase 1) 
Searches Period Searched Total Citations Included Citations 
PUBMED/MEDLINE 1950 – 20/05/2015 34 28 
COCHRANE (INLUCING CLINICAL 
TRIALS/CENTRAL, REVIEWS/CDSR, 
ABSTRACTS/DARE) 
1800 – 20/05/2015 58 20 
EBSCO HOST (INCLUDING CINAHL, 
ACADEMIC SEARCH PREMIER, CAB 
ABSRACTS, AFRICA WIDE) 
1865 – 20/05/2015 155 30 
ISI WEB OF KNOWLEDGE 1987 – 20/05/2015 98 53 
SCOPUS ABSTRACTS 1996 – 20/05/2015 257 56 
PROQUEST MEDICAL LIBRARY 1986 – 20/05/2015 108 21 
SCIENCE DIRECT 1823 – 20/05/2015 44 9 
SPRINGERLINK 1842 – 20/05/2015 201 15 
GOOGLE SCHOLAR 2004 – 20/05/2015 1185 34 
SABINET 2002 – 20/05/2015 0 0 
Sub-Total 2140 266 
Ongoing trials (+) 9 
Unpublished trials (+) 2 
Reference lists/Personal files (+) 30 
Sub-Total 307 
Correction for duplicates/multiple citations (-) 162 
Phase 1 TOTAL Citations 145 
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 Please note that in chapter 3 the referencing of the included studies will be as per the unique code given in 
Addendum 6.10. 




The 145 citations were independently reviewed by the investigator and the reviewer using pre-
specified inclusion and exclusion criteria. Of the 145 citations identified, 59 were excluded 
(Appendix 6.7). The main reasons for exclusion in phase 2 are summarised in Figure 3.1. Only 
English language studies were included, but all potentially eligible studies in non-English 
languages were documented to include in future systematic reviews (see Chapter 5). Eighty-six 

























Figure 3.1: Reasons for exclusion of citations (phase 2) 
The 86 citations were independently reviewed by the investigator and the reviewer using pre-
designed sheets to evaluate eligibility (Appendix 6.8). Another 62 publications were excluded 
(Appendix 6.9) and 24 were included in this systematic review (Appendix 6.10). The main reasons 
for study exclusion at this stage included study design and incorrect dosage (see Figure 3.2 for 
summary). The Prisma flow diagramme provides a diagrammatic representation of the full process 
followed in identifying and selecting studies (Figure 3.3).  
Excluded citations (n = 59) 
Reviews (n = 16) 
Foreign language (n = 10) 
Abstracts (n = 8) 
Comments/letters/editorials (n = 8) 
Multiple publications (n = 4) 
Ongoing trials (n = 9) 
Unpublished trials (n = 2) 
Practice guidelines (n = 1) 
Animal study (n = 1) 



























Figure 3.2: Reasons for exclusion of citations (phase 3) 
  
Excluded citations (n = 62) 
Study design (n = 22) 
Dosage (n = 12) 
Abnormal glucose values (n = 7) 
No surgery (n = 4) 
Concentration (n = 7) 
IV/enteral administration (n = 3) 
Osmolality (n = 2) 
Timing (n = 2) 
 >1 Active control (n = 3) 





Figure 3.3: Study identification and selection (Phase 1 to 3) 
3.2.2 General description of included studies 
Twenty-four trials met the criteria for inclusion in this review, and were published between 1995 
and 2014. The trials were conducted in a number of different countries: Canada (1 trial; 38 
participants), A74 Croatia (1 trial; 70 participants), A15 China (1 trial; 48 participants), A64 Czech 
Republic (2 trials; 299 participants), A68, A75 Denmark (1 trial; 86 participants), A115 Finland (2 trials; 
311 participants), A71, A90 Netherlands (1 trial; 19 participants), A94 New Zealand (1 trial; 142 
participants), A66 Sweden (7 trials; 526 participants), A3, A19, A105, A110, A121, A125, A131 Turkey (5 trials; 264 
participants) A6, A14, A16, A52, A84 and the United Kingdom (2 trials; 100 participants). A101, A106 Figure 3.4 
Records identified through database 
searching 






































































) Additional records identified through 
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Full-text articles assessed 
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Full-text articles excluded  
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qualitative synthesis 
(descriptive) 
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Primary Outcomes 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =  23) 
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Records excluded 
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Records after duplicates removed 
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gives a representation of the number of included participants per country. The majority of the trials 
included were from developed and emerging countries (not classified as developing countries). A3, 
A15, A19, A66, A68, A71, A74, A75, A90, A94, A101, A105, A106, A110, A115, A121, A125, A131 
 
Figure 3.4: Participant distribution per country 
In total, these trials included 1903 participants; eleven of the trials included less than 50 
participants, A3, A14, A19, A52, A64, A74, A94, A101, A110, A125, A131 six of the trials included 50 to 100 participants, 
A6, A15, A16, A84, A106, A115 three trials included 100 to 150 participants, A66, A75, A90 two trials included 150 
to 200 participants A68, A105 and two trials included more than 200 participants (Figure 3.5). A71, A121 
Five trials did not report on the gender of the participants, A6,A14,A19,A68,A101 and in the remaining 
trials, more female participants (56%) were recruited than male participants (44%). All participants 



























Figure 3.5: The number of trials by number of included participants 
High risk anaesthetic patients were not excluded from this systematic review. However, most trials 
included were based on healthy participants classified by the American Society of 
Anesthesiologists physical status classification system (ASA score)9 as ASA I – II (1240 
participants), A6, A14, A15, A16, A52, A64, A68, A75, A84, A101, A105, A110, A115, A121 except for four trials recruiting ASA 
I – III participants (413 participants) A3, A19, A66, A71 and one trial recruiting ASA I – IV participants 
(101 participants) A90 with the rest of the trials not reporting on the ASA scores. Six trials did not 
indicate the BMI of the participants A6, A14, A15, A16, A19, A101 but the rest of the included participants had 
a BMI below 30 kg/m2. All participants with diabetes mellitus type 1 and type 2, patients with 
abnormal blood glucose values prior to surgery, and patients with insulin resistance syndrome 
were excluded from this review. All trials reported that participants were undergoing elective 
surgery. Sixteen trials included participants that went for abdominal surgery (1605 participants) A14, 
A15, A16, A52, A64, A66, A68, A71, A75, A84, A101, A105, A106, A115, A121, A131 with the remaining going for orthopaedic 
(109 participants) A3, A19, A94, A110, A125 and other surgeries including cardiac, urology and spinal 
surgery (189 participants) [Figure 3.6]. A6, A74, A90 Where reported, the mean duration of abdominal 
and orthopaedic surgery seemed to be shorter than for cardiac surgery. A3, A19, A52, A64, A66, A68, A71, A74, 
A75, A90, A94, A105, A110, A115, A125 Most participants received general anaesthesia (n = 995) A14, A16, A64, A68, 
A71, A84, A90, A101, A105, A106 with the rest receiving spinal (n = 83), A19, A52 epidural (n = 29), A110, A125 or a 
combination of general and neuraxial anaesthesia (n = 785) [Figure 3.7]. A3, A66, A74, A75, A94, A115, A121, 
A131  
 
                                                          
9
 ASA score is the subjective assessment of a patient’s physical health that is based on five classes (I – V): I = patient is completely 
healthy and fit, II = patient has mild systemic disease, III = patient has severe systemic disease that is not incapacitating, IV = patient 











































Figure 3.6: Type of surgery by number of included participants 
 
Figure 3.7: Type of anaesthesia by number of included participants 
All participants in the experimental group (n = 788) received 400 ml of a 12% CHO-containing 
beverage at least 2 hours before induction of anaesthesia – most participants (n = 583) also 
received 400 to 800 ml of the beverage the evening before surgery. A3, A6, A14, A15, A16, A19, A52, A66, A68, 
A74, A84, A101, A105, A106, A110, A115, A121, A125 The majority of the trials used Nutricia Preop® as the oral CHO 
beverage (one trial used Nutricia AS that has the same nutritional analysis as Nutricia Preop®), 
A131 except one trial that used Vitajoule as the oral CHO beverage. A101 The actual time from 
ingestion of beverage to induction of anaesthesia and to the start of the surgery was unclear in 
most trials; however, it was stipulated that the beverage was consumed at least 2 hours before the 
induction of anaesthesia and the start of surgery. A placebo was used as an inactive control in 11 
of the trials (310 participants) consisting of water, A3, A101, A131 sweetened water, A110, A125 flavoured 
water, A64, A66, A105, A115, A121 and fluid and electrolytes. A106 All the trials using standard fasting as an 
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A16, A19, A52, A64, A68, A71, A74, A75, A84, A90, A94, A101, A105, A121 Two trials included IV CHO administration as an 
active control (132 participants). A68, A71 Even though some of the ERAS elements were used in 
most of the trials, only one trial indicated that an ERAS protocol was followed.A75  The details of the 
included trials are summarised in Appendix 6.11 and Appendix 6.12, and other trial characteristics 
are discussed under the relevant results sections. 
3.3 RISK OF BIAS IN INCLUDED STUDIES AND METHODOLOGICAL QUALITY 
The Cochrane Risk of Bias assessment tool was completed for each of the included trials to 
assess the methodological quality and to enable data entry into RevMan 5.3 (Appendix 6.13). The 
full details of the methodological quality of the trials are provided in Appendix 6.14. 
The quality assessments of the trial methodology were reported as a summary (Figure 3.8) and a 
graph (Figure 3.9). All trials included in this review were RCTs, and the sequence generation was 
not indicative of bias. More than half of the trials (16 of 24) A3, A6, A14, A15, A16, A19, A66, A68, A71, A75, A90, A94, 
A101, A110, A115, A125 confirmed allocation concealment with the remaining trials not clearly reporting on 
the method of concealment. Eleven trials reported to be double blinded; A3, A15, A19, A64, A66, A105, A106, 
A110, A115, A121, A125 seven trials were single blinded; A14, A16, A74, A84, A90, A94, A101 one trial did not blind the 
participants or personnel; A75 four trials did not indicate the blinding of participants and personnel. 
A6, A52, A68, A131 In the majority of the trials it was unclear whether the outcomes were blinded except 
for four trials were it was clearly stated that the outcomes were blinded. A3, A64, A66, A71  Seventeen of 
the 24 trials had incomplete outcome data, A3, A6, A14, A16, A64, A66, A68, A71, A74, A75, A90, A94, A101, A105, A110, A121, 
A131 indicating a high risk of bias for this domain. Intention to treat analysis was not reported in any 
trial. There was no clear evidence of selective reporting. High risk of bias was detected in the 
‘other’ category which included unclear eligibility criteria, uneven baseline comparability, loss to 
follow-up and funding of trials. The methodological graph (Figure 3.9) indicates no risk of bias with 
regards to sequence generation and low risk with regards to allocation concealment (selection 
bias). Uncertainty (unclear risk of bias) was found in especially the blinding of outcome 
assessment (detection bias) and the selective reporting (reporting bias) categories. High risk of 
bias was detected with blinding of participants and personnel (performance bias), incomplete 
outcome data (attrition bias) as well as other bias (including funding).  
The GRADE approach defines the quality of evidence for each outcome reported in a systematic 
review as the extent to which one can be confident that an estimate of effect is close to the quantity 
of specific interest. GRADE assessment was not completed for this review as it is a relative new 
initiative from the Cochrane Collaboration and this is not a Cochrane Review. Quality was not used 
to weigh the trials in the meta-analyses of this review but will be commented on, as appropriate, 
within this and the discussion chapter. Furthermore, the GRADE assessment will be incorporated 
into the systematic review before publishing the results. 



























Figure 3.8: Methodological quality summary – judgement about each methodological quality item for 










































































Figure 3.9: Methodological quality graph – judgement about each methodological quality item 
presented as percentages across all included studies 
3.4 EFFECTS OF INTERVENTION 
The primary and secondary outcomes addressed in this systematic review are summarised in 
Table 3.2. The primary outcomes, as stated, were reported by 23 of the trials (n = 1841), with 16 
trials (n = 1449) reporting on the patients’ psychosomatic experience with reference to the 
secondary outcomes. The outcomes addressed per trial are summarised in Appendix 6.15. The 
results of the primary outcomes will be presented per comparison in Chapter 3 but will be 
discussed per time interval in Chapter 4 (see Appendix 6.16 for a detailed explanation). The results 
of the secondary outcomes will be presented using a descriptive approach. Please note that four 
comparison groups were investigated per outcome, including: 
 comparison 1: oral CHO versus inactive control (fasting + placebo) [referred to as the 
inactive control] 
 comparison 2: oral CHO versus inactive control (fasting) [referred to as the fasting control] 
 comparison 3: oral CHO versus inactive control (placebo) [referred to as the placebo 
control] 
 comparison 4: oral CHO versus active control (intravenous) [referred to as the active 
control] 
  




Table 3.2: Outcomes addressed in the systematic review 
PRIMARY OUTCOMES 
BIOCHEMISTRY: GLUCOSE (HOMA-IR + QUICKI)* 
Comparison 1: Oral CHO versus inactive control  
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 2: Oral CHO versus fasting  
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 3: Oral CHO versus placebo  
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 4: Oral CHO versus active control 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
BIOCHEMISTRY: INSULIN (HOMA-IR + QUICKI)* 
Comparison 1: Oral CHO versus inactive control 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 2: Oral CHO versus fasting 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 3: Oral CHO versus placebo 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 4: Oral CHO versus active control 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 




PROTEIN STATUS: TOTAL BODY PROTEIN 
Comparison 1: Oral CHO versus inactive control 
 Baseline 
 Day 3 post-surgery 
 Day 7 post-surgery 
 Day 28 post-surgery 
Comparison 2: Oral CHO versus fasting 
 Baseline 
 Day 3 post-surgery 




 Day 7 post-surgery 
 Day 28 post-surgery 
Comparison 3: Oral CHO versus placebo 
 Baseline 
 Day 3 post-surgery 
 Day 7 post-surgery 
 Day 28 post-surgery 
Comparison 4: Oral CHO versus active control 
 Baseline 
 Day 3 post-surgery 
 Day 7 post-surgery 
 Day 28 post-surgery 
PROTEIN STATUS: MUSCLE STRENGTH 
Comparison 1: Oral CHO versus inactive control 
 Baseline 
 Day 1 post-surgery 
 Day 3 post- surgery 
 Day 7 post-surgery 
 Day 28 post-surgery 
Comparison 2: Oral CHO versus fasting 
 Baseline 
 Day 1 post-surgery 
 Day 3 post- surgery 
 Day 7 post-surgery 
 Day 28 post-surgery 
Comparison 3: Oral CHO versus placebo 
 Baseline 
 Day 1 post-surgery 
 Day 3 post- surgery 
 Day 7 post-surgery 
 Day 28 post-surgery 
Comparison 4: Oral CHO versus active control 
 Baseline 
 Day 1 post-surgery 
 Day 3 post- surgery 
 Day 7 post-surgery 
 Day 28 post-surgery 
IMMUNE STATUS: C-REATIVE PROTEIN 
Comparison 1: Oral CHO versus inactive control 
 Baseline 
 Before anaesthesia 
 Day 1 post-surgery 
 Day 3 post-surgery 
 Day 7 post-surgery 
Comparison 2: Oral CHO versus fasting 
 Baseline 
 Before anaesthesia 
 Day 1 post-surgery 
 Day 3 post-surgery 
 Day 7 post-surgery 
Comparison 3: Oral CHO versus placebo 
 Baseline 
 Before anaesthesia 
 Day 1 post-surgery 
 Day 3 post-surgery 
 Day 7 post-surgery 
Comparison 4: Oral CHO versus active control 
 Baseline 
 Before anaesthesia 
 Day 1 post-surgery 




 Day 3 post-surgery 
 Day 7 post-surgery 
RETURN OF INTESTINAL FUNCTION 
 Flatus/stool  
 Bowel movement 
LENGTH OF STAY: INTENSIVE CARE UNIT 
 Intensive care unit 
 Hospital  


















* The glucose and insulin results for the trials using the homeostatic model assessment (HOMA-IR) and quantitative 
insulin sensitivity check index (QUICKI) method were combined when analysing the glucose and insulin results 
respectively; whereas the results of the trials using the hyperinsulinaemic-euglycaemic clamp (HEC) method will be 
presented separately in the insulin resistance section. The glucose and insulin results of the trials using the HEC method 
to measure insulin resistance cannot be combined with the trials using the HOMA-IR and QUICKI methods since the 
HEC method is not physiologically the same as the other methods due to fact that insulin is infused to create a 
hyperinsulinaemic state whilst glucose is concomitantly infused to maintain euglycaemia. The HOMA-IR and QUICKI 
methods are based on physiological levels of glucose and insulin. Therefore, the biochemical results were grouped as 
follows: 
 Glucose (HOMA-IR and QUICKI)  
 Glucose (HEC) – will be presented in a table in the insulin resistance section 
 Insulin (HOMA-IR and QUICKI) 
 Insulin (HEC) – will be presented in a table in the insulin resistance section 
 Insulin resistance (HOMA-IR) 
 Insulin resistance (QUICKI) 
 Insulin resistance (HEC) 
** Day 0 Postoperative = within 24 hours postoperative; Day 1 Postoperative = 24 to 48 hours postoperative 




3.4.1 Primary outcomes 
3.4.1.1 Glucose (HOMA-IR and QUICKI) 
There were eight trials (864 participants) assessing glucose (HOMA-IR and QUICKI) as an 
outcome.A52,A66,A68,A71,A74,A84,A90,A106 The unit of measurement for glucose is mmol/l. The results that 
were pooled in meta-analyses for glucose (HOMA-IR and QUICKI) are summarised in Table 3.3. 
Note that Table 3.3 only provides results for the pooled data. The results of the trials reporting the 
outcomes as median (interquartile range) are presented in Appendix 6.17. There were five trials 
with missing or no data and could, therefore, not be included.A6,A16,A64,A121,A131  
 




Table 3.3: Results of trials evaluating glucose (HOMA-IR and QUICKI) that were pooled in a meta-analysis 
COMPARISON / TIME INTERVAL 
NUMBER 
OF 







COMPARISON 1: Oral CHO versus inactive control (fasting + placebo) 
Glucose at baseline  5 408 -0.03 [-0.15, 0.09] 0.62 6.68 40% 
Glucose before anaesthesia  4 456 0.34 [0.01, 0.68] 0.04** 6.37 53% 
Glucose at day 0 post surgery 1 101 0.10 [-0.49, 0.69] 0.74 Not applicable 
Glucose at day 1 post surgery  2 207 0.32 [-0.20, 0.85] 0.23 0.86 0% 
COMPARISON 2: Oral CHO versus fasting 
Glucose at baseline  3 287 -0.09 [-0.20, 0.02] 0.09 1.84 0% 
Glucose before anaesthesia  3 314 0.51 [0.24, 0.77] 0.0002** 0.99 0% 
Glucose at day 0 post surgery 1 101 0.10 [-0.49, 0.69] 0.74 Not applicable 
Glucose at day 1 post surgery  Results reported as median (interquartile range) * 
COMPARISON 3: Oral CHO versus placebo 
Glucose at baseline  2 207 -0.13 [-0.38, 0.13] 0.33 0.28 0% 
Glucose before anaesthesia  1 142 -0.10 [-0.54, 0.34] 0.65 Not applicable 
Glucose at day 0 post surgery Not reported by any of the trials 
Glucose at day 1 post surgery  2 207 0.32 [-0.20, 0.85] 0.23 0.86 0% 
COMPARISON 4: Oral CHO versus active control (IV CHO) 
Glucose at baseline  1 137 0.10 [-0.28, 0.48] 0.60 Not applicable 
Glucose before anaesthesia  1 137 -0.20 [-0.70, 0.30] 0.44 Not applicable 
Glucose at day 0 post surgery Results reported as median (interquartile range) *  
Glucose at day 1 post surgery  Results reported as median (interquartile range) * 
 
* see Appendix 6.17 for results reported as median (interquartile range); all results showed no statistically significant difference between groups 
** Statistical significant result (p <  0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous; p = p-value 
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3.4.1.1.1 Comparison 1: Oral CHO versus inactive control (fasting + placebo) 
a. Glucose (HOMA-IR and QUICKI) at baseline 
Eight trials reported results on glucose at baseline. A52,A66,A68,A71,A74,A84,A90,A106 Results from six trials 
were pooled in a meta-analysis but the results cannot be reported because of significant 
heterogeneity between the trials (Chi2 = 11.56, df = 5, p = 0.04, I2 = 57%). An investigation of the 
source of heterogeneity was carried out using both subgroup analysis and sensitivity analysis. 
Heterogeneity remained significant after subgroup analyses with respect to dose and duration of 
experimental intervention, type of surgery, type of anaesthesia and anaesthetic risk. Since the 
forest plot clearly shows that the trial by Yagci 2008 had outlying results compared to all the other 
trial results, a sensitivity analysis was carried out to determine the effect of removing this one trial 
from the meta-analysis on heterogeneity.A84 After removing this trial from the meta-analysis, 
heterogeneity between studies was no longer significant (Chi2 = 2.19, df = 4, p = 0.70, I2 = 40%, 
Appendix 6.18 Analysis 1.1) but there was no significant difference in glucose levels at baseline 
between the oral CHO and the inactive control (fasting or placebo) groups (MD -0.10, 95%CI: -0.20 
to 0.00, 495 participants, 5 trials, Appendix 6.18 Analysis 1.1). The results of Yagci 2008 showed a 
significantly higher glucose level at baseline in the oral CHO group compared to the fasting group 
(MD 0.67, 95%CI: 0.19 to 1.15, 70 participants, 1 trial, Appendix 6.18 Analysis 1.1).A84 Kaska 2010 
and Tran 2009 reported results as median (interquartile range) but there was no significant 
difference in glucose at baseline between the oral CHO and fasting groups in the two studies 
(Appendix 6.17).A68,A74 
b. Glucose (HOMA-IR and QUICKI) before anaesthesia 
Four trials reported results on glucose before anaesthesia and their meta-analysis showed 
significantly (p = 0.04) higher glucose levels in the oral CHO group compared to the fasting or 
placebo groups (MD 0.34, 95% CI: 0.01 to 0.68, 456 participants, 4 trials, Appendix 6.18 Analysis 
1.2).A66,A71,A84,A90 No significant heterogeneity was detected between the trials (Chi2 = 6.37, df = 3, 
p = 0.10, I2 = 53%, Appendix 6.18 Analysis 1.2). Two trials had missing data and could not be 
included.A16,A52 
c. Glucose (HOMA-IR and QUICKI) at day 0 postoperative 
Three trials reported results on glucose at day 0 post surgery.A68,A74,A90 Results from Järvelä 2008 
showed no significant difference in glucose levels between the oral CHO and fasting groups (MD 
0.10, 95%CI: -0.49 to 0.69, 101 participants, 1 trial, Appendix 6.18 Analysis 1.3).A90 Kaska 2010 
and Tran 2009 presented results as median (interquartile range) and the authors reported a 
significantly higher glucose level in the oral CHO group compared to the fasting group in the two 
trials (Appendix 6.17).A68,A74 One trial had missing data and could not be included.A52 




d. Glucose (HOMA-IR and QUICKI) at day 1 postoperative 
Three trials reported results on glucose at day 1 post surgery.A66,A68,A106 Results from two trials 
were pooled in a meta-analysis but there was no significant difference in glucose levels between 
the oral CHO and placebo groups (MD 0.32, 95%CI: -0.20 to 0.85, 207 participants, 2 trials, 
Appendix 6.18 Analysis 1.4).A66,A106 There was no significant heterogeneity detected between the 
trials (Chi2 = 0.86, df = 1, p = 0.35, I2 = 0%, Appendix 6.18 Analysis 1.4). Kaska 2010 reported 
results as median (interquartile range) but there was no significant difference between the oral 
CHO and fasting groups (Appendix 6.17).A68 
3.4.1.1.2 Comparison 2: Oral CHO versus fasting 
a. Glucose (HOMA-IR and QUICKI) at baseline 
Six trials reported results on glucose at baseline.A52,A66,A71,A74,A84,A90 Results from four trials were 
pooled in a meta-analysis but the results cannot be reported because of significant heterogeneity 
between the trials (Chi2 = 11.01, df = 3, p = 0.01, I2 = 73%).A52,A71,A84,A90 An investigation of the 
source of heterogeneity was carried out using both subgroup analysis and sensitivity analysis. 
Heterogeneity remained significant after subgroup analyses with respect to dose and duration of 
experimental intervention, type of surgery, type of anaesthesia and anaesthetic risk. Since the 
forest plot clearly shows that the trial by Yagci 2008 had outlying results compared to the other 
three trial results, a sensitivity analysis was carried out to determine the effect of removing this trial 
from the meta-analysis on heterogeneity.A84 After removing this trial from the meta-analysis, 
heterogeneity between studies was no longer significant (Chi2 = 1.84, df = 2, p = 0.40, I2 = 0%, 
Appendix 3.18 Analysis 2.1) but there was no significant difference in glucose levels at baseline 
between the oral CHO and the inactive control (fasting or placebo) groups (MD -0.09, 95%CI: -0.20 
to 0.02, 287 participants, 3 trials, Appendix 3.16 Analysis 2.1). The results of Yagci 2008 showed a 
significantly higher glucose level at baseline in the oral CHO group compared to the fasting group 
(MD 0.67, 95%CI: 0.19 to 1.15, 70 participants, 1 trial, Appendix 3.18 Analysis 2.1). Mathur 2010 
and Tran 2009 reported results as median (interquartile range) but there was no significant 
difference between the oral CHO and fasting groups in the two trials (Appendix 3.17).A66,A74 
b. Glucose (HOMA-IR and QUICKI) before anaesthesia 
Three trials reported results on glucose before anaesthesia and their results were pooled in a 
meta-analysis which showed significantly higher (p = 0.0002) glucose levels in the oral CHO group 
compared to the fasting group (MD 0.51, 95%CI: 0.24 to 0.77, 314 participants, 3 trials, Appendix 
3.18 Analysis 2.2).A71,A84, A90 No significant heterogeneity was detected between the trials 
(Chi2 = 0.99, df = 2, p = 0.61, I2 = 0%, Appendix 3.18 Analysis 2.2). Two trials had missing data and 
could not be included.A16,A52 




c. Glucose (HOMA-IR and QUICKI) at day 0 postoperative 
Three trials reported results on glucose at Day 0 post surgery.A68,A74,A90 Results from Järvelä 2008 
showed no significant difference in glucose levels between the oral CHO and fasting groups (MD 
0.10, 95%CI: -0.49 to 0.69, 101 participants, 1 trial, Appendix 3.18 Analysis 2.3).A90 Kaska 2010 
and Tran 2009 reported results as median (interquartile range) and there was a significantly higher 
glucose level in the oral CHO group compared to the fasting group in the two trials (Appendix 
3.17).A68,A74 One trial had missing data and could not be included.A52 
d. Glucose (HOMA-IR and QUICKI) at day 1 postoperative 
One trial reported results as median (interquartile range) but there was no significant difference 
between the oral CHO and fasting groups (Appendix 3.17).A68 
3.4.1.1.3 Comparison 3: Oral CHO versus placebo 
a. Glucose (HOMA-IR and QUICKI) at baseline 
Results from two trials were pooled in a meta-analysis but there was no significant difference in 
glucose levels at baseline between the oral CHO and placebo groups (MD -0.13, 95%CI: -0.38 to 
0.13, 207 participants, 2 trials, Appendix 3.18 Analysis 3.1).A66,A106 No significant heterogeneity was 
detected between the trials (Chi2 = 0.28, df = 1, p = 0.59, I2 = 0%, Appendix 3.18 Analysis 3.1). 
b. Glucose (HOMA-IR and QUICKI) before anaesthesia 
Results from one trial showed no significant difference in glucose levels before anaesthesia 
between the oral CHO and the placebo groups (MD -0.10, 95%CI: -0.54 to 0.34, 142 participants, 1 
trial, Appendix 3.18 Analysis 3.2).A66 
c. Glucose (HOMA-IR and QUICKI) at day 0 postoperative 
This outcome was not reported by any of the trials assessing this comparison. 
d. Glucose (HOMA-IR and QUICKI) at day 1 postoperative 
Results from two trials were pooled in a meta-analysis but there was no significant difference in 
glucose levels at Day 1 post surgery between the oral CHO and placebo groups (MD 0.32, 95%CI: 
-0.20 to 0.85, 207 participants, 2 trials, Appendix 3.18 Analysis 3.3).A66,A106 There was no 
significant heterogeneity detected between the trials (Chi2 = 0.86, df = 1, p = 0.35, I2 = 0%, 
Appendix 3.18 Analysis 3.3). 




3.4.1.1.4 Comparison 4: Oral CHO versus active control 
a. Glucose (HOMA-IR and QUICKI) at baseline 
Two trials reported results on glucose at baseline.A68,A71 Results from Helminen 2009 showed no 
significant difference in glucose levels between the oral CHO and IV CHO groups (MD 0.10, 
95%CI: -0.28 to 0.0.48, 137 participants, 1 trial, Appendix 3.18 Analysis 4.1).A71 Kaska 2010 
reported results for glucose at baseline as median (interquartile range) but there was no significant 
difference between the oral CHO and IV CHO groups (Appendix 3.17).A68 
b. Glucose (HOMA-IR and QUICKI) before anaesthesia 
Helminen 2009 showed no significant difference in glucose levels before anaesthesia between the 
oral CHO and IV CHO groups (MD -0.20, 95%CI: -0.70 to 0.30, 137 participants, 1 trial, Appendix 
3.18 Analysis 4.2).A71 
c. Glucose (HOMA-IR and QUICKI) at day 0 postoperative 
Kaska 2010 reported results for glucose at day 0 post surgery as median (interquartile range) but 
there was no significant difference between the oral CHO and IV CHO groups (Appendix 3.17).A68 
d. Glucose (HOMA-IR and QUICKI) at day 1 postoperative 
Kaska 2010 reported results for glucose at Day 1 post surgery as median (interquartile range) but 
there was no significant difference between the oral CHO and IV CHO groups (Appendix 3.17).A68 
3.4.1.2 Insulin (HOMA-IR and QUICKI) 
There were six trials (569 participants) assessing insulin (HOMA-IR and QUICKI) as an 
outcome.A52,A66,A71,A74,A84,A106  The unit of measurement for insulin is microunits/l. The results that 
were pooled in meta-analyses for glucose (HOMA-IR and QUICKI) are summarised in Table 3.4. 
Note that Table 3.4 only provides results for the pooled data. The results of the trials reporting the 
outcomes as median (interquartile range) are presented in Appendix 6.17. There were six trials 
with missing or no data that could not be included.A6,A64,A68,A90,A121,A131 
 




Table 3.4: Results of trials evaluating insulin (HOMA-IR and QUICKI) that were pooled in a meta-analysis 
COMPARISON / TIME INTERVAL 
NUMBER OF 







COMPARISON 1: Oral CHO versus inactive control (fasting + placebo) 
Insulin at baseline  2 89 -1.84 [-3.28, -0.40] 0.01** 0.51 0% 
Insulin before anaesthesia  2 115 1.64 [-1.53, 4.82] 0.22 1.48 32% 
Insulin at day 0 post surgery Results reported as median (interquartile range)  
Insulin at day 1 post surgery  1 65 7.70 [5.97, 9.43] < 0.00001** Not applicable 
COMPARISON 2: Oral CHO versus fasting 
Insulin at baseline  2 89 -1.84 [-3.28, -0.40] 0.01** 0.51 0% 
Insulin before anaesthesia  2 115 1.64 [-1.53, 4.82] 0.31 1.48 32% 
Insulin at day 0 post surgery Results reported as median (interquartile range) 
Insulin at day 1 post surgery  Not reported by any of the trials 
COMPARISON 3: Oral CHO versus placebo 
Insulin at baseline  1 65 3.90 [1.17, 6.63] 0.005** Not applicable  
Insulin before anaesthesia  Results reported as median (interquartile range)* 
Insulin at day 0 post surgery Not reported by any of the trials 
Insulin at day 1 post surgery  1 65 7.70 [5.97, 9.43] < 0.00001** Not applicable 
COMPARISON 4: Oral CHO versus active control (IV CHO) 
Insulin at baseline  1 41 2.90 [-1.39, 7.19] 0.19 Not applicable 
Insulin before anaesthesia  1 41 0.40 [-5.38, 6.18] 0.89 Not applicable 
Insulin at day 0 post surgery Not reported by any of the trials 
Insulin at day 1 post surgery  Not reported by any of the trials 
* see Appendix 6.17 for results reported as median (interquartile range); all results showed no statistically significant difference between groups 
** Statistical significant result (p < 0.05) 
 
CHO = oral carbohydrate treatment group; IV = intravenous; p = p-value 
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3.4.1.2.1 Comparison 1: Oral CHO versus inactive control (fasting + placebo) 
a. Insulin (HOMA-IR and QUICKI) at baseline 
Six trials reported results on insulin at baseline.A52,A66,A71,A74,A84,A106 Results from four trials were 
pooled in a meta-analysis but the results cannot be reported because of significant heterogeneity 
between the trials (Chi2 = 124.64, df = 3, p < 0.00001, I2 = 98%).A52,A71,A84,A106 An investigation of the 
source of heterogeneity was carried out using both subgroup analysis and sensitivity analysis. 
Heterogeneity remained significant after subgroup analyses with respect to dose and duration of 
experimental intervention, type of surgery, type of anaesthesia and anaesthetic risk. Since the 
forest plot clearly shows that two of the trials (Yagci 2008, Yuill 2005) had outlying results 
compared to the other results, a sensitivity analysis was carried out to determine the effect of 
removing these two trials from the meta-analysis on heterogeneity.A84,A106 After removing the two 
trials from the meta-analysis, heterogeneity between studies was no longer significant (Chi2 = 0.51 
df = 1, p = 0.47, I2 = 0%, Appendix 6.19 Analysis 1.1) and the meta-analysis showed significantly 
lower insulin levels at baseline in the oral CHO group compared to the inactive control (fasting or 
placebo) groups (MD -1.84, 95%CI: -3.28 to -0.40, 89 participants, 2 trials, Appendix 6.18 Analysis 
1.1).A52,A71 However, the results of both Yagci 2008 (MD 13.78, 95%CI: 11.43 to 16.13, 70 
participants, 1 trial, Appendix 6.19 Analysis 1.1)A84 and Yuill 2005 (MD 3.90, 95%CI: 1.17 to 6.63, 
65 participants, 1 trial, Appendix 6.19 Analysis 1.1)A106 showed significantly higher insulin levels at 
baseline in the oral CHO group compared to the inactive (fasting or placebo) groups. Mathur 2010 
and Tran 2009 reported results as median (interquartile range) but there was no significant 
difference between the oral CHO and placebo groups in the two trials (Appendix 6.17).A66,A74 
b. Insulin (HOMA-IR and QUICKI) before anaesthesia 
Three trials reported results on insulin before anaesthesia,A66,A71,A84 and results from two trials were 
pooled in a meta-analysis but there was no significant difference in insulin levels between the oral 
CHO and inactive control groups (MD 1.64, 95%CI: -1.53 to 4.82, 115 participants, 2 trials, 
Appendix 6.19 Analysis 1.2).A71,A84 No significant heterogeneity was detected between the trials 
(Chi2 = 1.48, df = 1, p = 0.22, I2  = 32%, Appendix 6.19 Analysis 1.2). Mathur 2010 reported results 
as median (interquartile range) but there was also no significant difference between the oral CHO 
and placebo groups (Appendix 6.17).A66 
c. Insulin (HOMA-IR and QUICKI) at day 0 postoperative 
Tran 2009 reported results as median (interquartile range) but there was no significant difference 
between the oral CHO and fasting groups (Appendix 6.17).A74 




d. Insulin (HOMA-IR and QUICKI) at day 1 postoperative 
Two trials reported results on insulin at Day 1 post surgery.A66,A106 Results from Yuill 2005 showed 
significantly higher insulin levels in the oral CHO group compared to the placebo group (MD 7.70, 
95%CI: 5.97 to 9.43, 65 participants, 1 trial, Appendix 3.19 Analysis 1.3).A106 Mathur 2010 reported 
results as median (interquartile range) but there was no significant difference between the oral 
CHO and placebo groups (Appendix 3.17).A66 
3.4.1.2.2 Comparison 2: Oral CHO versus fasting 
a. Insulin (HOMA-IR and QUICKI) at baseline 
Four trials reported results on insulin at baseline,A52,A71,A74,A84 and three trials were pooled in a 
meta-analysis but the results cannot be reported because of significant heterogeneity between the 
trials (Chi2 = 123.72, df = 2, p < 0.00001, I2 = 98%).A52,A71,A84 An investigation of the source of 
heterogeneity was carried out using both subgroup analysis and sensitivity analysis. Heterogeneity 
remained significant after subgroup analyses with respect to dose and duration of experimental 
intervention, type of surgery, type of anaesthesia and anaesthetic risk.  
Since the forest plot clearly shows that one of the trials (Yagci 2008) had outlying results compared 
to the other two trial results,A84 a sensitivity analysis was carried out to determine the effect of 
removing this one trial from the meta-analysis on heterogeneity. After removing this trial from the 
meta-analysis, heterogeneity between studies was no longer significant (Chi2 = 0.51, df = 1, 
p = 0.47, I2 = 0%, Appendix 6.19 Analysis 2.1) and the meta-analysis showed significantly lower 
insulin levels at baseline in the oral CHO group compared to the fasting group (MD -1.84, 95%CI: -
3.28 to -0.40, 89 participants, 2 trials, Appendix 6.19 Analysis 2.1).A52,A71 However, the results of 
Yagci 2008 showed significantly higher insulin levels at baseline in the oral CHO group compared 
to the fasting group (MD 13.78, 95%CI: 11.43 to 16.13, 70 participants, 1 trial, Appendix 6.19 
Analysis 2.1). Tran 2009 reported results as median (interquartile range) and there was no 
significant difference between the oral CHO group compared to the fasting group (Appendix 
6.17).A74 
b. Insulin (HOMA-IR and QUICKI) before anaesthesia 
Two trials reported results on insulin before anaesthesia and were pooled in a meta-analysis but 
there was no significant difference in insulin levels between the oral CHO and fasting groups (MD 
1.64, 95%CI: -1.53 to 4.82, 115 participants, 2 trials, Appendix 3.19 Analysis 2.2).A71,A84 No 
significant heterogeneity was detected between the trials (Chi2 = 1.48, df = 1, p = 0.22, I2 = 32%, 
Appendix 6.19 Analysis 2.2). 




c. Insulin (HOMA-IR and QUICKI) at day 0 postoperative 
Tran 2009 reported results as median (interquartile range) and there was no significant difference 
between the oral CHO group compared to the fasting group (Appendix 3.17).A74 
d. Insulin (HOMA-IR and QUICKI) at day 1 postoperative 
This outcome was not reported by any of the trials assessing this comparison. 
3.4.1.2.3 Comparison 3: Oral CHO versus placebo 
a. Insulin (HOMA-IR and QUICKI) at baseline 
Two trials reported this outcome.A66,A106 In Yuill 2005, the oral CHO group had higher insulin levels 
compared to the placebo group (MD 3.90, 95%CI: 1.17 to 6.63, 65 participants, 1 trial, Appendix 
3.19 Analysis 3.1).A106 However, results from Mathur 2010, which were reported as median 
(interquartile range), found no significant difference between the oral CHO and placebo groups 
(Appendix 6.17).A66 
b. Insulin (HOMA-IR and QUICKI) before anaesthesia 
Mathur 2010 reported results as median (interquartile range) but there was no significant difference 
between the oral CHO and placebo groups (Appendix 3.17).A66 
c. Insulin (HOMA-IR and QUICKI) at day 0 postoperative 
This outcome was not reported by any of the trials assessing this comparison. 
d. Insulin (HOMA-IR and QUICKI) at day 1 postoperative 
Two trials reported results on insulin at Day 1 post surgery.A66,A106 Results from Yuill 2005 showed 
significantly higher insulin levels in the oral CHO group compared to the placebo group (MD 7.70, 
95% CI: 5.97 to 9.43, 65 participants, 1 trial, Appendix 3.19 Analysis 3.2).A106 Mathur 2010 reported 
results as median (interquartile range) but there was no significant difference between the oral 
CHO and placebo groups (Appendix 3.17).A66 
3.4.1.2.4 Comparison 4: Oral CHO versus active control (IV CHO) 
a. Insulin (HOMA-IR and QUICKI) at baseline 
Helminen 2009 showed no significant difference in insulin levels at baseline between the oral CHO 
and IV CHO groups (MD 2.90, 95%CI: -1.39 to 7.19, 41 participants, 1 trial, Appendix 3.19 
Analysis 4.1).A71 




b. Insulin (HOMA-IR and QUICKI) before anaesthesia 
Helminen 2009 showed no significant difference in insulin levels before anaesthesia between the 
oral CHO and IV CHO groups (MD 0.40, 95%CI: -5.38 to 6.18, 41 participants, 1 trial, Appendix 
3.19 Analysis 4.2).A71 
c. Insulin (HOMA-IR and QUICKI) at day 0 postoperative 
This outcome was not reported by any of the trials assessing this comparison. 
d. Insulin (HOMA-IR and QUICKI) at day 1 postoperative 
This outcome was not reported by any of the trials assessing this comparison. 
3.4.1.3 Insulin resistance 
Six trials (270 participants) assessed insulin resistance as an outcome.A3,A19,A66,A74,A110,A125 The 
different methods to measure insulin resistance included the HOMA-IR, QUICKI and HEC 
methods. Results for the different methods will be reported separately. The results of the trials 
reporting the outcomes as median (interquartile range) are presented in Appendix 6.17. Three 
trials had missing or no data, and could not be included.A6,A64,A68  
3.4.1.3.1 Insulin resistance: HOMA-IR 
Only two trials assessed insulin resistance as measured by the HOMA-IR method.A66,A74 Mathur 
2010 compared oral CHO intake to placebo with no significant difference at baseline (MD 0.29, 
95%CI: -0.22 to 0.80, 142 participants, 1 trial), before anaesthesia (MD 0.17, 95%CI: -0.15 to 0.49, 
142 participants, 1 trial) or day 1 postoperative (MD 0.15, 95%CI: -0.54 to 0.84, 142 participants, 1 
trial) [Appendix 6.20].A66 Tran 2009 reported results as median (interquartile range) when 
comparing oral CHO intake to standard fasting with no significant difference between groups at 
baseline or day 0 postoperative (Appendix 6.17).A74 
3.4.1.3.2 Insulin resistance: QUICKI 
Ljunggren 2012 included both the HEC and QUICKI method but the QUICKI method was excluded 
since the HEC method is the golden standard and glucose and insulin levels were kept at a certain 
level;A19 Kaska 2010 had missing data.A68 Therefore, no data was analysed for this outcome.  
3.4.1.3.3 Insulin resistance: HEC 
Four trials assessed insulin resistance by the HEC method.A3,A19,A110,A125 The comparison between 
the different trials using the HEC method to calculate insulin resistance is challenging because 
there is no fixed consensus on the important parameters, including optimal procedure duration, 
infusion rate of insulin to create a hyperinsulinaemic state, glucose infusion rate to maintain 
euglycaemia, and reporting of results. Descriptive statistics were used to presents the studies 




utilising the ‘gold standard’ method for determining insulin resistance (Table 3.5). Note that a 
greater reduction in insulin sensitivity indicates a greater development of insulin resistance.  
Table 3.5: Insulin resistance as measured by the HEC method 
Study 
Number of 
Participants Groups Time Interval Results p-value 
Ljunggren 
2014 
22 Oral CHO 
versus 
placebo 
Day before surgery to 
first postoperative 
day.  
Insulin sensitivity decreased by 
51% (35–61) after ingesting the 
CHO beverage compared to 
39% (21–51) after ingesting 
water.  
p > 0.05 
Ljunggren 
2012 
39 Oral CHO 
versus 
fasting 
Day before surgery to 
first postoperative 
day. 
Insulin sensitivity decreased by 
51% (0–74) after ingesting the 
CHO beverage compared to 
43% (19–77) after fasting. 
p > 0.05 
Soop 2004 14 Oral CHO 
versus 
placebo 
1 week preoperatively 
and on the third day 
postoperative.  
Insulin sensitivity decrease by 
36% (±10%) in the oral CHO 
group versus 49% (±7%) in the 
placebo group. 
p > 0.05 
Soop 2001 15 Oral CHO 
versus 
placebo 
1 week preoperatively 
to immediate 
postoperative. 
Insulin sensitivity decreased by 
18% (±6%) in the oral CHO 
group versus 43% (±9%) in the 
placebo group. 
p < 0.05* 
* Statistical significant result (p < 0.05) 
 
CHO = oral carbohydrate treatment group; HEC = hyperinsulinaemic euglycaemic clamp; p = p-value 
3.4.1.4 Total body protein 
Two trials (45 participants) assessed total body protein as an outcome.A66,A110 None of the trials 
assessed oral CHO intake to standard fasting or IV CHO administration. Mathur 2010 and Soop 
2004 compared oral CHO intake to a placebo at different time intervals with no significant 
difference between groups at any of the time points (Table 3.6) [Appendix 6.21]. A66,A110 
Table 3.6: Results of trials evaluating total body protein  
Study 
Number of 
Participants Time Interval 
Mean Difference  
(95% Confidence Interval) p-value 
Oral CHO versus Placebo 
Mathur 2010 31 Baseline 
(Preoperative) 
-0.33 (-1.77; 1.11) p = 0.65 
Soop 2004 14 Day 3 
Postoperative 
2.24 (-8.47; 12.95) p = 0.68 
Mathur 2010 31 Day 7 
Postoperative 
-0.07 (-0.42; 0.28) p = 0.70 
Mathur 2010 31 Day 28 
Postoperative 
0.03 (-0.42; 0.28) p = 0.90 
 
3.4.1.5 Muscle strength 
One trial assessed muscle strength as an outcome.A66 None of the trials assessed oral CHO intake 
to standard fasting or IV CHO administration. Mathur 2010 compared oral CHO intake to a placebo 




with no difference between groups at any of the time points (Table 3.7) [Appendix 6.22]. Two trials 
were excluded due to missing data.A68,A101  
Table 3.7: Results of trials evaluating muscle strength 
Study 
Number of 
Participants Time Interval 
Mean Difference  
(95% Confidence Interval) p-value 
Oral CHO versus Placebo 
Mathur 2010 142 Baseline (Preoperative) Missing data Missing data 
Mathur 2010 142 Day 1 Postoperative -2.22 (-7.75;3.31) p = 0.43 
Mathur 2010 142 Day 3 Postoperative -1.11 (-5.97;3.75) p = 0.65 
Mathur 2010 142 Day 7 Postoperative -3.16 (-10.23;3.91) p = 0.38 
Mathur 2010 142 Day 28 Postoperative 0.07 (-6.82;6.96) p = 0.98 
3.4.1.6 C-reactive protein 
Three trials with 406 participants assessed C-reactive protein (CRP) as an outcome.A15,A66,A68 
Mathur 2010 reported results as median (interquartile range); Kaska 2010 also reported results as 
median (interquartile range) except CRP at day 1 postoperative was reported as a mean (standard 
deviation); Zelic 2013 reported results as a mean (standard deviation). There were no significant 
differences between the comparisons except at day 1 postoperative the oral CHO group had a 
significant lower CRP than the fasting group (Appendix 6.23 Analysis 1.3 Analysis 2.3). The results 
are summarised in Table 3.8. One trial was excluded due to missing data.A74  




Table 3.8: Results of trials evaluating CRP 
COMPARISON / TIME 
INTERVAL 








Participants Mean Difference p-value 
COMPARISON 1: Oral CHO versus inactive control (fasting + placebo) 
CRP at baseline 2 291 NS** 0 0 NR 
CRP before anaesthesia 2 291 NS** 0 0 NR 
CRP at Day 1 postoperative 2 291 NS** 2 219 -8.77 (-15.05,-2.50) p = 0.006* 
CRP at Day 3 postoperative 2 291 NS** 0 0 NR 
CRP at Day 7 postoperative 2 291 NS** 0 0 NR 
COMPARISON 2: Oral CHO versus fasting 
CRP at baseline  1 149 NS** 0 0 NR 
CRP before anaesthesia 1 149 NS** 0 0 NR 
CRP at Day 1 postoperative 0 0 NR 2 219 -8.77 (-15.05,-2.50) p = 0.006* 
CRP at Day 3 postoperative 1 149 NS** 0 0 NR 
CRP at Day 7 postoperative 1 149 NS** 0 0 NR 
COMPARISON 3: Oral CHO versus placebo 
CRP at baseline 1 142 NS** 0 0 NR 
CRP before anaesthesia 1 142 NS** 0 0 NR 
CRP at Day 1 postoperative 1 142 NS** 0 0 NR 
CRP at Day 3 postoperative 1 142 NS** 0 0 NR 
CRP at Day 7 postoperative 1 142 NS** 0 0 NR 
COMPARISON 4: Oral CHO versus active control (IV CHO) 
CRP at baseline 1 149 NS** 0 0 NR 
CRP before anaesthesia 1 149 NS** 0 0 NR 
CRP at Day 1 postoperative 0 0 NR 0 0 NR 
CRP at Day 3 postoperative 1 149 NS** 0 0 NR 
CRP at Day 7 postoperative 1 149  NS** 0 0 NR 
 
* Statistical significant result (p < 0.05) 
** see Appendix 6.17 for results reported as median (interquartile range); all results showed no statistically significant difference between groups 
 
CHO = oral carbohydrate treatment group; CRP = C-reactive protein; IV = intravenous; NR = not reported; NS = not significant 
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3.4.1.7 Return of intestinal function 
Two trials (140 participants) assessed return of intestinal function as an outcome.A75,A101 The 
outcome was measured by the length in days from surgery to first flatus/stool or bowel movement. 
Serclova 2009 reported the results as means (standard deviations) while Noblett 2006 reported the 
results as median (without indicating the interquartile range). The results are summarised per 
comparison: flatus/stool (Table 3.9) and bowel movements (Table 3.10). Results from Šerclová 
2009, showed that the oral CHO group had significantly fewer days for the return of intestinal 
function than the fasting group (inactive control) [stool/flatus: Appendix 6.24; bowel movement 
Appendix 6.25].A75 Noblett 2006 reported that there was no significant difference between the oral 
CHO and the inactive control (fasting or placebo groups) [Appendix 6.17].A101 None of the trials 
assessed oral CHO intake to the active control (i.e. IV CHO administration). 




Table 3.9: Results of trials evaluating flatus / stool (days) 
Comparison Trial 
Number of 






Oral CHO versus inactive control 
Serclova 2009 103 -1.80 (-2.22;-1.38) p < 0.00001* Noblett  
2006 




Oral CHO versus fasting 
Serclova 2009 103 -1.80 (-2.22;-1.38) p < 0.00001* Noblett  
2006 
35 Oral CHO: 2 
Fasting: 3 
COMPARISON 3 
Oral CHO versus placebo 
NR Noblett  
2006 
35 Oral CHO: 2 
Placebo: 3 
COMPARISON 4 
Oral CHO versus active control 
NR NR 
* Statistical significant result (p < 0.05) 
** Results reported as median without indicating the interquartile range 
CHO = oral carbohydrate treatment group; NR = not reported by any of the trials 
 
Table 3.10: Results of trials evaluating bowel movements (days) 
Comparison Trial 
Number of 






Oral CHO versus inactive control 
Serclova 2009 103 -1.80 (-2.15;-1.45) p < 0.00001* Noblett  
2006 




Oral CHO versus fasting 
Serclova 2009 103 -1.80 (-2.15;-1.45) p < 0.00001* Noblett  
2006 
35 Oral CHO: 2 
Fasting: 3.5 
COMPARISON 3 
Oral CHO versus placebo 
NR Noblett  
2006 
35 Oral CHO: 2 
Placebo: 5 
COMPARISON 4 
Oral CHO versus active control 
NR NR 
 
* Statistical significant result (p < 0.05) 
** Results reported as median without indicating the interquartile range 
CHO = oral carbohydrate treatment group; NR = not report by any of the trials 
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3.4.1.8 Length of stay 
Ten trials (885 participants) reported on length of stay.A19,A66,A68,A74,A75,A90,A105,A106,A110,A125 Length of 
stay was divided into the days in the ICU, days in the hospital and the days until fit for discharge. 
The results are summarised in Table 3.11.  




Table 3.11: Results of length of stay that were pooled in a meta-analysis 
 



















Oral CHO versus 
inactive control 
1 101 -2.10 (4.84, 0.64) 0.13 2 187 -0.04 (-0.27, 0.19) 0.37 1 142 median (interquartile range)** 
4 439 median (interquartile range)** 
COMPARISON 2 
Oral CHO versus 
fasting 
1 101 -2.10 (-4.84, 0.64) 0.13 1 113 -0.10 (-0.40, 0.20) > 0.05 Not reported by any of the trials 
1 103 -3.00 (-3.92, 2.08) < 0.05* 
2 232 median (interquartile range)** 
COMPARISON 3 
Oral CHO versus 
placebo 
NR 2 129 0.01 (-0.23, 0.25) 0.95 1 142 median (interquartile range)** 
2 207 median (interquartile range)** 
COMPARISON 4 
Oral CHO versus 
active control 
NR NR NR 
 
* Statistical significant result (p < 0.05) 
** see Appendix 6.17 for results reported as median (interquartile range) 
*** Results could not be pooled due to significant heterogeneity between the studies (Chi
2 
= 34.92, df = 1, p < 0.00001, I
2 
= 97%) 
CHO = oral carbohydrate treatment group; ICU = intensive care unit; n = number of participants; NR = not reported by any of the trials 
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3.4.1.8.1 Length of ICU stay 
a. Comparison 1: Oral CHO versus inactive control (fasting + placebo) 
Järvelä 2008 assessed the length of stay in ICU (days) but there was no difference between the 
oral CHO and fasting groups (MD -2.10, 95%CI: -4.84 to 0.64, 101 participants, 1 trial, Appendix 
6.26).A90 
b. Comparison 2: Oral CHO versus fasting 
Järvelä 2008 assessed the length of stay in ICU (days) but there was no difference between the 
oral CHO and fasting groups (MD -2.10, 95%CI: -4.84 to 0.64, 101 participants, 1 trial, Appendix 
6.26). A90 
c. Comparison 3: Oral CHO versus placebo 
This outcome was not reported by any of the trials assessing this comparison. 
d. Comparison 4: Oral CHO versus active control (IV CHO) 
This outcome was not reported by any of the trials assessing this comparison. 
3.4.1.8.2 Length of hospital stay 
a. Comparison 1: Oral CHO versus inactive control (fasting + placebo) 
Eight trials reported results on length of hospital stay.A66,A68,A74,A75,A105,A106,A110,A125 Results from 
Hausel 2005, Serclova 2009 and Soop 2001 were pooled in a meta-analysis but the results could 
not be reported because of significant heterogeneity between the trials (Chi2 = 38.07, df = 2, 
p < 0.00001, I2 = 95%).A75,A105,A125  An investigation of the source of heterogeneity was carried out 
using both subgroup analysis and sensitivity analysis. Heterogeneity remained significant after 
subgroup analyses with respect to dose and duration of experimental intervention, type of surgery, 
type of anaesthesia and anaesthetic risk. Since the forest plot clearly shows that one of the trials 
(Šerclová 2009) had outlying results compared to the other two trial results, a sensitivity analysis 
was carried out to determine the effect of removing this one trial from the meta-analysis on 
heterogeneity.A75 After removing this trial from the meta-analysis, heterogeneity between studies 
was no longer significant (Chi2 = 0.97, df = 1, p = 0.60, I2 = 0%, Appendix 6.27) but there was no 
significant difference in the length of hospital stay between the oral CHO and the inactive control 
(fasting or placebo) groups (MD -0.04, 95%CI: -0.27 to 0.19, 187 participants, 2 trials, Appendix 
6.27). However, the results of Šerclová 2009 showed significantly shorter hospital stay in the oral 
CHO group compared to the fasting group (MD 10.40, 95%CI 11.32 to 9.48, 103 participants, 1 
trial, Appendix 6.27). Soop 2004 reported results as mean (standard deviation) but since the 
standard deviations for the two groups were both zeros, no treatment effect could be 
calculated.A110 The trial authors reported no significant difference between the oral CHO and the 




placebo group. The remaining four trials reported results as median (interquartile 
range).A66,A68,A74,A106 In three of these trials there was no significant difference between the oral 
CHO and the inactive control (fasting or placebo) groups (Appendix 6.17).A66,A68,A106 Results from 
Tran 2009 showed a significantly shorter hospital stay in favour of the oral CHO group (p = 0.008) 
(Appendix 6.17).A74 
b. Comparison 2: Oral CHO versus fasting 
Four trials reported results on length of hospital stay.A68,A74,A75,A105 Results from two trials were 
pooled in a meta-analysis but the results could not be reported because of significant 
heterogeneity (Chi2 = 34.92, df = 1, p < 0.00001, I2 = 97%). No investigation of the source of 
heterogeneity was carried out because there were only two trials in the meta-analysis. Results are 
therefore reported separately for the two trials. Although the results of the Hausel 2005 study 
showed no significant difference in hospital stay between the two groups (MD -0.10, 95%CI: -0.40 
to 0.20, 113 participants, 1 trial, Appendix 6.27),A105 the results from Šerclová 2009 showed 
significantly shorter hospital stay in the oral CHO group compared to the fasting group (MD -3.00, 
95%CI: -3.92 to -2.08, 103 participants, 1 trial, Appendix 6.27).A75 Two trials reported results as 
median (interquartile range).A68,A74 In Kaska 2010 there was no significant difference between the 
oral CHO and fasting groups (Appendix 6.17).A68 However, results from Tran 2009 showed a 
significantly shorter hospital stay in favour of the oral CHO group (p = 0.008) compared to the 
fasting group (Appendix 6.17).A74 
c. Comparison 3: Oral CHO versus placebo 
Five trials reported results on length of hospital stay.A66,A105,A106,A110,A125 Results from two trials were 
pooled in a meta-analysis but there was no significant difference in length of hospital stay between 
the oral CHO and the placebo groups (MD 0.01, 95%CI: -0.23 to 0.25, 129 participants, 2 trials, 
Appendix 6.27).A105,A125 No significant heterogeneity was detected between the trials (Chi2 = 0.21, 
df = 1, p = 0.64, I2 = 0%, Appendix 6.27). Soop 2004 reported results as mean (standard deviation) 
but since the standard deviations for the two groups were both zeros, no treatment effect could be 
calculated.A110 The trial authors reported no significant difference between the oral CHO and the 
placebo group. The remaining two trials reported results as median (interquartile range) but there 
was no significant difference between the oral CHO and placebo groups (Appendix 6.17).A66,A106 
d. Comparison 4: Oral CHO versus active control (IV CHO) 
This outcome was not reported by any of the trials assessing this comparison. 




3.4.1.8.3 Fit for discharge 
a. Comparison 1: Oral CHO versus inactive control (fasting + placebo) 
Mathur 2010 reported the number of days until fit for discharge as median (interquartile range) but 
there were no significant difference between the oral CHO and placebo groups (Appendix 6.17).A66 
b. Comparison 2: Oral CHO versus fasting 
This outcome was not reported by any of the trials assessing this comparison. 
c. Comparison 3: Oral CHO versus placebo 
One trial reported the number of days until fit for discharge as median (interquartile range) but 
there were no significant difference between the oral CHO and placebo groups (Appendix 6.17).A66 
d. Comparison 4: Oral CHO versus active control (IV CHO) 
This outcome was not reported by any of the trials assessing this comparison. 
3.4.1.9 Adverse events 
The majority of trials reported on one or more of the adverse events of the intervention (i.e. 
regurgitation, aspiration, morbidity and mortality). The major adverse events associated with the 
intervention are summarised in Table 3.12 using descriptive statistics. Adverse events were 
accounted for by the number of patients experiencing an event. According to the available data 
there were no regurgitation (n = 1345; 13 trials),A16,A64,A68,A71,A74,A84,A90,A101,A105,A106,A110,A115,A121 
aspiration (n = 1509; 16 trials),A14,A16,A64,A68,A71,A74,A75,A84,A90,A94,A101,A105,A106,A110,A115,A121 morbidity (n = 
1178; 13 trials)A16,A19,A64,A68,A74,A75,A84,A101,A105,A106,A110,A115,A121 or mortality (n = 1697; 22 
trials)A3,A6,A14,A15,A16,A19,A52,A64,A66,A71,A74,A75,A84,A90.A94,A101,A105,A106,A110,A115,A121,A125 directly as a result of 
the intake of the oral CHO beverage.  
 









n REGURGITATION ASPIRATION MORBIDITY MORTALITY 
LJUNGGREN 2014 (A3) 22 NR NR NR No* 
CANBY 2014 A6) 50 NR NR NR No* 
YILMAZ 2013 (A14) 40 NR No NR No* 
ZELIC 2013 (A15) 70 NR NR NR No* 
YILDIZ 2013 (A16) 60 No No No No 
LJUNGGREN 2012 (A19) 39 NR NR No^ No 
YAGMURDUR 2011 (A52) 44 NR NR NR No* 
WANG 2010 (A64) 48 No No No No* 
MATHUR 2010 (A66) 142 NR NR NR No* 
KASKA 2010 (A68) 194 No No No^ NR 
HELMINEN 2009 (A71) 210 No No NR No* 
TRAN 2009 (A74) 38 No No No^ No* 
SERCLOVA 2009 (A75) 105 NR No No^ No 
YAGCI 2008 (A84) 70 No No No No 
JARVELA 2008 (A90) 101 No No NR No* 
MELIS 2006 (A94) 19 NR No NR No* 
NOBLETT 2006 (A101) 35 No No No^ No* 
HAUSEL 2005 (A105) 172 No No No^ No* 
YUILL 2005 (A106) 65 No No No^ No* 
SOOP 2004 (A110) 14 No No No No* 
BISGAARD 2003 (A115) 86 No No No No* 
HAUSEL 2001 (A121) 252 No No No No* 
SOOP 2001 (A125) 15 NR NR NR No* 
NYGREN 1995 (A131) 12 NR NR NR NR 
^ no complications directly related to the intake of the oral CHO beverage (i.e. allergic reaction, intolerability requiring discontinuation of the beverage, or clinical signs of electrolyte abnormalities); 
complications related to surgery; psychosomatic complications will be discuss separately as secondary outcomes 
* trial did not indicate mortality but it was extrapolated that there was no mortality if the same number of participants that started the trial finished the trial (excluding the participants that were lost to follow up 
due to not meeting inclusion criteria) 
n = number of participants; NR = not reported 
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3.4.2 Secondary outcomes 
Sixteen trials assessed the secondary outcomes as stated (n = 1449). A6, A14, A15, A16, A52, A64, A66, A71, 
A74, A75, A90, A94, A105, A115, A121, A131 Not one of the trials defined the terms as it is self-evident. The 
results of the trials indicated considerable variability in terms of type of data (continuous versus 
dichotomous), unit of measurement (visual analogue scale, verbal descriptive scale, ordinal scale, 
state-trait anxiety inventory), time of measurements (preoperative and/or postoperative), 
interventions (oral CHO versus standard fasting versus placebo versus IV CHO) and comparisons 
(intragroup versus intergroup). Continuous data refers to the severity of the outcomes while 
dichotomous data refers to the number of participants experiencing the outcomes. Given the wide 
variety of methodologies used to evaluate these measures and the subjective nature of their report, 
a descriptive approach was adopted. 
3.4.2.1 Thirst 
Eleven trials assessed thirst as an outcome (932 participants). A6, A15, A16, A52, A64, A66, A71, A74, A94, A121, 
A131 All the trials reported on the severity of thirst experienced (continuous data). Ten of the trials 
used a 100 mm Visual Analogue Scale (VAS) while one trial made use of a 4-point Likert scale.A6 
Only four of the trials indicated that they made use of self-reporting; A52, A64, A66, A131 one trial 
indicated that the nurse administered the score; A121 and the rest did not comment on the scoring 
method. Eight trials assessed thirst in the preoperative phase only; A6, A52, A64, A71, A74, A94, A121, A131 one 
trial assessed thirst in the postoperative phase only; A15 two trials assessed thirst both in the 
preoperative and postoperative phase. A16, A66 Six trials compared oral CHO intake to standard 
fasting only; A6, A15, A16, A52, A74, A94 two trials compared oral CHO intake to placebo only; A66, A131 two 
trials compared oral CHO intake to both fasting and placebo; A64, A121 and one trial compared oral 
CHO intake to both fasting and IV CHO. A71 Three of the trials had incomplete data. A66, A94, A121 The 
main findings of the trials assessing thirst are summarised in Table 3.13 (see Appendix 6.29 for 
comparison of results). 
 








































































Canby, 2014 (A6) 50 Likert scale         CHO group less thirsty preop than fasting group  
(p < 0.05)* 
Zelic, 2013 (A15) 70 100 mm VAS         CHO group less thirsty postop than fasting group  
(p > 0.05) 
Yildiz, 2013 (A16) 60 100 mm VAS 
 
        CHO group less thirsty preop than fasting group  
(p < 0.05)*; 
CHO group less thirsty 2 hours postop than fasting group 
(p < 0.05)*; 
No difference between groups at 24 hours postop  
(p > 0.05) 
Yagmurdur, 2011 
(A52) 
44 100 mm VAS 
(self-reported) 
        CHO group less thirsty from baseline to preop  
(p < 0.05)*; 
Fasting group more thirsty from baseline to preop  
(p < 0.05)*; 
CHO group less thirsty preop than fasting group  
(p < 0.05)* 
Wang, 2010 (A64) 48 100 mm VAS 
(self-reported) 
 
        CHO group no change from 18 hours to 1 hour preop  
(p = 0.921); 
Fasting group more thirst from 18 hours to 1 hour preop  
(p = 0.001)*; 
Placebo group more thirst from 18 hours to 1 hour preop  
(p = 0.015)*; 
@18 hours preop: no difference in thirst between groups  
(p = 0.967); 
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@1 hour preop: difference in thirst between the groups  
(p = 0.005)*; 
CHO vs placebo group @ 1 hour preop: no difference in 
thirst (p = 0.970) 
Mathur, 2010 (A66) 142 100 mm VAS 
(self-reported) 
        All between group comparisons before anaesthesia and 
postop were not different (p > 0.05) 
Helminen, 2009 (A71) 
 
210 100 mm VAS         CHO group: thirst increased before intake of beverage 
(p < 0.05)* with decrease in thirst after intake of beverage 
(p < 0.05)*; 
Fasting group: increase in thirst from evening before surgery 
until anaesthesia the following day (p < 0.05)*; 
IV group: increase in thirst from evening before surgery until 
anaesthesia the following day (p < 0.05)* 
Tran, 2009 (A74) 25 100 mm VAS         CHO group less thirsty preop than fasting group  
(p = 0.01)* 
Melis, 2006 (A94) 19 100mm VAS 
 
        CHO group less thirsty preop than other groups (p value 
missing) 
Hausel, 2001 (A121) 
 
252 100 mm VAS 
(nurse reported) 
 
        Fasting group: increase in thirst preop (p < 0.001)*; 
Placebo group: no consistent trend; 
CHO group less thirsty preop compared to fasting group 
(p < 0.001)* 
Nygren, 1995 (A131) 
 
12 100 mm VAS 
(self-reported) 
 
        CHO group thirst reduced for 60 minutes (p < 0.01)*; 
Placebo group thirst reduced for 40 minutes (p < 0.05)* 
* Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; VAS = visual 
analogue scale 
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Ten trials assessed 862 participants’ severity of hunger (continuous data). A6, A16, A52, A64, A66, A71, A74, 
A94, A121, A131 Nine of the trials used a 100 mm VAS; one of the trials made use of a 4-point Likert 
scale.A6 Only four of the studies indicated that they made use of self-reporting; A52, A64, A66, A131 one 
study indicated that the nurse administered the score; A121 and the rest did not comment on the 
scoring method. Seven trials assessed hunger in the preoperative phase; A6, A52, A64, A71, A74, A94, A121, 
A131 none of the trials assessed hunger in the postoperative phase only; two trials assessed hunger 
both in the preoperative and postoperative phase.A16, A66 Five trials compared oral CHO intake to 
standard fasting only; A6, A16, A52, A74, A94 two trials compared oral CHO intake to placebo only; A66, A131 
two trials compared oral CHO intake to both fasting and placebo; A64, A121 one trial compared oral 
CHO intake to both fasting and IV CHO. A71 Two of the trials had incomplete data. A94, A121 The main 
findings of the trials assessing hunger are summarised in Table 3.14 (see Appendix 6.30 for 
comparison of results). 
 








































































Canby, 2014 (A6) 50 Likert scale         CHO group less hungy preop than fasting group  
(p < 0.05)* 
Yildiz, 2013 (A16) 60 100 mm VAS 
 
        CHO group less hungry preop than fasting group  
(p < 0.05)*; 
CHO group less hungry 2 hours postop than fasting group 
(p < 0.05)*; 
No difference between groups at 24 hours postop 
(p > 0.05) 
Yagmurdur, 2011 
(A52) 
44 100 mm VAS 
(self-reported) 
        CHO group less hungry from baseline to preop  
(p < 0.05)*; 
Fasting group more hungry from baseline to preop  
(p < 0.05)*; 
CHO group less hungry preop than fasting group  
(p < 0.05)* 
Wang, 2010 (A64) 48 100 mm VAS 
(self-reported) 
 
        CHO group no change from 18 hours to 1 hour preop (p = 
0.147); 
Fasting group more hungry from 18 hours to 1 hour preop 
(p = 0.006)*; 
Placebo group no change from 18 hours to 1 hour preop (p 
= 0.291); 
@18 hours preop: no difference in hunger between groups 
(p = 0.968); 
@1 hour preop: difference in hunger between the groups (p 
= 0.041)*; 
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CHO vs Placebo group @ 1 hour preop: no difference in 
hunger (p = 0.146) 
Mathur, 2010 (A66) 142 100 mm VAS 
(self-reported) 
        All between group comparisons before anaesthesia and 
postop were not different (p > 0.05). 
Helminen, 2009 (A71) 
 
210 100 mm VAS         CHO group: decrease in hunger after intake of beverage  
(p < 0.05)*; 
Fasting group: increase in hunger preop  
(p < 0.05)*; 
IV group: no change in hunger preop  
(p > 0.05) 
CHO group less hungry than fasting group preop 
(p < 0.05)* 
Tran, 2009 (A74) 25 100 mm VAS         CHO group less hungry preop than fasting group 
(p = 0.04)* 
Melis, 2006 (A94) 19 100 mm VAS 
 
        CHO group less hungry preop than other groups 
(p value missing) 
Hausel, 2001 (A121) 
 
252 100 mm VAS 
(nurse reported) 
        Fasting group: increase in hunger preop  
(p < 0.05)*; 
Placebo group: no consistent trend; 
CHO group less hungry preop compared to fasting group 
(p < 0.05) 
Nygren, 1995 (A131) 
 
12 100 mm VAS 
(self-reported) 
 
        CHO group no change in hunger 
(p = 0.1); 
Placebo group hunger reduced for 20 minutes  
(p < 0.05)* 
 
* Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; VAS = visual 
analogue scale 
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Twelve trials assessed nausea as an outcome (1 139 participants); A14, A15, A16, A52, A64, A66, A75, A90, A94, 
A105, A115, A121 Seven trials reported on continuous data (i.e. the severity of nausea experienced); A14, 
A16, A52, A64, A66, A94, A121 two trials reported on dichotomous data (i.e. number of patients experiencing 
nausea and number of episodes per patients); A75, A90 three trials reported on both continuous and 
dichotomous data. A15, A105, A115 All trials reporting on the severity of nausea used a VAS; A15, A16, A52, 
A64, A66, A94, A105, A121 except one trial using a verbal descriptive scale (VDS) A14 and one trial using an 
ordinal scale. A115 Four of the trials indicated that they made use of self-reporting; A52, A64, A66, A105 two 
trials indicated that the nurse administered the score; A15, A121 the rest of the trials did not report on 
the scoring method. Nausea was assessed in four of the trials in the preoperative period only; A52, 
A64, A94, A121 five of the trials assessed nausea in the postoperative period only; A14, A15, A75, A90, A115 two 
trials assessed nausea in both the preoperative and postoperative period; A16, A66, A105 one trial 
assessed the severity of nausea experienced in both the preoperative and postoperative period, 
and the number of patients experiencing nausea only in the postoperative period.A105 Seven trials 
compared oral CHO intake to standard fasting; A14, A15, A16, A52,  A75, A90, A94 two trials compared oral 
CHO intake to a placebo; A66, A115  three trials compared oral CHO intake to both standard fasting 
and a placebo; A64, A105, A121 none of the trials compared oral CHO intake to IV CHO administration. 
One of the trials had incomplete data. A94 The main findings of the trials assessing nausea are 
summarised in Table 3.15 (see Appendix 6.31 for comparison of results). 
 








































































Yilmaz,  2013 (A14) 40 VDS         *CHO group less nauseous postop than fasting group  
(p < 0.001) ** 
Zelic, 2013 (A15) 70 100 mm VAS 
(nurse reported) 
        CHO group overall less nauseous postop than fasting group 
(p > 0.05) 
Number of episodes         
Yildiz, 2013 (A16) 60 100 mm VAS         No difference between groups  
(p > 0.05) 
Yagmurdur, 2011 
(A52) 
44 100 mm VAS  
(self reported) 
        No difference between groups  
(p > 0.05) 
Wang, 2010 (A64) 48 100 mm VAS  
(self reported) 
 
        CHO group no change from 18 hours to 1 hour preop  
(p = 0.139); 
Fasting group no change from 18 hours to 1 hour preop  
(p = 0.116); 
Placebo group no change from 18 hours to 1 hour preop  
(p = 0.135); 
@18 hours preop: no difference in nausea between groups 
 (p = 0.984); 
@1 hour preop: no difference in nausea between the groups  
(p = 0.995); 
CHO vs placebo group @ 1 hour preop: no difference in 
nausea (p = 0.788) 
Mathur, 2010 (A66) 142 100 mm VAS  
(self reported) 
        All between group comparisons before anaesthesia and 
postop were not different (p > 0.05). 
Šerclová, 2009 (A75) 105 Number of patients         Fewer patients experienced nausea in the CHO group than the 
fasting group on day 2 to 4 postoperative  
(p < 0.05)** 
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Järvelä, 2008 (A90) 
 
101 Number of patients         More patients experienced nausea in the CHO group than the 
fasting group on day 1 postoperative  
(p = 0.044)** 
Melis, 2006 (A94) 19 100 mm VAS         CHO group less nauseous preop than other groups 
(p value missing) 
Hausel, 2005 (A105) 172 100 mm VAS 
(self reported) 
        Fasting group more nauseous postop than preop  
(p = 0.018)** 
Placebo group more nauseous postop than preop 
(p < 0.001)** 
No difference between groups  
(p > 0.05) 
Number of patients         *CHO group: fewer patients experienced nausea as time 
passed (p <  0.001)** 
*Placebo group: fewer patients experienced nausea as time 
passed (p = 0.006)** 
*Fasting group: no difference in number of patients 
experiencing nausea (p = 0.067) 
*No difference between groups (p = 0.305) 
Bisgaard, 2003 
(A115) 
86 Ordinal scale         No difference between groups 
(p = 0.871) 
Number of episodes         No difference between groups  
(p = 1.000) 
Hausel,  2001 (A121) 
 
252 100 mm VAS (nurse 
reported) 
        CHO group: no change in nausea preop (p > 0.05) 
Fasting group: no change in nausea preop (p > 0.05); 
Placebo group: more nausea preop (p < 0.0001)** 
* Results combined for postoperative nausea and vomiting 
 
** Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; VAS = visual 
analogue scale; VDS = verbal descriptive scale 
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Six trials assessed vomiting as an outcome (574 participants). A14, A15, A75, A90, A105, A115 Three trials 
reported on dichotomous data (i.e. number of patients vomiting and number of episodes per 
patient); A75, A90, A105 one trial reported on continuous data; A14 two trials reported on both continuous 
and dichotomous data. A15, A115 The different scales used include: VDS, A14 VAS, A15 and an ordinal 
scale. A115 Only one trial indicated that the nurse administered the score; A15 all the other trials did 
not comment on the scoring method. All the trials assessed vomiting only in the postoperative 
period. Four trials compared oral CHO intake to standard fasting; A14, A15, A75, A90 one trial compared 
oral CHO intake to a placebo; A115 one trial compared oral CHO intake to both standard fasting and 
a placebo; A105 none of the trials compared oral CHO intake to IV CHO administration. The main 
findings of the trials assessing vomiting are summarised in Table 3.16 (see Appendix 6.32 for 
comparison of results). 
 








































































Yilmaz, 2013 (A14) 40 VDS         
*CHO group less vomiting postop than fasting group  
(p < 0.001)** 
Zelic, 2013 (A15) 70 
100 mm VAS 
(nurse reported) 
        CHO group overall less vomiting postop than fasting group 
(p > 0.05) 
Number of episodes         
Šerclová, 2009 (A75) 105 Number of patients         
Fewer patients experienced vomiting in the CHO group than the 
fasting group on day 2 postoperative  
(p < 0.05)** 
Järvelä, 2008 (A90) 
 
101 Number of patients         
No difference between CHO and fasting groups on day 1 
postoperative  
(p = 0.437) 
Hausel, 2005 (A105) 172 Number of patients         
*CHO group: fewer patients experienced vomiting as time 
passed (p <  0.001)** 
*Placebo group: fewer patients experienced vomiting as time 
passed (p = 0.006)** 
*Fasting group: no difference in number of patients experiencing 
vomiting (p = 0.067)  




Ordinal scale         
No difference between groups 
(p = 0.278) 
Number of episodes         
No difference between groups  
(p = 0.336) 
 
* Results combined for postoperative nausea and vomiting 
** Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; VAS = visual 
analogue scale; VDS = verbal descriptive scale 
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Eleven trials assessed anxiety as an outcome (902 participants); A6, A14, A16, A52, A64, A66, A71, A74, A94, A121, 
A131 All the trials reported on the severity of anxiety experienced (continuous data). Two types of 
scales were used to measure anxiety: The 100 mm VAS A16, A52, A64, A66, A71, A74, A94, A121, A131 and the 
State-Trait Anxiety Inventory (STAI). A6, A14 Four of the studies indicated that they made use of self-
reporting; A52, A64, A66, A131 one study indicated that the nurse administered the score; A121 and the rest 
did not comment on the scoring method. Nine of the trials assessed anxiety only in the 
preoperative period; A14, A16, A52, A64, A71, A74, A94, A121, A131 none of the trials assessed anxiety only in the 
postoperative period; two trials assessed anxiety both in the preoperative and postoperative 
period. A6,  A66  Six trials compared oral CHO intake to standard fasting; A6, A14, A16, A52,  A74, A94 two trials 
compared oral CHO intake to aplacebo; A66,  A131 two trials compared oral CHO intake to both 
fasting and a placebo; A64, A121 one trial compared oral CHO intake to both fasting and IV CHO 
administration.A71  One trial had incomplete outcome data.A94  The main findings of the trials 
assessing anxiety are summarised in Table 3.17 (see Appendix 6.33 for comparison of results). 
 








































































Canby, 2014 (A6) 50 State-Trait Anxiety 
Inventory 
        No difference between CHO and fasting groups  
(p > 0.05) 
Yilmaz, 2013 (A14) 40 State-Trait Anxiety 
Inventory 
        CHO group less anxious preop than fasting group 
(p = 0.035)* 
Yildiz,  2013 (A16) 60 100 mm VAS         No difference between CHO and fasting groups  
(p > 0.05) 
Yagmurdur, 2011 
(A52) 
44 100 mm VAS 
(self-reported) 
        CHO group less anxious from baseline to preop  
(p < 0.05)*; 
CHO group less anxious preop than fasting group  
(p < 0.05)* 
Wang, 2010 (A64) 48 100 mm VAS 
(self-reported) 
 
        CHO group no change from 18 hours to 1 hour preop  
(p = 0.080); 
Fasting group no change from 18 hours to 1 hour preop  
(p = 0.278); 
Placebo group no change from 18 hours to 1 hour preop  
(p = 0.712); 
@18 hours preop: no difference in anxiety between groups  
(p = 0.442); 
@1 hour preop: no difference in anxiety between groups  
(p = 0.104); 
CHO vs placebo group @ 1 hour preop: no difference in 
anxiety (p = 0.940) 
Mathur, 2010 (A66) 142 100 mm VAS 
(self-reported) 
        All between-group comparisons were not different  
(p > 0.05) 
Helminen, 2009 (A71) 
 
210 100 mm VAS         CHO group: no change in anxiety (p > 0.05); 
Fasting group: increase in anxiety (p < 0.05)*; 
IV group: increase in anxiety (p <  0.05)* 
Stellenbosch University  https://scholar.sun.ac.za




Tran, 2009 (A74) 25 100 mm VAS         CHO group less anxious preop than fasting group 
(p = 0.01)* 
Melis, 2006 (A94) 19 100 mm VAS         CHO group less anxious preop than other groups 
(p-value missing) 
Hausel, 2001 (A121) 
 
252 100 mm VAS 
(nurse reported) 
 
        Fasting group: no change (p > 0.05); 
Placebo group: no change (p > 0.05); 
CHO group less anxious preop compared to fasting group 
(p <  0.001)* 
Nygren, 1995 (A131) 
 
12 100 mm VAS 
(self-reported) 
 
        CHO group: no change in anxiety for 90 minutes after intake 
(p = 0.11); 
Placebo group: anxiety reduced for 90 minutes after intake 
(p <  0.05)* 
* Statistical significant result (p < 0.05) 
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Eight trials assessed pain as an outcome (1 081 participants). A15, A52, A66, A71, A75, A105, A115, A121 All the 
trials reported on the severity of pain experienced (continuous data) using a 100 mm VAS; three of 
the trials indicated that they made use of self-reporting; A52, A66, A105 one trial indicated that the nurse 
administered the score; A121 and the other trial did not comment on the scoring method. Three of 
the trials assessed pain only in the preoperative period; A52, A71, A121 two trials assessed pain only in 
the postoperative period; A15, A75 three trials assessed pain both in the preoperative and 
postoperative period. A66 , A105, A115 Three trials compared oral CHO intake to standard fasting; A15, A52, 
A75 two trials compared oral CHO intake to placebo; A66, A115 two trials compared oral CHO intake to 
both fasting and a placebo; A105, A121 one trial compared oral CHO intake to both fasting and IV CHO 
administration.A71 One trial was excluded due to incomplete data. A110 The main findings of the trials 
assessing pain are summarised in Table 3.18 (see Appendix 6.34 for comparison of results). 
 








































































Zelic,  2013 (A15) 70 100 mm VAS         CHO group overall less pain postop than fasting group 
(p > 0.05) 
Yagmurdur, 2011 
(A52) 
44 100 mm VAS  
(self reported) 
        No difference between groups  
(p > 0.05) 
Mathur, 2010 (A66) 142 100 mm VAS  
(self reported) 
        All between-group comparisons before anaesthesia and postop 
were not different (p > 0.05). 
Helminen, 2009 (A71) 210 100 mm VAS         No difference between groups (p > 0.05) 
Šerclová, 2009 (A75) 105 100 mm VAS         CHO group less pain than the fasting group  
(p < 0.05)* 
Hausel, 2005 (A105) 172 100 mm VAS 
(self reported) 
        No difference between groups  
(p > 0.05) 
Bisgaard, 2003 
(A115) 
86 100 mm VAS         No difference between groups 
(p = 0.228) 
Hausel, 2001 (A121) 
 
252 100 mm VAS (nurse 
reported) 
        CHO group: no change in pain preop (p > 0.05) 
Fasting group: no change in pain preop (p > 0.05); 
Placebo group: no change in pain preop (p > 0.05) 
 
* Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; VAS = visual 
analogue scale 
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Three trials assessed fatigue as an outcome (288 participants); A16, A66, A115  All trials reported on the 
severity of fatigue experienced (continuous data) with two trials using a 100 mm VAS A16, A66 and 
one trial using an ordinal scale.A115 One of the trials indicated that they made use of self-reporting. 
A66 All trials assessed fatigue in both the preoperative and postoperative period. One trial compared 
oral CHO intake to standard fasting; A16 two trials compared oral CHO intake to a placebo; A66, A115 
none of the trials compared oral CHO intake to IV CHO administration. The main findings of the 
trials assessing fatigue are summarised in Table 3.19 (see Appendix 6.35 for comparison of 
results). 
 








































































Yildiz, 2013 (A16) 60 100 mm VAS         CHO group less fatigue preop compared to fasting group 
(p < 0.05)*; 
No difference between groups postop  
(p > 0.05) 
Mathur, 2010 (A66) 142 100 mm VAS  
(self reported) 
        CHO group increase in fatigue from preop to postop 
(p < 0.005)*; 
Placebo group increase in fatigue from preop to postop 
(p < 0.005)*; 
No difference between group (p > 0.05) 
Bisgaard, 2003 
(A115) 
86 Ordinal scale         No difference between groups 
(p = 0.228) 
 
* Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; 
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Five trials assessed weakness as an outcome (589 participants). A16, A64, A71, A94, A121 All of the trials 
reported on the severity of weakness experienced (continuous data), and used a 100 mm VAS. 
One of the trials indicated that they made use of self-reporting; A64 one trial indicated that the nurse 
administered the score; A121 and the other trials did not comment. Four trials assessed weakness in 
the preoperative period A64, A71, A94, A12 with one trial assessing weakness in both the preoperative 
and postoperative period.A16 Two trials compared oral CHO intake to standard fasting; A16, A94 two 
trials compared oral CHO intake to both fasting and placebo; A64, A121 one trial compared oral CHO 
intake to both fasting and IV CHO administration; A71 none of the trials compared oral CHO intake 
to only placebo or IV CHO administration. Only one trial had incomplete data.A94  The main findings 
of the trials assessing weakness are summarised in Table 3.20 (see Appendix 6.36 for comparison 
of results). 
 








































































Yildiz, 2013 (A16) 60 100 mm VAS         CHO group less weak than fasting group preop  
(p < 0.05)* 
CHO group less week than fasting group postop  
(p < 0.05)* 
Wang, 2010 (A64) 48 100 mm VAS 
(self-reported) 
 
        CHO group no change from 18 hours to 1 hour preop  
(p = 0.198); 
Fasting group no change from 18 hours to 1 hour preop  
(p = 0.775); 
Placebo group no change from 18 hours to 1 hour preop 
(p = 0.868); 
@18 hours preop: no difference in weakness between groups  
(p = 0.886); 
@1 hour preop: no difference in weakness between groups  
(p = 0.832); 
CHO vs Placebo group @ 1 hour preop: no difference in 
weakness (p = 0.584) 
Helminen, 2009 (A71) 
 
210 100 mm VAS         CHO group: no change in weakness (p > 0.05); 
Fasting group: increase in weakness (p < 0.05)*; 
IV group: no change in weakness (p > 0.05) 
Melis, 2006 (A94) 19 100 mm VAS         CHO group less weak preop than other groups 
(p-value missing) 
Hausel, 2001 (A121) 252 100 mm VAS 
(nurse reported) 
 
        CHO group: no change ( p > 0.05) 
Fasting group: increase in weakness (p < 0.05)*; 
Placebo group: no change (p > 0.05) 
* Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; VAS = visual 
analogue scale 
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Five trials assessed tiredness as an outcome (573 participants). A52, A64, A71, A94, A121 All trials reported 
on the severity of tiredness (continuous data) by using a 100 mm VAS. Two of the trials indicated 
that they made use of self-reporting; A52, A64 one trial indicated that the nurse administered the 
score; A121 and the other trials did not comment. All trials assessed tiredness in the preoperative 
period only. Two trials compared oral CHO intake to standard fasting only; A52, A94 two trials 
compared oral CHO intake to both fasting and a placebo; A64, A121 one trial compared oral CHO 
intake to both fasting and IV CHO administration; A71 none of the trials compared oral CHO intake to 
placebo or IV CHO administration only.  Only one trial had incomplete data.A94  The main findings of 
the trials assessing tiredness are summarised in Table 3.21 (see Appendix 6.37 for comparison of 
results). 
 










































































44 100 mm VAS 
(self reported) 
        No difference between CHO and fasting groups  
(p > 0.05) 
Wang, 2010 (A64) 48 100 mm VAS 
(self reported) 
 
        CHO group no change from 18 hours to 1 hour preop  
(p = 0.150); 
Fasting group no change from 18 hours to 1 hour preop  
(p = 0.299); 
Placebo group no change from 18 hours to 1 hour preop  
(p = 0.223); 
@18 hours preop: no difference in tiredness between groups 
(p = 0.889); 
@1 hour preop: no difference in tiredness between groups  
(p = 0.615); 
CHO vs placebo group @ 1 hour preop: no difference in 
tiredness (p = 0.509) 
Helminen, 2009 (A71) 
 
210 100 mm VAS         CHO group: no change in tiredness (p > 0.05); 
Fasting group: increase in tiredness (p < 0.05)*; 
IV group: no change in tiredness (p > 0.05) 
Melis, 2006 (A94) 19 100 mm VAS         CHO group less tired preop than other groups 
(p value missing) 
Hausel, 2001 (A121) 252 100 mm VAS 
(nurse reported) 
 
        CHO group: no change in tiredness (p > 0.05) 
Fasting group: increase in tiredness (p < 0.0001)*; 
Placebo group: increase in tiredness (p < 0.001)*; 
* Statistical significant result (p < 0.05) 
CHO = oral carbohydrate treatment group; IV = intravenous carbohydrate treatment group; n = number of participants; postop = postoperative; preop = preoperative; 
VAS = visual analogue scale 
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Five trials assessed malaise as an outcome (584 participants). A16, A52, A66, A115, A121 All of the trials 
reported on the severity of malaise experienced by using a 100 mm VAS; two of the trials indicated 
that they made use of self-reporting; A52, A66 one trial indicated that the nurse administered the 
score; A121 and the other trial did not comment.  Three trials assessed malaise in the preoperative 
period only; A52, A66, A121 two trials assessed malaise in both the preoperative and postoperative 
period; A16, A115 none of the trials assessed malaise in the postoperative period only. Two trials 
compared oral CHO intake to standard fasting; A16, A52 two trials compared oral CHO intake to 
placebo; A66, A115 one trial compare oral CHO intake to both standard fasting and a placebo; A121 
none of the trials compared oral CHO intake to IV CHO administration. The main findings of the 
trials assessing malaise are summarised in Table 3.22 (see Appendix 6.38 for comparison of 
results). 
 








































































Yildiz, 2013 (A16) 60 100 mm VAS         No difference between group preop  
(p > 0.05); 
CHO group experienced less malaise than fasting group 
postop (p < 0.05)* 
Yagmurdur, 2011 
(A52) 
44 100 mm VAS 
(self reported) 
 
        CHO group: decrease in malaise (p < 0.05)*; 
CHO group experienced less malaise than fasting group 
preop (p < 0.05)* 
Mathur, 2010 (A66) 
 
142 100 mm VAS 
(self reported) 
        No difference between group (p > 0.05) 
Bisgaard, 2003 
(A115) 
86 100 mm VAS         No difference between group (p = 0.349) 
Hausel, 2001 (A121) 
 
252 100 mm VAS 
(nurse reported) 
 
        Fasting group: no change (p > 0.05); 
Placebo group: decrease in malaise (p < 0.01)*; 
CHO group experienced less malaise compared to fasting 
group (p < 0.01)* 
 
* Statistical significant result (p < 0.05) 
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CHAPTER 4: DISCUSSION 
  





POCL up to two hours before the induction of anaesthesia is one of the main nutrition elements of 
the ERAS Society’s recommendations.194-202 This review examined data from 24 trials including 
1903 participants receiving POCL undergoing various types of anaesthesia (mainly general or a 
combination of general and neuraxial anaesthesia) and elective surgical procedures (mainly 
abdominal surgery). POCL was compared to standard fasting and/or placebo in the majority of 
trials with only two trials examining IV carbohydrate administration. The trials were conducted in a 
wide geographical setting with most participants from Sweden. The majority of trials included in this 
systematic review were still relatively small (< 100 participants). More female than male 
participants were included in the review with the majority of participants being older than 50 years. 
It is worth mentioning that many trials limited inclusion to otherwise healthy participants with an 
ASA score of I – II. Trials that included participants with ASA scores of III and IV generally reported 
smaller numbers due to the fact that these participants were less likely to undergo elective surgery. 
Amongst trials included in this review, experimental and control groups were well matched with no 
significant differences between groups at baseline. A combination of heterogeneous surgical 
procedures and anaesthetic protocols introduced a number of variables that could have diminished 
the possibility of detecting any clinical benefit of POCL. Also, trials did not clearly indicate which of 
the ERAS protocol components formed part of the intervention and this could have a direct effect 
on the outcomes. The results of the trials were conflicting with some trials showing positive results 
and others negative or no results. The results of the systematic review will be discussed per 
outcomes (where applicable, results were grouped together to avoid repetition). 
4.2 PRIMARY OUTCOMES  
Results were reported as mean (standard deviation) and median (interquartile range), and 
therefore, all results could not be pooled together. Therefore, the discussion will focus on the data 
that could be pooled together, single trials as well as trials not included in the review but relevant to 
the topic.  
4.2.1 Biochemical status 
4.2.1.1 Glucose  
Traditionally, hyperglycaemia was considered a normal adaptive response; today based on 
physiological data, it is evident that glycaemic control is fundamental in reducing postoperative 
morbidity and mortality.164 Hyperglycaemia is associated with increased infectious complications 
(decreased phagocytosis and glycosylation of immune globulins), poor wound healing (altered 
collagen synthesis), fluid and electrolyte abnormalities, nutritional depletion (preventing optimal 
nutritional utilisation), hypertriglyceridemia (decreased lipoprotein lipase activity), accelerated 
catabolic state, and aggravated symptoms of gastroparesis.144 Even though neurohormonal 
alterations (i.e. cortisol, catecholamines and glucagon) and cytokine release (i.e. interleukin-1, 




interleukin-6 and tumor necrosis factor α) contributes to stress hyperglycaemia, the primary force 
still remains gluconeogenesis and insulin resistance.221 While hyperglycaemia must be avoided the 
questions still remain what is the optimal glucose level that maximises benefit and minimises risk, 
and do these levels differ between different population groups.  
The results of this review showed that there was no significant difference in glucose levels at 
baseline between groups (one trial with significant heterogeneity was excluded). However, the 
POCL group had a significant higher glucose level at the induction of anaesthesia (i.e. after the 
intake of the carbohydrate beverage) when compared to the fasting group (p = 0002). Two trials 
respectively showed that the glucose levels was significantly increased in the POCL group 
compared to the fasting group on day 0 postoperative222,223 with one trial showing no significant 
difference.224 Due to standard physiological processes this is a normal appearance that glucose 
levels will increase when you give oral glucose (i.e. oral carbohydrates) compared to nothing (i.e. 
standard fasting). Even though the glucose levels were significantly higher in the POCL group it 
was still within normal physiological range.  Unfortunately, none of the trials evaluated POCL to a 
placebo group on Day 0 postoperative to compare to the effect of fasting on glucose levels. 
Interestingly, there was no significant difference in glucose levels between groups on day 1 
postoperative. Table 4.1 gives a summary of the trials included in the review at different time 
intervals (see Appendix 6.16 for clarification of the discussion process). 
Table 4.1: Summary of trials assessing glucose at different time intervals in this review 
TIME INTERVAL COMPARISON 
BASELINE No significant difference between groups when data pooled together; 
A52, A66, A71, 
A90, A106 
one trial was excluded due to heterogeneity and significant higher glucose 
levels in the POCL group 
A84
 
BEFORE ANAESTHESIA Significant difference between POCL and fasting groups (p = 0.0002);* 
A71, A84, A90 
no difference between POCL, placebo and IV groups 
DAY 0 POSTOPERATIVE One trial reported results as mean (standard deviation) with no significant results 
between groups; 
A90
 two trials reported results as median (interquartile range) with 




DAY 1 POSTOPERATIVE No significant difference between the POCL, fasting, placebo and IV groups 
* Statistical significant result (p < 0.05) 
IV = intravenous, POCL = preoperative oral carbohydrate loading 
4.2.1.2 Insulin 
During the metabolic response there is an increase in glucose production with simultaneous 
increase in insulin secretion. Therefore, theoretically as the glucose levels increase the insulin 
levels will increase. POCL mimics the intake of breakfast and causes the release of endogenous 
insulin to levels seen after a normal meal. It was proposed that the postoperative effect of POCL 
on insulin sensitivity is related to the enhanced insulin levels at the onset of surgery.121 Data on 
insulin levels in this review are conflicting with differences at baseline and no trend observed 




(Table 4.2).  It is of no clinical value to compare the pooled glucose and insulin values in this 
review since the same trials were not included at the specified time points due to methodological 
differences and missing data.  
Table 4.2: Summary of trials assessing insulin at different time intervals in this review 
TIME INTERVAL COMPARISON 
BASELINE Significant lower insulin levels in the POCL group versus inactive control when 
data pooled together (two trials were excluded due to significant heterogeneity) 
[p = 0.01].* The trials comparing the POCL group to fasting showed significant 
lower insulin levels when pooled (p =  0.01).*In contrast, the single trial evaluating 
the POCL group to placebo showed significant higher insulin levels in the POCL 
group (p = 0.005).* Data reported as median did not record any significant 
difference between POCL and inactive control groups. One trial compared POCL 
to IV glucose administration with no significant difference between groups. 
BEFORE ANAESTHESIA No significant difference between the POCL, fasting, placebo and IV groups. 
DAY 0 POSTOPERATIVE One trial investigated POCL to fasting at this point with no significant difference
 
between groups. None of the trials compared POCL to placebo or IV glucose 
administration.  
DAY 1 POSTOPERATIVE One trial investigated POCL to placebo at this point with a significant difference
 
between groups (p < 0.00001).* None of the trials compared POCL to fasting or IV 
glucose administration. 
* Statistical significant result (p < 0.05) 
IV = intravenous, POCL = preoperative oral carbohydrate loading 
4.2.1.3 Insulin resistance 
Due to the antagonistic effects of the stress hormones released during surgery, there is a decrease 
in insulin sensitivity with subsequent insulin resistance that is characterised by hyperglycaemia. 
See Figure 4.1 for a diagrammatic representation of the effect of fasting, POCL and numerous 
ERAS elements on the effect of different biochemical parameters during surgery (as per author’s 
interpretation). Even though the trauma of surgery itself causes insulin resistance the severity of 
insulin resistance and hyperglycaemia increase even more with open surgical techniques.15 The 
type of anaesthesia used also has an impact on the metabolic response since the use of epidural 
anaesthesia decreases the release of stress hormones opposing less insulin resistance than 
expected during general anaesthesia.164 Standard fasting before surgery also poses a metabolic 
risk by inducing a catabolic state and enhancing the patient’s response to trauma. Therefore, 
theoretically the patient that was fasted before receiving general anaesthesia for open surgery will 
have the worst metabolic response. See Figure 4.2 for a diagrammatic representation of the effect 
of various parameters on insulin resistance (as per author’s interpretation).  The main aim during 
the perioperative period is to manage glycaemic control by reducing insulin resistance and creating 
a more anabolic environment to reduce complications. The intake of a preoperative oral 
carbohydrate beverage containing approximately 12% carbohydrates (in the form of maltodextrin to 
decrease to osmolality and increase the gastric emptying time) initiates a more anabolic state.164 
The mechanism by which POCL attenuates postoperative insulin resistance is not fully understood 
(see Chapter 1). 
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INSULIN SENSITIVITY INSULIN RESISTANCE HYPERGLYCAEMIA 
Figure 4.1: Theoretical representation of the effect of POCL and/or multiple ERAS elements on 
biochemical parameters during surgery 
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Figure 4.2: Theoretical representation of the effect of various parameters on insulin resistance 
 
 




Data with regards to insulin resistance should be interpreted with caution since the different 
methods measure different parameters that are not comparable. The most common methods on 
this topic include the hyperinsulinaemic euglycaemic clamp (HEC), insulin tolerance test (ITT), 
homeostatic model assessment – insulin resistance (HOMA-IR) and quantitative insulin sensitivity 
check index (QUICKI). See Table 4.3 for a comparison of these methods.16,225 Other methods to 
measure insulin resistance include the frequently sampled intravenous glucose tolerance test, 
insulin suppression test, continuous infusion of glucose with model assessment, insulin sensitivity 
test, oral glucose tolerance test, lipid-based fasting formulae, glucose/insulin ratio, and fasting 
insulin resistance index. Note that some methods measure insulin resistance while others measure 
insulin sensitivity; a greater reduction in insulin sensitivity is associated with a greater development 
of insulin resistance.  
The HEC method is the gold standard to measure insulin resistance since it measures insulin 
resistance in the carbohydrate fed state, and can differentiate between hepatic and peripheral 
insulin resistance. The HOMA-IR and QUICKI equations measure insulin resistance using the 
basal glucose and insulin concentrations during the fasted state, making it less sensitive and less 
accurate.17 The HOMA-IR and ITT measure different aspects of insulin resistance: HOMA-IR 
employs simultaneous measures of glucose and insulin to measure insulin resistance whereas ITT 
uses the rate of glucose disposal in response to insulin to measure insulin sensitivity.17 The ITT is 
more reproducible than HOMA-IR, therefore where repetitive measurements are taken for 
comparison, the ITT should give a more reliable result.226 A high ITT value indicates benefit by 
signifying high insulin sensitivity and consequently, reduced insulin resistance whereas a high 
HOMA-IR value indicates harm by signifying high insulin resistance.  






Insulin is infused intravenously at a constant rate for a specific period while glucose is also 
infused simultaneously at a variable rate to maintain blood glucose levels at 4.5 mmol/l. 
Conducted under very controlled circumstances. Entire body glucose disposal calculated (M). 
ITT 
Invasive test 
Uses the rate of glucose disposal in response to insulin as a measure of insulin sensitivity (the 
reciprocal of insulin resistance). 
HOMA-IR 
Non-invasive test 
Equation used to calculate insulin resistance. 
HOMA-IR = insulin (uu/ml) x blood glucose level (mg/dl) / 405 
QUICKI 
Non-invasive test 
Crude estimation of insulin sensitivity derived from the inverse of the sum of the decimal 
logarithms of the fasting insulin and fasting glucose levels.  
 
HEC = hyperinsulinaemic normoglycaemic clamp; ITT = insulin tolerance test; HOMA-IR = homeostatic model 
assessment – insulin resistance; QUICKI = quantitative insulin sensitivity check index  
The number of trials included in this review was limited with only six trials assessing insulin 
resistance. Four trials used the HEC method and two trials used the HOMA-IR method. None of 
the included trials used the QUICKI or ITT methods. The trials using the HEC method to measure 
insulin resistance included a relatively small number of participants.186,227-229 Interestingly, the four 




trials using this method were conducted by only two authors. Descriptive statistics were used to 
present trials using the HEC method since the comparison between the trials were challenging with 
regards to comparison groups (i.e. POCL versus placebo, POCL versus fasting), time intervals (i.e. 
day before surgery to day 1 postoperative, 1 week preoperative to third day postoperative, 1 week 
preoperative to immediate postoperative), and no fixed consensus on the important parameters 
(i.e. duration of infusion, infusion rate).  Both the trials using the HOMA-IR method to calculate the 
insulin resistance did not find any significant difference between the POCL, fasting and placebo 
groups.223,230 To note is that none of the trials compared POCL to fasting and placebo in the same 
trial since the emphasis here will be on the amount of oral carbohydrate intake rather than the 
volume of fluid intake. Table 4.4 gives a summary of numerous trials available in the literature 
evaluating the effect of POCL on the development of postoperative insulin resistance.  
From Table 4.4 it is evident that there is great variability in trials assessing these outcomes: 
 Different measurement methods i.e. HEC, HOMA-IR, QUICKI, ITT; 
 Sample size i.e. small sample size with HEC method as the gold standard including the 
least number of participants; 
 Type of surgery i.e. minor versus major surgery, laparoscopic versus open surgery; 
 Type of anaesthesia i.e. general versus neuraxial versus combination; 
 Experimental groups i.e. amount of CHO and volume of POCL, evening dose of POCL; 
 Control groups i.e. inactive (standard fasting, placebo), active (IV POCL), no control 
 Time of measurement i.e. baseline (one week before surgery to day before surgery), 
postoperative (immediate after surgery versus a day or two after surgery). 
Trials evaluating insulin resistance by the HEC method. Eight trials assessed this outcomes but 
were conducted by a limited number of authors: two trials were conducted by Ljunggren et al, two 
trials by Svanfeldt et al, two trials by Soop et al, and Olle Ljungqvist was principal or co-author in 
six of the trials.161,185,186,189,227,228,229,231 The majority of trials evaluated insulin resistance at baseline 
and within the first 24 hours postoperative. Insulin resistance develops within hours after surgery; 
therefore, results from immediate postoperative compared to 24 hours or more postoperative will 
be different and cannot be pooled together. Soop 2004 et al evaluated insulin resistance at 
baseline and at day 3 postoperative, and concluded that the sites of postoperative insulin 
resistance shifts from mainly or exclusively peripheral tissues in the first 24 hours after surgery to 
involve also the liver to a substantial degree on day 3 postoperative.186 
 




Table 4.4: Trials evaluating the effect of POCL on the development of insulin resistance 








Findings p - value 




22 Hip replacement General + spinal POCL 800 ml (pm) + 400 ml 
(am) 
Placebo Before surgery 
and on day 1 
postoperative 
IS decreased by 51% in POCL group 











and on day 1 
postoperative 
IS decreased by 51% in POCL group 
compared to 43% in the fasting 
group; no significant difference 
between POCL and placebo 




12 Colorectal surgery General + 
epidural 
High POCL (125 mg/ml 
CHO) – 175 – 200 g CHO 
Low POCL (25 mg/ml 
CHO) – 35 – 40 g CHO 
Before surgery 
and on day 1 
postoperative 







6 Simulated setting 
(no surgery) 
No anaesthesia POCL 800 ml (pm) 
POCL 400 ml (am)  
POCL 800 ml (pm) + 400 ml 
(am) 
Standard fasting 120 minutes 
after the 
morning drink 
(i.e. onset of 
‘surgery’) 
IS increase by 50% three hours after 
intake of morning drink 




14 Hip replacement Epidural POCL 800 ml (pm) + 400 ml 
(am) 
Placebo 1 week 
preoperative 
and on day 3 
postoperative 
IS decreased by 36% in POCL group 





15 Hip replacement  Epidural POCL 800 ml (pm) + 400 ml 
(am) 




IS decreased by 18% in POCL group 
compared to placebo group 












Hip: spinal + 
epidural 
















Colorectal: 24% greater reduction in 
IS in fasted group than in POCL 
group at 24 hours postoperative; 
Hip replacement: 37% reduction in IS 
in placebo group immediately after 
surgery; no significant reduction in IS 
in POCL group 
< 0.05 ** 
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General IV glucose infusion Standard fasting 3 days 
preoperative 
and on day 1 
postoperative 
IS reduced in fasting group compared 
with IV glucose group 
< 0.01 ** 




120 Colorectal surgery General + 
epidural 
POCL + Postop Placebo; 
Preop Placebo + Postop 
ONS; 
POCL + Postop ONS 
Preop placebo + Postop 
placebo 
Before surgery 
and day 1, 2, 3 
postoperative 
IR lower in group receiving 











POCL with pea protein 
hydrolysate: 400ml (pm) + 
200ml (am) 
Standard fasting Before surgery 
and on day 1 
postoperative 










General POCL with water + 
maltodextrin + glutamine 
Standard fasting; 
water (placebo); 
POCL with water + 
maltodextrin (POCL) 




IR greater in control group than 









Unknown POCL with whey: 474 ml 
(pm) + 237 ml (am) 




IR significantly lower in POCL-whey 









POCL 800 ml (pm) + 400 ml 
(am) 
Placebo Baseline to days 
1, 5, 7 
postoperative 
IR significantly higher in placebo 
group  





48 Colorectal surgery General POCL 400 ml (am) Standard fasting 
Placebo 




IR increased significantly in all study 
groups but were significantly lower in 







38 Coronary artery 
bypass and spinal 
surgery 
General POCL 800 ml (pm) + 400 ml 
(am) 
Standard fasting Baseline (after 
12 hour fast) 
and immediately 
postoperative 

















18 Coronary artery 
bypass 
Unknown POCL 400 ml (pm) + 400 ml 
(am) 
Standard fasting Day before 
surgery to days 
1, 2 and 6 
IR is higher in POCL group than 
fasting group on day 6.  
< 0.05 ** 
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194 Colorectal surgery General POCL: 400 ml (pm) + 400 ml 
(am) 
Standard Fasting 
500 ml 10% IV glucose 





1, 3 and 7 
postoperative 
IS reduced in fasting group when 
compared with the other groups 
< 0.05 ** 





120 Colorectal surgery General + 
epidural 
POCL + Postop placebo; 
Preop placebo + Postop 
ONS; 
POCL + Postop ONS 
Preop placebo + Postop 
placebo 
Before surgery 
and day 1, 2, 3 
postoperative 
IS increased in group receiving POCL 






38 Coronary artery 
bypass and spinal 
surgery 
General POCL 800 ml (pm) + 400 ml 
(am) 
Standard fasting Baseline (after 
12 hour fast) 
and immediately 
postoperative 
No significant difference. 0.41 
 
* measured insulin resistance by both HOMA-IR and ITT 
** Statistical significant result (p < 0.05) 
n = number of participants; POCL = preoperative oral carbohydrate loading; CHO = carbohydrate; IR = insulin resistance; IS = insulin sensitivity; pm = evening before surgery; am = 
morning of surgery; ? = information missing; ONS = oral nutritional supplementation 
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The hypocaloric nutrition and immobilisation that are common during the postoperative period 
exacerbate the development of insulin resistance. It is known that insulin resistance develops in 
healthy volunteers after three days of hypocaloric feeding234 and after 6–7 days of bed rest.235 
Therefore, the results should be interpreted according to the time of postoperative measurement 
(i.e. immediate postoperative versus 24 hours or more postoperative). Nygren et al compared 
POCL to standard fasting and placebo with a significant decrease in insulin sensitivity in the 
standard fasting and placebo groups; unfortunately, there were confounding factors with regards to 
type of surgery (fasting group received colorectal surgery while the placebo group received hip 
replacement) since the degree of postoperative insulin resistance is related to the magnitude of 
surgical trauma, and the time interval of measuring the outcomes (colorectal surgery group within 
24 hours and hip replacement group immediately postoperative) since hypocaloric nutrition during 
the first few days postoperative is associated with increased insulin resistance.185 In contrast, 
Ljunggren 2012 et al compared POCL to standard fasting and placebo in patients receiving hip 
replacement surgery with a significant decrease in insulin sensitivity in the POCL group compared 
to the fasting group, and no significant difference between the POCL and placebo groups.228 
Ljunggren 2014 et al completed another trial with no significant difference between the POCL and 
placebo groups.227 Svanfeldt 2005 et al reported a 50% reduction in insulin sensitivity in the POCL 
group three hours after the intake of the beverage. Unfortunately, this was a simulated situation 
with no surgery or anaesthesia.231 The landmark study by Ljungqvist et al in 1994 showed that the 
administration of IV glucose had a significant lower reduction in insulin sensitivity when compared 
with standard fasting.161 
Trials evaluating insulin resistance by the HOMA-IR method. The trials evaluating insulin 
resistance by means of HOMA-IR included different carbohydrate beverages i.e. standard 
POCL,138,223,230,232 POCL with pea protein hydrolysate,167 POCL with glutamine,174 POCL with whey 
protein,166 and POCL with postoperative oral nutritional supplementation.226 Pexe-Machado et al 
used a carbohydrate drink which contained a pea protein hydrolyse; there was no significant 
difference between the groups, which can be attributable to the fact that the HOMA-IR 
measurement only took place on day 2 postoperative when patients were already established on 
oral or enteral nutrition.167 Dock-Nascimento et al compared a carbohydrate drink with added 
glutamine (total of 0.77g of body weight), carbohydrate drink without glutamine, water and standard 
fasting; there was a significant increase in insulin resistance in the fasting group compared with the 
other groups.174 The authors of this trial took the necessary precautions of the effect of nutrition 
into account and evaluated insulin resistance ten hours postoperative before nutrition intake. There 
was no significant difference between the two POCL groups (one with glutamine and one without 
glutamine). Most likely, the minor type of surgery might have influenced these results, and might be 
different in larger trials with major surgery. Perrone et al. compared POCL with added whey protein 
to a placebo of water intake; the POCL-whey group had significant lower insulin resistance. It is 




difficult to draw a conclusion since there was no POCL group without whey protein or just a whey 
group to act as control, so theoretically these results may also reflect only the effect of POCL.166 
Lidder et al investigated the effect of combining POCL with postoperative oral nutritional 
supplementation, and concluded that when POCL are combined with a postoperative oral 
nutritional supplementation, benefit is seen when compared with no supplements; and with patients 
adhering to POCL or a postoperative oral nutritional supplementation, an intermediate effect is 
seen.226 Rapp-Kesek et al reported severe insulin resistance postoperative in both the POCL and 
standard fasting groups – only significant difference on day 6 postoperative.233  The severity of 
insulin resistance could be attributable to the fact that the study population was elderly and that the 
participants received POCL as well as glucose infusion. Nevertheless, five trials indicated that the 
POCL groups (with or without added protein) had significant less insulin resistance in the 
postoperative period when compared with standard fasting or placebo.166,174,226,230,232 Two trials had 
no difference in postoperative insulin resistance between POCL and fasting groups.167,223 Two trials 
had significant higher postoperative insulin resistance in the POCL group than compared to 
fasting.138,233  
Trials evaluating insulin resistance by the QUICKI method. Kaska et al was the only trial using this 
method to measure insulin resistance.222 The trial focused exclusively on POCL as an element of 
the ERAS protocol. POCL was compared with standard fasting and IV glucose administration. The 
fasting group had significant higher insulin sensitivity levels immediate postoperative with the 
POCL group having the best results by preserved insulin sensitivity in the postoperative period. 
Keep in mind that the QUICKI method only provided a crude estimation of insulin sensitivity (since 
basal glucose and insulin concentrations were used for its calculation), and could not be compared 
to the HEC method.  
Trials evaluating insulin resistance by the ITT method. The trials by Lidder et al and Tran et al used 
the HOMA-IR as well as the ITT methods.223,226 The ITT uses the rate of glucose disposal in 
response to insulin as a measure of insulin sensitivity (the reciprocal of insulin resistance), and are 
more reproducible than the HOMA-IR since serum insulin and glucose fluctuate even under strict 
controlled conditions. Lidder et al had four comparison groups with POCL and/or postoperative 
ONS: HOMA-IR reported a significant decrease in insulin resistance in the group receiving both 
POCL and postoperative ONS (p = 0.011) confirmed by the ITT method which showed significant 
increased levels of insulin sensitivity in the group receiving both POCL and postoperative ONS (p < 
0.001).226 In contrast, Tran et al reported no significant difference between the POCL or standard 
fasting groups whether measured by HOMA-IR or ITT (p > 0.05).223 
4.2.2 Protein status  
The catabolic state of surgery and fasting is associated with depleted glycogen stores, which 
increase the demand for protein and in return, causes loss of protein stores.236 Confounding factors 




like bed rest increases protein loss with malnutrition exacerbating the response even further.164 By 
reducing insulin resistance, any energy and protein consumed will be utilised in a more anabolic 
fashion, hyperglycaemia reduced, less lean body mass will be lost and patients will be mobilised 
quicker.193 Since muscle function correlates closely with total body protein, a loss of muscle mass 
results in decreased muscle strength, and decreased muscle strength is associated with loss of 
physical functionality and negative impact on recovery.237 Some authors studied POCL and the 
effect on muscle preservation by attenuating protein catabolism but further studies are needed to 
prove that POCL is able to significantly preserve muscle mass and function. The varied outcome 
and methodology measures used could be a contributing factor to the uncertainty. Different 
methods were employed to measure muscle mass and strength i.e. blood tests, mid-arm 
circumference, dynamometer and digital tension meter. The question still remained whether the 
energy provided during POCL can minimise the loss of lean tissue brought about by increased 
gluconeogenesis during the early postoperative period.  
4.2.2.1 Total body protein (Muscle mass) 
Muscle mass was expressed as total body protein when derived from measuring total body 
nitrogen (total body protein = total body nitrogen X 6.25).230 Data included in this review with 
regards to protein status was limited with no trial assessing the effect of POCL to standard fasting 
or IV glucose administration. Mathur et al and Soop 2004 et al compared POCL to a placebo with 
no significant difference between the groups at any of the stipulated time points with regards to 
total body protein.186,230 In contrast, Yuill et all concluded that muscle mass as indicated by mid-
arm muscle circumference was significantly more in the placebo group than the POCL group (p < 
0.05).188 Worth mentioning is that the influence of gender should be accounted for if it is not the 
same in the different groups due to gender differences in body composition.186 Postoperative 
nitrogen losses are associated with increased peripheral proteolysis while protein synthesis is not 
that much affected.238 Furthermore, the attenuation of postoperative endogenous glucose release 
may be associated with reduced nitrogen losses.186 Increased levels of insulin-like growth factor 
type 1 with its insulin-like effects on glucose uptake have been described as an underlying 
mechanism when POCL increases glycogen synthesis and reduces postoperative catabolism. 186 
4.2.2.2 Muscle strength (muscle function) 
Handgrip strength is an indicator of nutritional status as well as functional status with a predictive 
importance to show morbidity and mortality.239,240 Impaired handgrip strength is a predictor of 
increased postoperative complications, increased length of stay and decreased physical status.237  
Mathur et al reported that compared with the baseline, grip strength in both the POCL and placebo 
groups, when measured with a dynamometer was reduced for the first seven days postoperative 
(p < 0.010), returning to baseline by day 28, with no significant difference between groups.230 
Furthermore, Kaska et al confirmed that there was no significant difference in handgrip (as 
measured by a digital tension meter) between the POCL, fasting and IV glucose groups on 




postoperative days one to seven.222 In contrast, Noblett et al reported that the fasted group had a 
significant reduction in grip strength (as measured by the dynamometer) on discharge when 
compared with baseline (p < 0.05), with a mean drop of 11% (compared to the 5% drop of the 
POCL and 8% of the placebo groups).236 The exact mechanism underlying the change in handgrip 
strength is unclear but may be related to a reduction in protein loss. One limitation of handgrip 
strength is that it is only an indicator of upper limb strength.237 Nevertheless, it is a simple bedside 
measurement that provides valuable information on nutritional and/or functional status.  
4.2.3 Immune status: C-reactive protein 
Surgical stress involves the activation of the sympathetic nervous system, secretion of catabolic 
hormones and cytokine responses, which cause tissue damage.130 The stress response has 
developed as an evolutionary response to allow injured beings to survive without food and still heal 
their wounds. However, in a highly controlled surgical environment this response is associated with 
deleterious effects (i.e. immunosuppression and impaired wound healing).241 Because of wide 
availability, good reproducibility, and low-cost plasma, CRP concentrations could be an attractive 
biomarker to evaluate the inflammatory response to surgery.242 CRP is a positive acute phase 
protein produced in the liver as a response to a stimulation by interleukin-6 (IL-6).243 The hepatic 
synthesis of CRP start six to eight hours after the onset and peaks 36 to 50 hours after the 
infection has started, whereas IL-6 (proinflammatory cytokines) appear within one hour after the 
onset of infection.244 The effect of POCL needs to be evaluated as soon as possible (within 
24hours) postoperative to account for the confounding factors that may affect the outcomes when 
the measurement is delayed (i.e. initiation of enteral nutrition or food intake, effect of medication). 
Therefore, IL-6 may be a better indicator of inflammation than CRP within the first 24 hours 
postoperative due to its early appearance. Interestingly, in this review the only significant difference 
between the groups was reported on day 1 postoperative when the POCL group had a significantly 
lower CRP than the fasting group (p = 0.006). Therefore, the results must be interpreted with 
caution since there are no comparable IL-6 results available.  
4.2.4 Complication status  
4.2.4.1 Return of intestinal function 
Literature differentiates between return of intestinal function as days from surgery to first 
flatus/stool or bowel movement. In this review only two trials reported on this outcome: Serclova et 
al reported a significant fewer days (MD -1.80 days; p < 0.00001) for return of intestinal function in 
the oral CHO group compared to the fasting group;245 Noblett et al reported no significant 
difference in return of intestinal function between the oral CHO, fasting and placebo groups (even 
though there was a trend towards increased return of intestinal function in the oral CHO group).236 
A Cochrane Review concluded that POCL is associated with a small increase in the return of 
intestinal function when measured as time to first flatus/stool when compared with fasting or 




placebo (MD -0.39; (95% CI 0.70 to -0.07 days).122 The reason for this is that the Cochrane Review 
included additional trials: An et al reported a significant reduction in time to passage of flatus246  
and Ozdemir et al reported on time to first bowel movement with no evidence of treatment effect.247 
The effect of the other ERAS elements on the return of intestinal function must be taken into 
account when reporting on these outcomes i.e. the type of surgery (laparoscopic versus open; 
major versus minor) and type of anaesthesia. An intestinal ischaemia reperfusion animal model 
showed that POCL preserves the intestinal function (by increased jejunal motility) which results in 
decreased inflammation and reduced bacterial translocation which consequently promotes early 
enteral feeding.248 It is important to remember that it may not always be possible to directly 
extrapolate results obtained in animal models to the clinical situation in humans. The early return of 
intestinal function could also be a contributing factor to reduced length of stay since one of the 
discharge criteria from a hospital is a functional intestinal tract. The question still remains that 
whether any changes seen were due to the preoperative calories received through the POCL 
and/or due to the hydration and maintenance of peristalsis by fluid intake.236 Findings from this 
review suggest further research on this outcome. 
4.2.4.2 Length of stay  
Although ten trials were included in this review; only a limited number could be pooled together 
since statistical results were reported as mean and median, and they were categorised according 
to ICU length of stay, hospital length of stay and fit for discharge. Jarvela et al was the only trial 
reporting on the length of ICU stay with no significant difference between the POCL and fasting 
groups (p = 0.13).224 The majority of trials reported on hospital length of stay but there were 
significant heterogeneity between trials and results were reported as mean and median. Results for 
two trials comparing POCL to the inactive control (fasting and placebo) were pooled together with 
no significant difference in length of stay between the groups (p = 0.37).229,249 The results of 
Serclova et al could not be pooled due to heterogeneity but reported significant shorter hospital 
stay in the POCL group compared to the fasting group (p < 0.05).245 Another trial by Soop 2004 et 
al could not be pooled due to missing data but reported no significant difference between POCL 
and placebo groups.186 The other trials on hospital length of stay reported results as 
median/interquartile range with three trials showing no significant difference between 
groups188,222,230 and one trial showing significant shorter hospital stay in favour of the POCL group 
(p = 0.008).223 Mathur et al was the only trial reporting on length of stay as fit for discharge with no 
significant difference between the POCL and placebo groups.230 Unfortunately, none of the trials 
compared POCL to IV glucose administration. A meta-analysis by Awad et al indicated that POCL 
had no significant effect on length of stay; however, when a subgroup analysis was performed on 
the type of surgery the group receiving major abdominal surgery had a significant shorter length of 
stay (-1.08 days; p = 0.007).121 Evidently, it is important to do subgroup analyses on the type of 
surgery performed since patients going for minor surgery (i.e. day surgery or minimal invasive 




laparoscopic surgery) would have an expected short length of stay and it would be impossible to 
demonstrate a measurable difference in length of stay between POCL and control groups. The 
main underlying mechanism in the difference in length of stay between POCL and control groups 
are thought to be enhanced recovery and/or reduction in complications – both associated with the 
magnitude of insulin resistance.121 Insulin resistance is an independent predictor in length of 
stay.132 Minor surgery is associated with minimal insulin resistance and complication rates; 
therefore, an intervention such as POCL would not be expected to improved clinical outcomes 
(primary outcomes) but rather improved patient well-being (secondary outcomes).191,192 The 
Cochrane Review concluded that POCL was associated with a decrease in length of hospital stay 
when compared with fasting or placebo (by 0.30 days; 95% CI 0.56 to 0.04); however, no 
significant difference was detected between the POCL and placebo groups (-0.13 days; 95% CI -
0.38 to 0.12).122  The analysis of major surgery when using the fast track ERAS protocol showed a 
reduction in length of stay by 2.0 to 2.5 days and complications reduced by 30 to 50%.208  
4.2.4.3 Adverse events  
Adverse events can be classified as major (i.e. aspiration, regurgitation, morbidity and mortality) 
and minor (i.e. thirst, hunger, nausea, vomiting, anxiety, pain, fatigue, weakness, tiredness and 
malaise). The major adverse events will be discussed in this section while the minor adverse 
events will be discussed in section 4.3 as secondary outcomes. As expected, the data in relation to 
major adverse events was limited per specific outcome. However, no incidence of major adverse 
events was reported in this review (either directly or indirectly). This is in line with other reviews 
published on the same topic stating no decrease or increase in adverse events.16,74,122,122 Though 
some trials did report on regurgitation and aspiration as an outcome most relied on surrogate 
indicators of risk i.e. participants’ gastric volume and pH, and doctor reported incidence. The 
influence of H2-receptor antagonists should be clearly stated since this will have a direct effect on 
the gastric volume and pH; however, the routine use of this medication is not recommended for the 
population group studied in this review. Furthermore, no events involving aspiration pneumonitis 
due to POCL have been registered in any clinical trial up to now.183 When reporting on the 
morbidity of the intervention it is important to distinguish between complications directly related to 
the intake of the oral CHO beverage (i.e. allergic reaction, intolerability requiring discontinuation of 
the beverage, or clinical signs of electrolyte abnormalities) and other indirect confounding factors. 
Few trials specifically reported on mortality as an adverse event; therefore, the data was 
extrapolated from data provided in the published articles by assuming that there was no mortality if 
the same number of participants that started with the trial completed the trial (taking into account 
participants who were lost to follow-up due to not meeting inclusion criteria). From the data 
published in the literature no definite conclusion can be made with respect to major adverse events 
due to limited data. However, there is no indication that participants drinking a preoperative oral 
carbohydrate beverage are at increased risk compared to participants who followed a standard fast 




or had a placebo to drink. Therefore, the intake of a carbohydrate drink preoperatively is safe 
(taking into account timing of the intervention).  
4.3 SECONDARY OUTCOMES 
POCL affects the well-being of a patient during the perioperative period. However, data on well-
being presented in this systematic review are conflicting with variability in terms of type of data, unit 
of measurement, time of measurement, interventions and comparisons. It is important to 
differentiate between the intragroup (i.e. measurements from the beginning to the end in the same 
intervention groups) and intergroup comparisons (i.e. measurements from the beginning to the end 
in different intervention groups), different scales used to measure the same outcomes, as well the 
time of measurement (i.e. preoperative and/or postoperative) when reporting on these outcomes.  
4.3.1 Thirst and hunger 
The majority of data shows that the intake of oral CHO significantly decrease the sense of thirst 
and hunger during the preoperative period when compared with fasting.190,191,223,232,250,251,252 Yildiz 
et al also indicated that the oral CHO group felt significantly less thirsty and hungry two hours 
postoperative than the fasting group while at 24 hours postoperative there was no significant 
difference.251 The results between thirst and hunger in the oral CHO and placebo groups are 
contradictory, and the question still remains if a CHO drink reduces thirst more than the 
placebo.57191,230,232 Trials by Wang et al and Mathur et al comparing oral CHO intake to placebo 
during the perioperative period indicated no significant difference between the groups with regards 
to thirst and hunger.230,232 Nygren et al indicated that patients drinking an oral CHO drink felt less 
thirsty for 60 minutes compared to the placebo group feeling less thirsty for 40 minutes 
preoperatively; with regards to hunger the CHO group had no change in the sense of hunger while 
the placebo group felt significantly less hungry for a short period of 20 minutes.57  There is little 
indication that patients given different beverages preoperatively experience different levels of thirst 
and hunger.74 The obvious reasoning would be that the intake of fluid would decrease the sense of 
thirst without considering the type of fluid (i.e. oral CHO versus placebo). The volume of fluid 
ingested will also have an effect on the intensity of thirst experienced.  
Brady et al (Cochrane Review) reported that there was a decrease in thirst in the low volume 
intake (< 150 ml) and high volume intake (> 150 ml) in the preoperative period; attributable to the 
fact that given access to an unlimited volume of fluid intake preoperatively it is likely that most 
patients will exercise a natural restraint in the volume of their intake. 74  In the same review, the 
fasted group reported increasing hunger while the group given a high volume (> 150 ml) reported 
feeling less hungry or a experiencing a reduction in the sense of hunger; however, no difference in 
the hunger rating was reported when unlimited fluid intake was compared with standard fasting. 74 
Further, IV CHO administration does not decrease the sense of thirst and hunger as effectively as 
oral CHO.253 The effect of hunger in the oral CHO group is probably directly related to the intake of 




energy, and may have an indirect positive effect on anxiety by making the patient more at ease.191 
The outcome of receiving additional oral CHO the evening before surgery might influence the thirst 
and hunger scoring preoperatively and must be investigated.  
4.3.2 Nausea and vomiting 
Postoperative nausea and vomiting occurs in 20 to 40% of patients despite preventative 
measures.254 Nausea and vomiting may cause electrolyte imbalance, infections, dehydration, 
increase the risk for aspiration and delay recovery and hospital discharge. From the patient’s 
perspective, nausea and vomiting may be even worse than pain after surgery and the effect will 
definitely delay hospital discharge.255 Several trials assessed nausea190-
192,224,230,232,245,249,251,252,254,255 and vomiting224,245,249,254,255,192 as an outcome with conflicting results.  
Preoperatively, there was no difference in severity of nausea experienced between the oral CHO 
and fasting groups.232,252 However, Hausel 2001 et al reported that the placebo group felt 
significantly more nauseous during the preoperative period.191 Postoperatively, Yilmaz et al 
reported a significant reduction in the severity of nausea on day 1 in the CHO group compared to 
the fasting group with Zelic et al reporting a non-significant reduction in the severity of nausea on 
day 2 in the same group.254,255 However, Bisgaard et al reported no difference in the severity of 
nausea between oral CHO and placebo groups on day 1 postoperative (worth mentioning is that 
Bisgaard et al used an ordinal scale and not a VAS like the other trials measuring this outcome).192 
The number of patients experiencing postoperative nausea varied with Hausel et al indicating no 
difference between groups on day 1,249 Jarvela et al indicating that significantly more patients felt 
nauseous in the CHO group compared to the fasting group on day one postoperative,224 Serclova 
et al indicating significantly fewer patients felt nauseous in the CHO group compared to the fasting 
group on day two to four.245 However, Bisgaard et al reported no significant difference in the 
number of patients experiencing postoperative nausea in the oral CHO and placebo groups. A115  
The three trials reporting on the severity of nausea experienced during the perioperative period 
reported no significant difference between the oral CHO, fasting and placebo groups.230,249,251 
These findings are in line with another systematic review indicating no difference in the rates of 
nausea between oral CHO intake versus standard fasting or placebo.120  
Vomiting was only assessed in the postoperative period, but it should be noted that carbohydrate 
loading takes place during the preoperative period. Therefore, factors influencing vomiting should 
be taken into account, and there should be distinction between vomiting due to illness, type of 
anaesthesia, type and duration of surgery, and the direct effect of drinking a clear fluid 
preoperatively.249 The severity of vomiting was significant less when oral CHO was compared to 
fasting on day one postoperative;254 however, there was no difference between the oral CHO and 
placebo group on day one postoperative.192 Although the trial by Serclova et al indicated that the 
number of patients vomiting in the oral CHO group was significant less than the fasting group 




during the postoperative period,245 the other trials failed to show a significant effect even though 
there was a trend of less vomiting in the oral CHO group.192,224,249,255  
The majority of trials did not take the immediate postoperative emetic effect of anaesthesia and 
surgery into account as well as the anti-emetics drugs used. Although anti-emetic drugs are not 
routinely recommended, they will definitely decrease the incidence and severity of nausea and 
vomiting and should be taken into consideration when trials are reviewed. A Cochrane review 
concluded the following regarding nausea and vomiting: it rarely occurred when a shortened fluid 
fast was compared to a standard fast (timing of intake); there was no difference in nausea and 
vomiting when water was compared to a standard fast and little indication that participants given 
different drinks preoperatively experienced different levels of nausea and vomiting (type of intake); 
no indication that the volume of fluid intake increased the sense of nausea and vomiting (volume of 
intake).74 Another Cochrane Review confirmed that the evidence is insufficient to show whether 
oral CHO beverages increase or decrease postoperative nausea and vomiting.122  
4.3.3 Anxiety 
The majority of trials indicated that preoperative oral CHO intake significantly decreased anxiety in 
the preoperative period when compared to standard fasting223,252,254,191 and IV CHO 
administration.253 However, the same is not true when oral CHO is compared to a placebo in the 
preoperative and postoperative period – there was no significant difference between the 
groups.191,230,232 A Cochrane Review confirmed that participants given a preoperative oral CHO 
beverage reported less anxiety than those in the standard fasting group, but emphasised that less 
anxiety was reported by participants permitted an oral CHO beverage when compared with a 
placebo or water.74 It is important to take the external triggers of anxiety into consideration when 
commenting on these findings, and the timing of measuring the outcomes (i.e. preoperative versus 
postoperative). The preoperative waiting period itself is a cause of anxiety and the exact 
preoperative time of the preoperative waiting period should be indicated in trials. Yagmurdur et al 
indicated that even though anxiety decreased preoperatively after the intake of the oral CHO, it 
increased intraoperative due to the conscious state of the patient during the surgical procedure 
without any sedation.252 Furthermore, perioperative anxiety is associated with postoperative pain, 
healing and length of hospital stay.256  
4.3.4 Pain 
Even though pain increased from the preoperative to the postoperative period, the majority of trials 
indicated that the patients experience no significant difference in pain between the different 
groups.191,192,230,249,252,253,255 Serclova et al was the only trial indicating that pain was significantly 
better controlled in the oral CHO group when compared to standard fasting.245 Note that this trial 
measured the results in the postoperative period up to day five. Intraoperative pain was assessed 
in a trial by Yagmurdur et al with no difference between the oral CHO intake and standard fasting 




group. It is worthwhile to mention that pain should not differ after spinal anaesthesia (without 
sedation) between groups, and therefore, the type of anaesthesia should be considered when 
commenting on the severity of pain experienced.252 A Cochrane Review confirmed that the 
duration of fasting, type of fluid ingested or the volume of the fluid ingested had no significant 
difference on the pain experienced.74 It is important that the effect of postoperative pain 
management by an epidural catheter with constant infusion as well as oral medication must be 
considered when comparing these results. 
4.3.5 Fatique/weakness/tiredness/malaise 
Due to the direct insult of surgery there is increased discomfort with regards to fatigue, weakness, 
tiredness and malaise from the preoperative to the postoperative period in all groups. The oral 
CHO intake group experienced less discomfort in trends of fatigue, weakness, tiredness and 
malaise during the preoperative period when compared with standard fasting.190,191,251,252 The 
fasted group had a notable increase in discomfort during the preoperative period while the placebo 
group did not differ significantly from the oral CHO group during this period.230,232 The data for the 
postoperative period is limited with results for only fatigue and malaise. The trial by Yildiz et al 
indicated no difference in fatigue between the oral CHO and fasting group while there was 
significantly less malaise experienced in the oral CHO group compared to the fasting group.251 
Unsurprisingly, there was no difference in the severity of fatigue and malaise experienced between 
the oral CHO and placebo groups.192,230 Interestingly, both oral CHO and IV CHO alleviates 
feelings of discomfort, specifically weakness and tiredness.253 A systematic review on the 
outcomes concluded that oral CHO intake led to a vast improvement in discomfort.16  
4.4 METHODOLOGICAL QUALITY 
The methodological quality of trials have been described in detail in Chapter 3. The overall quality 
of trials focussing on POCL was moderate with most trials having one or more domains of 
uncertainty or high risk of bias. We considered a trial as having a low risk of bias if all domains 
were assessed as adequate, and high risk of bias if one or more domains were assessed as 
unclear or a definite high risk of bias. The risk of bias assessment was performed using the risk of 
bias tool in The Cochrane Handbook of Systematic Reviews of Interventions. Unfortunately, the 
small study numbers per outcomes led to the decision that GRADE assessment is beyond the 
scope of the review at this stage.  
The majority of trials included in this review were from developed and emerging countries (and 
could not be directly compared to a developing country like South Africa). Even though there was a 
wide range of geographical settings for the trials, the methodological consistency was remarkable 
to include a total of 24 trials in this review. All trials included in this review had detailed lists of 
inclusion and exclusion criteria minimising the possibility of bias. All trials also stated adequate 
methods of generating the randomisation sequence with more than half of the trials confirming 




concealment of allocation. Double blinding in preoperative fasting trials is difficult since the patient 
will know if they were fasted or received a preoperative drink. By definition, only trials in which a 
carbohydrate drink is compared to a placebo can be adequately blinded. Single blinding will be 
possible if different personnel give the drink and evaluate the outcomes. Inadequate blinding will 
not have an effect on the biochemical primary outcomes (i.e. glucose, insulin, insulin resistance, 
protein status, immune status) evaluated in this review since they are clinical outcomes based on 
physiological processes, but it will definitely have an impact on the primary outcomes where 
clinicians will be involved (i.e. return of intestinal function, length of stay) and patient-reported 
psychosomatic secondary outcomes (i.e. thirst, hunger, nausea, vomiting, anxiety, pain, fatigue, 
weakness, tiredness, malaise). It was easy to keep all dietary exposures identical for all 
participants in the included trials since they only received a preoperative drink (i.e. oral 
carbohydrate drink or a placebo) or were fasted.  All participants lost to follow-up were reported, 
but the majority of the trials had incomplete outcome data increasing the risk of bias since this data 
had to be excluded from the review and could not form part of the meta-analysis. Protocols for the 
included trials were not available to compare if all outcomes were addressed in the published 
articles. Therefore, no clear evidence was available for selective reporting. Funding of trials is a 
high risk of bias since the majority of preoperative oral carbohydrate drinks used in this review was 
sponsored by the same company, and one of the authors holds the patent for the drink. 
Participants were recruited from a very specific surgical population group (i.e. otherwise healthy 
individuals with no increased risk of regurgitation or aspiration) making the information provided 
biased to a specific group.  
As with all systematic reviews there was a potential for bias at all the different stages of the review 
process. Publication bias is always a concern since trials with negative results are not always 
published and may easily be missed during the search process, skewing the overall result of the 
question posed. We recommend that the results of this review should be interpreted with caution 
since not all trials included in this review scored a low risk of bias.  
4.5 AGREEMENTS AND DISAGREEMENTS WITH OTHER REVIEWS 
Initially, when the protocol for this review was submitted the authors could not identify any other 
systematic review addressing this question. Subsequently there were several reviews (including 
narrative and systematic) published on the same topic: Pogatschnik 2015, Nygren 2015, Hill 2015, 
Smith 2014, Bilku 2014, Awad 2013, Li 2012, Jones 2011, Brady 2010 and Shanley 
2009.16,74,119,120,121,122,164,183,257,258 
Pogatschnik et al published a narrative review in 2015 - Review of preoperative carbohydrate 
loading. 164 The following topics were discussed: carbohydrate metabolism (fasting versus fed 
state), effect of surgery on carbohydrate metabolism (glycaemic control and insulin resistance), 
traditional fasting and its complications (risk of aspiration and new fasting guidelines), potential 




benefits of CHO beverages (insulin resistance and immune response; preservation of muscle mass 
and function; postoperative well-being; surgical complications and length of stay), and the 
enhanced recovery after surgery concept. Even though the metabolic effects of lowering insulin 
resistance cannot be attributable to POCL alone, the authors concluded that POCL is safe and 
improves patient comfort prior to surgery.  
Nygren et al published a narrative review in 2015 - Preoperative oral carbohydrate therapy.183 This 
review, by three of the renowned authors on the topic, summarises the current evidence and 
rationale for avoiding preoperative fasting and rather implementing POCL. The use of oral 
carbohydrate was favoured in light of their role in reducing the response to surgical stress and in 
improving patient outcomes. The authors concluded that the impact of POCL was most evident in 
patients receiving major abdominal surgery.  
Hill et al published a narrative review in 2015 - Carbohydrate loading in the preoperative setting. 257  
This short review was the first to be published on local grounds in the South African Medical 
Journal. The review addressed the issues of permitting preoperative clear fluids in lack of 
associated aspiration risk, and actively promoted POCL due to the associated benefit. The authors 
concluded that a change in culture is necessary to ensure that practice is based on evidence and 
not on individual beliefs aroused by fear. They recommended a proactive, multidisciplinary 
approach to optimise the nutrition support in the surgical population.  
Smith et al conducted a Cochrane review in 2014 - Preoperative carbohydrate treatment for 
enhancing recovery after elective surgery. 122 The objectives of this review were to assess the 
effects of POCL, compared with a placebo or preoperative fasting, on postoperative recovery and 
insulin resistance in adult patients undergoing elective surgery. Databases were searched from 
inception up to March 2014 with no language restrictions. Only randomised controlled trials were 
included in this review. The treatment group needed to receive at least 45 g of carbohydrates 
within four hours before surgery or anaesthesia start time. A total of 27 trials involving 1976 
participants undergoing mainly elective abdominal surgery were included. In 19 trials (1351 
participants), preoperative carbohydrate treatment was associated with shortened hospital stay 
compared with the placebo or fasting groups (by 0.30 days; 95% confidence interval 0.56 to 0.04; 
very low quality evidence). No significant effect on length of stay was noted when preoperative 
carbohydrate treatment was compared with the placebo (14 trials including 867 participants; mean 
difference -0.13 days, 95% confidence interval -0.38 to 0.12). Preoperative carbohydrate treatment 
was associated with shortened time to passage of flatus when compared with the placebo or 
fasting groups (2 trials including 86 participants; mean difference 0.39 days; 95% confidence 
interval 0.70 to 0.07) as well as increased postoperative peripheral insulin sensitivity (3 trials 
including 41 participants; mean increase in glucose infusion rate measured by hyperinsulinaemic 
euglycaemic clamp of 0.76 mg/kg/min; 95% confidence interval 0.24 to 1.29; high quality 




evidence). In 14 trials (913 participants) preoperative carbohydrate treatment was not associated 
with an increased or decreased risk of postoperative complications compared with placebo or 
fasting (risk ration of complications 0.98; 95% confidence interval 0.86 to 1.11; low quality 
evidence). Aspiration pneumonitis was not reported in any of the treatment groups. Postoperative 
well-being (4 trials including 310 participants; moderate quality evidence), nausea (2 trials including 
292 participants; moderate quality evidence), vomiting (4 trials including 407 participants; risk 
ration 1.25 confidence interval 0.77 to 2.04; low quality evidence) and fatigue (6 trials including 576 
participants; moderate quality evidence) could not be reported on since the confidence intervals 
included no effects, making the data insufficient to show whether preoperative carbohydrate drinks 
had an effect on postoperative outcomes.  
Bilku et al conducted a systematic review in 2014 – Role of preoperative carbohydrate loading: a 
systematic review.16 The objectives of this review were to analyse the effect of POCL on insulin 
resistance, gastric emptying, gastric acidity, patient well-being, immunity and nutrition in adult 
patients undergoing general surgery. The authors did not elaborate on the systemic process 
followed during the searches. PubMed was the only electronic database searched (up to 
September 2011) to obtain articles for inclusion in the review. Reference lists of all articles were 
cross-checked to include all relevant articles. English language restriction was applied during the 
searches. A total of 17 trials consisting of 1 445 participants met the inclusion criteria where only 
randomised controlled trials were included in the review. The treatment group received 
carbohydrates – the type of beverage, volume consumed and time taken preoperative differed 
between trials. The control group consisted of standard fasting and/or placebo and/or low oral CHO 
intake and/or IV glucose administration. Data were too heterogeneous for a meta-analysis due to 
multiple combinations of outcomes. Seven trials (328 participants) investigated the effect of POCL 
on insulin sensitivity with various methods used to analyse insulin resistance (i.e. HEC, HOMA-IR, 
artificial pancreas closed loop system, QUICKI); six trials showed a significant reduction in insulin 
resistance and one trial showed no effect. Five trials (584 participants) investigated the effect of 
preoperative carbohydrate treatment on gastric emptying; all trials reported no difference in gastric 
emptying between groups (after variability was ruled out). Three trials (543 participants) 
investigated the effect of carbohydrate treatment on gastric acidity; all trials demonstrated that 
there was no difference between groups (even though the modes of assessing gastric acidity 
varied between trials). Eight trials examined the effect of carbohydrate treatment on patient well-
being (1151 participants) with various measurements including a visual analogue scale (i.e. thirst, 
hunger, anxiety, depression, pain, tiredness, weakness, inability to concentrate, mouth dryness 
and nausea), modified Beck questionnaire (assessing the psychosomatic status of the patients) 
and a combination of the visual analogue scale and objective analysis by nursing staff. POCL led 
to a significant reduction in thirst, hunger, anxiety and malaise compared with fasting and placebo 
in two trials; two other trials demonstrated that fasted patients had increased thirst, hunger, 




tiredness, anxiety and mouth dryness scores compared to oral and IV carbohydrate administration; 
both oral and IV carbohydrate administration alleviated tiredness and weakness. IV carbohydrate 
administration did not decrease thirst and hunger as effectively as oral carbohydrates. One trial 
concluded that between 12 to 24 hours postoperative there was a significant lower incidence of 
nausea and vomiting in the oral carbohydrate group than the fasting group while three trials 
demonstrated no beneficial effect of carbohydrate drinks on general well-being. Two trials 
examined the effect of carbohydrate treatment on immunity and clinical outcomes: one showed no 
difference in infection, length of stay and time to intake of oral diet between carbohydrate and 
placebo groups; while the other trial showed a significant decrease in the length of hospital stay 
and a trend to earlier return of gut function in the carbohydrate group when compared with the 
placebo. Five trials examined the effect of preoperative carbohydrate treatment on postoperative 
nutritional status i.e. anthropometric measurements, triceps skinfold thickness, mid-arm 
circumference, and handgrip strength. No significant differences between groups were reported. 
One trial examined the effect in diabetic patients with no delayed gastric emptying reported.   
Awad et al conducted a systematic review in 2013 – A meta-analysis of randomised controlled 
trials on preoperative oral carbohydrate treatment in elective surgery.121 The objectives of this 
review were to address the effects of preoperative carbohydrate treatment on length of hospital 
stay, insulin resistance, complications (i.e. vomiting, aspiration or pneumonia), and postoperative 
nausea and vomiting. The review was conducted according to the standard methods 
recommended by The Cochrane Collaboration. Multiple electronic databases were searched from 
January 1980 to April 2012. Additionally, reference lists of published trials were scanned and 
companies manufacturing preoperative carbohydrate drinks were contacted for unpublished data. 
Inclusion criteria included randomised controlled trials of adult patients undergoing elective 
surgery. No language restriction was placed on the searches. Preoperative carbohydrate treatment 
of at least 50 g was administered two to four hours preoperatively compared with a control 
(fasting/placebo). This review did not include IV carbohydrate administration as a control. Twenty-
one trials (1685 participants) were included in this review. GRADE assessment revealed significant 
heterogeneity amongst trials with low to moderate quality evidence. Twelve trials (1198 
participants) reported on length of stay: preoperative carbohydrate treatment was associated with a 
reduction in length of stay after major abdominal surgery [mean difference, 95% confidence 
interval: -1.08 (-1.87 to -0.29); p = 0.007], but that was not the case after minor surgery (expected 
stay of ≤ 2 days) or orthopaedic surgery. Insulin resistance was measured by three trials using the 
HEC method (all trials showed significant reduction in postoperative insulin resistance in the POC 
group when compared with the control), 6 trials using the HOMA-IR method (two trials showed 
significant reduction in insulin resistance between POC and control) and 1 trial using the QUICKI 
method (significant reduction in insulin resistance in the POC group). Nine trials (878 participants) 
reported on the occurrence of drink-related complications in the hospital with no occurrence in any 




of the study groups [risk ration, 95% confidence interval: 0.88 (0.50 – 1.53); p = 0.640]. Five trials 
reported on postoperative nausea and vomiting: three trials reported no difference in occurrence 
between groups, one trial reported fewer episodes in the POC group and one trial reported more 
episodes in the POC group.  
Li et al conducted a systematic review in 2012 – Preoperative carbohydrate loading for elective 
surgery: a systematic review and meta-analysis.120 The review consisted of a systematic literature 
search of multiple electronic databases up to September 2010 on POCL in surgical patients. 
Reference lists from relevant review articles were also hand-searched. English and Chinese 
language restriction applied during the searches and only randomised controlled trials were 
included. The POC loading was compared to fasting, placebo and/or IV glucose administration. 
The administration time, dose and amount of CHO ingested were not considered, which may have 
affected the clinical outcomes. Quality of the trials was graded according to the recommendations 
provided in the Cochrane Handbook of Systematic Reviews and Interventions including the 
GRADE approach with the majority of outcomes having low to very low quality ratings. Multiple 
reviewers identified the 22 trials (1919 participants) included in this review measuring a variety of 
outcomes. No statistically significant difference was found in the changes in the glucose levels at 
the induction of anaesthesia, at the end of surgery or on day one postoperative between the 
different groups. There was no statistically significant difference in the changes in the insulin levels 
at the induction of anaesthesia and at the end of surgery between groups; however, there was a 
significant increase in the insulin levels in the CHO group on the first day after surgery when 
compared with the fasting and IV groups, but no differences were found between the CHO and 
placebo groups. A significant difference in the change in insulin sensitivity was seen between the 
CHO and placebo groups, but no differences were found in the other two comparisons. No 
significant differences were reported for the changes in postoperative insulin resistance between 
groups. There was also no statistically significant differences in length of stay (ICU and hospital) 
between the groups or in the postoperative gastric pH and volume between groups. Also, there 
were no significant differences in the incidence of postoperative vomiting or any reported 
aspiration. Results of the preoperative well-being were inconsistent and contradictory. This review 
also did subgroup analysis of patients undergoing different surgical procedures, including 
colorectal surgery, laparoscopic cholecystectomy, total hip replacement and cardiac surgery.  
Jones et al conducted a systematic review in 2011 – The role of carbohydrate drinks in pre-
operative nutrition for elective colorectal surgery.119 The review was based on a systematic 
literature search of three electronic databases. Limitations of the review included English language 
restriction, searches conducted over the previous 10 years, only included patient scheduled for 
colorectal surgery, and it was not restricted for study type. Eleven trials (743 participants) were 
included in the review. The data was not statistically pooled in a meta-analysis but the authors 
concluded that preoperative carbohydrate treatment is both safe and effective since it does not 




alter gastric pH or volume and there were no increased complications. The results of this review 
were not comparable due to the lack of methodological quality assessment, lack of statistical 
analysis and different preoperative carbohydrate regimens.  
Brady et al conducted a Cochrane review in 2010 – Preoperative fasting for adults to prevent 
perioperative complications.74 The objectives were to systematically review the effect of different 
preoperative fasting regimens (duration, type and volume of permitted intake) on perioperative 
complications and patient well-being (including aspiration, regurgitation, morbidity, thirst, hunger, 
pain, nausea, vomiting and anxiety) in different adult populations going for elective surgery. 
Databases were searched from inception up to August 2003, conference proceedings and 
reference lists were searched and experts in the field were consulted. Only randomised controlled 
trials were included in this review. The quality of the trials was graded according to the 
recommendations provided in the Cochrane Handbook of Systematic Reviews and Interventions 
and were classified as high methodological quality (note that the GRADE approach was not utilised 
in this review). Preoperative fluids evaluated included water, coffee, fruit juice, sport drinks and 
other carbohydrate containing drinks. A total of 22 trials (2270 participants) were included.  The 
review concluded that there was no evidence to suggest a shortened fluid fast resulted in 
increased risk of aspiration, regurgitation or morbidity when compared with a standard fast, and 
that the volume of fluid permitted during the preoperative period had no effect on the outcomes.  
Shanley conducted a systematic review in 2009 – Preoperative carbohydrate loading: a review of 
the current evidence.258 A structured review was carried out in a systematic manner including 
randomised controlled trials. The searches were limited to trials published between 1998 and 2008, 
English language restrictions applied and only four electronic databases were searched. Thirteen 
randomised controlled trials were included in this review. The study intervention consisted of 
preoperative carbohydrate loading two to three hours before elective surgery. The review reported 
that no statistical significant results were reached, and that none of the trials reported any adverse 
effects with regards to preoperative carbohydrate loading. The review concluded that further 
research is warranted since small sample sizes lead to trends rather than conclusive evidence, and 
that a meta-analysis may produce more conclusive results.  
To conclude, the findings of the above-mentioned reviews were in line with the findings of this 
systematic review. All reviews reported that there is a trend to improved clinical outcomes but data 
is insufficient to draw firm conclusions. Data shows that POCL has no proven adverse effects, 
which makes it a safe option during the preoperative period. Due to heterogeneity, limited data can 
be pooled in meta-analyses - indicating the need for larger randomised controlled trials on the topic 
with standardised interventions.  




4.6 STUDY LIMITATIONS 
Systematic reviews are only as good as its components i.e. the included trials. The limitations of a 
systematic review should always be kept in mind when interpreting results. Well conducted 
systematic reviews still provide the user with the best available evidence through accumulation of 
scientific data. However, systematic reviews can only contribute but never replace sound clinical 
judgement. The limitations as discussed below did not directly affect the outcomes of this 
systematic review since it is standard limitations associated with the POCL concept and systematic 
reviews. None the less, these limitations should be kept in mind when implementing the concept in 
practice.  
Limitations as a direct result of the study design as it was implemented: 
 Methodological quality was assessed according to the details described in the Cochrane 
Handbook for Systematic Reviews and Interventions; however, GRADE assessment was 
not conducted.  
 Numerous studies were excluded based on the volume of the preoperative oral 
carbohydrate drink consumed (see Chapter 3). The volume of intake in this review was 
restricted to 400ml 90 – 300 minutes preoperative. However, when participants received 
150 to 1000ml the volume did not appear to have an impact on the participants’ gastric 
volume or pH when compared to a standard fast. Therefore, larger volumes can be 
consumed preoperatively without increased risk.  
 Including co-interventions with different macronutrient profiles into the review were not 
possible since the change in macronutrient profile would increase the osmolality above 
300mOsm/kg and immediately exclude the trial from the systematic review since a higher 
osmolality poses an increased risk for delayed gastric emptying. Now it is known that the 
type of macronutrient added might increase the osmolality but not necessarily delay gastric 
emptying.  
 The high degree of incomplete outcome data due to poor reporting in the published articles 
and no response upon request had an impact on the number of trials included per 
outcomes. As per protocol the authors were contacted twice to obtain missing data. 
Other limitations that appeared in the review that was not directly as a result of the design but 
rather due to the design of the included POCL studies and systematic reviews in general included: 
 Majority of the included trials had a small sample size (17 trials < 100 participants). 
 Complete blinding of both participant and investigator as to intake of a beverage or fasting 
is impossible to achieve. They cannot be blinded as to whether or not they consumed 
something to drink, and the volume of the beverage consumed. This limitation will not affect 
the primary outcomes but will definitely impact the psychosomatic secondary outcomes.  




 POCL is just one of many components linked to the success in the ERAS protocol. Trials 
evaluating the effect of POCL do not always clearly state all the ERAS components present 
in the trial. Therefore, the results must be interpreted with caution since the beneficial effect 
of POCL can be as a result of other ERAS elements implemented in combination. In future 
it is going to be difficult to evaluate the effect of preoperative oral CHO treatment as the 
only intervention since the ERAS protocol is implemented in many hospitals.  
 Publication bias is always a concern when a systematic review is conducted since trials 
with negative results are mostly not published causing trials to indirectly be excluded from 
the review that might cause misleading results. All stages of conducting a systematic 
review poses potential risk of bias.  
4.7 DIFFERENCES BETWEEN PROTOCOL AND REVIEW 
 Inclusion of co-interventions with different macronutrient profiles were planned but due to 
an increase in osmolality, once other macronutrients are added to the carbohydrate 
beverage, these trials were excluded from the review.  
 High-risk anaesthetic patients with an ASA score of III and IV were included in five trials 
due to the trials not differentiating between ASA scores. The other high risk anaesthetic 
groups (i.e. obese patients, elderly, pregnant women, patients with abnormal blood glucose 
levels, emergency cases) were still excluded as planned in the protocol. 
 Statistical analyses were planned for all primary outcomes but due to the small number of 
trials, this could not be performed for all the outcomes.  
 Statistical analyses were planned for the secondary outcomes but due to heterogeneity 
descriptive statistics were used.  
 Subgroup and sensitivity analyses were planned for all outcomes but due to the small 
number of trials per comparison, this could not be performed. 
 The aim was to make clear recommendations regarding preoperative oral carbohydrate 
loading in practice, but due to limited trials included per comparison, the results must be 
interpreted with caution.  
 
  














CHAPTER 5: CONCLUSION 
  




5.1 AUTHOR’S CONCLUSION 
Even though POCL is considered safe and is recommended by numerous anaesthesia societies, 
preoperative fasting is still the standard of care in most hospitals around the world, including South 
Africa. Standard fasting is associated with deleterious effects on the metabolism with consequent 
negative clinical outcomes of the surgical patient. POCL is considered a safe alternative to 
standard fasting; therefore, the preoperative focus should be on what to give (dose specific), when 
to give it (time specific) and to whom to give it too (patient specific) to improve patient outcomes. 
The ‘what to give’ focuses on the specific type of clear fluid with emphasis on a beverage 
containing at least 45 g of CHO (mainly maltodextrin to ensure rapid gastric emptying) that pass 
the stomach within the recommended time. The ‘when to give it’ refers to the safety of giving a 
clear fluid up to two hours before induction of anaesthesia to avoid the risk of aspiration. The 
‘whom to give it too’ refers to the specific population, which include low-risk elective surgery 
patients. This review confirmed that the concept of POCL is safe and no adverse events were 
associated with the intake of the beverage. Well-being of patients receiving POCL was also 
improved or at least maintained in most of the trials included in this review. No evidence of effect 
for POCL was demonstrated for any other clinical outcomes due to the heterogeneity of trials, 
small number of included trials per comparison, small sample size and available data. The role of 
confounding parameters, such as the impact of the magnitude of surgery and the effect of the 
different elements of the ERAS protocol, must be taken into account. There is, however, not 
enough evidence in this review to draw conclusions with absolute certainty. Therefore, the potential 
benefits with respect to clinical outcomes and well-being needs to be balanced against the cost of 
this intervention as well as participant preference before implementing it into hospitals as an 
isolated standard of care. At this stage POCL should be seen as a single element of the ERAS 
protocol, and the combination of these elements might produce more beneficial results than a 
single element by itself.   
5.2 RECOMMENDATIONS FOR PRACTICE 
The traditional practice of overnight fasting before surgery has been shown to be unnecessary and 
numerous anaesthesia societies have changed or are in the process of changing their guidelines to 
allow clear fluid intake up to two hours before induction of anaesthesia. To further optimise the 
practice, POCL is recommended to create a more anabolic milieu for enhancement of surgical 
outcomes. The goal is to achieve a CHO loading typical to a meal but with low osmolality to ensure 
rapid gastric emptying. POCL forms an integral part of the ERAS® protocol; however, since POCL 
is only one element of the ERAS protocol the beneficial effects of these elements as a whole 
should be taken into account. The methodological quality of this review is of concern since it is 
rated as moderate to low; therefore, caution should be practiced when these results are applied 
into practice. Emphasis should be on the type of surgery performed since most of the trials in this 
review were based on otherwise healthy participants receiving abdominal surgery. Furthermore, 




there should be a distinction made between minor and major surgery due to the different effects on 
various outcomes.  
Glucose control during the perioperative period is frequently emphasised to improve surgical 
outcomes. Findings in this review showed that glucose increased after POCL before induction of 
anaesthesia, but on day 1 postoperative there was no significant difference in glucose levels seen 
between the groups. Data on insulin levels were conflicting with differences at baseline and no 
trend to follow in this review. Theoretically, POCL has the metabolic benefit of lowering insulin 
resistance; unfortunately, it is difficult to prove that POCL is the only parameter in the surgical 
journey improving outcomes, and due to limited data and methodological differences between trials 
data in this review could not be pooled. Furthermore, data on insulin resistance must be interpreted 
with caution due to the different methods measuring different parameters. The magnitude of the 
surgery (i.e. minor versus major) and postoperative care pathways have an immense impact on the 
outcomes. Therefore, POCL in combination with these parameters are worth considering to ensure 
enhanced recovery after surgery.  
Trials included in this review did not find a significant difference between the protein status (i.e. 
muscle mass and strength) of POCL, placebo and IV glucose groups; however, there was a trend 
for weaker protein status in the standard fasting group. Therefore, the question still remains if 
muscle preservation is maintained by the attenuation of protein catabolism through the energy 
provided by the POCL. The effect of confounding factors like bed rest, malnutrition and gender 
differences in body composition should be taken into account when evaluating this outcome.  
The immune status in this review was evaluated by means of the CRP value. The POCL group had 
a significantly lower CRP level than the standard fasting group on day one postoperative (p = 
0.006). However, the CRP values should be interpreted with caution within the first 24 hours since 
it only peaks after 36 to 50 hours of infection. It is recommended that the immune status be 
evaluated within the first 24 hours postoperatively to exclude confounding factors (like the initiation 
of enteral or food intake, effect of medication).  
There is no indication that patients drinking a preoperative oral carbohydrate beverage are at an 
increased risk compared to patients who followed a standard fast or had a placebo to drink. The 
trials evaluating return of intestinal function could not be pooled but there was an increase in the 
return of intestinal function in the POCL group. The overall trend between trials was that there was 
no significant difference in length of stay between groups. However, no subgroup analysis on the 
magnitude of surgery was performed to differentiate between minor versus major surgery. Since 
minor surgery has an expected shorter length of stay compared to major surgery, it will be difficult 
to detect change between comparison groups.  




The data on well-being presented in this review is conflicting mainly due to different methods used 
to measure the change, different time intervals and different surgical procedures. The POCL group 
experienced less thirst and hunger when compared with standard fasting; however, there was no 
difference in thirst and hunger between the POCL and placebo groups; and IV glucose does not 
decrease thirst and hunger as effectively as POCL. No evidence of effect could be concluded for 
nausea and vomiting since the results have shown no trend. The majority of trials indicated that 
POCL significantly decreases anxiety when compared with standard fasting and IV glucose 
administration; but there was no difference when POCL was compared with a placebo. The 
evidence of this review was insufficient to show whether POCL reduces pain, fatigue, weakness, 
tiredness and malaise significantly more than the other groups. To note, the majority of the trials 
showed that overall well-being was improved or at least maintained in the POCL group.  
Currently in South Africa, there are numerous clear fluids available (preOp®, Fortijuce®, Provide 
Xtra®, Fresubin Jucy®, Ensure Plus Juce®). When choosing a clear fluid for POCL, the following 
must be considered: macronutrient profile (i.e. carbohydrate content, added protein), osmolality 
together with gastric emptying time, palatability, cost and patient preference. Implementing the 
POCL concept in a developing country like South Africa will be challenging since there is an 
immense difference in structural and operational procedures between the private versus state 
sector. Nonetheless, it is challenging to move evidence into practice and implementation of a new 
concept takes commitment and patience from all parties involved. 
5.3 RECOMMENDATIONS FOR FUTURE RESEARCH 
A large volume of evidence on the topic is already available but as other authors have indicated, it 
is recommended that further research be done on this topic since the current recommendations are 
based on moderate to low quality heterogeneous data. The strength of the evidence to support 
POCL could be improved by well-designed, double blind placebo controlled trials. It is very difficult 
to blind participants who received a preoperative beverage from participants who do not receive a 
beverage. The aim would be to double blind the participants and staff by putting participants who 
receive or who do not receive a beverage in separate or single rooms, and ensure that the same 
individual who hands out the beverage to the participant does not measure the outcomes as well. 
Double blinding in a country like South Africa might be impossible due to constant bed and 
personnel shortage.  
The advantage of including more than one comparison group would be that the different elements 
of the groups can be compared, and the exact element for clinical benefit can be pointed out. The 
ideal trial would include the following groups: POCL-protein group, POCL group, IV glucose group, 
water group (placebo) and a standard fasting group. By including different groups, different effects 
are measured; for example comparing the standard fasting and placebo groups, the safety of 
giving a preoperative fluid compared to nothing will be evaluated; by comparing the placebo and 




POCL groups, the benefit of giving a carbohydrate load will be evaluated; by comparing POCL and 
POCL-protein groups, the benefit of giving added protein will be evaluated; by comparing POCL 
and IV glucose groups, the effect of the route of administration (i.e. per os or intravenous) will be 
evaluated.   
Sample size is of great concern because the majority of trials on this topic used a small sample 
size, which degrades the quality of the current recommendations. The number of patients included 
in a trial should be of size to add value to the methodological quality: small enough to be feasible 
and large enough to detect difference. GRADE assessment should be considered as a standard 
tool for all meta-analyses to ensure that the outcome of a trial is graded according to the 
methodological quality. Therefore, attention should be on above mentioned recommendations to 
improve the overall methodological quality of the trials in future.  
At this stage, the researcher is aware of nine ongoing trials and two unpublished trials focusing on 
various surgical populations, i.e. colorectal, gastric, oral, orthopaedic and cardiac surgery 
(Appendix 6.7). These trials should be evaluated for inclusion in future systematic reviews to 
hopefully provide further evidence for POCL. It is also advised that foreign language trials should 
be considered for inclusion in future if possible. Ten foreign language citations (i.e. Chinese, 
German, French, Portuguese and Turkish) were identified for possible inclusion but were excluded 
due to language constraints (Appendix 6.7).  
It is important to establish which patient population will be most likely to benefit from POCL. Well-
documented trials in different surgical populations could contribute usefully to the literature and 
future meta-analyses. Focus should be on major open abdominal surgery, minimally invasive 
laparoscopic surgery, orthopaedic and cardiac surgery. Different medical settings across different 
countries would also contribute valuable information for future meta-analyses. Since data is limited, 
further trials on high risk anaesthetic patients (i.e. obese patients, patients with an ASA score > II, 
patients with diabetes mellitus and patients undergoing emergency surgery) should be employed to 
investigate the effect on POCL in this population group. Trials could also focus on the beneficial 
effect of giving POCL in the paediatric population. 
The main requirement of POCL is that the beverage must contain at least 45 g of carbohydrates to 
mimic the intake of breakfast and evoke an insulin release, and it must pass the stomach fast 
enough to avoid aspiration during induction of anaesthesia. Trials should investigate whether the 
volume of permitted CHO intake has an effect on outcomes since this review only included trials 
where the participants received 400 ml two hours before the induction of anaesthesia and/or 
800 ml the evening before surgery. The majority of trials gave POCL two hours before the 
induction of anaesthesia, as well as the evening before surgery. To what extent the evening dose 
of CHO contributed to clinical outcomes has not been established and should be investigated. The 




rationale for giving CHO the evening before surgery is to prevent glycogen depletion. Numerous 
trials exist on the effect of adding glutamine, whey protein or hydrolysed protein to the POCL 
beverage. Data should be pooled to investigate whether there is benefit in adding protein to the 
CHO beverage. Noteworthy for future trials, it is important for investigators to record how much of 
the POCL beverage was actually consumed by the participants, and report on the actual time of 
ingestion of the POCL beverage to the induction of anaesthesia and start of surgery. 
Future trials should aim to measure as many outcomes as possible by using standardised 
measurements. Trials using the gold standard of the hyperinsulinaemic euglycaemic clamp method 
to measure insulin resistance, especially in major abdominal surgery patients, will be of utmost 
value. The trials measuring length of stay should focus on major abdominal surgery where the 
expected length of stay is long enough to detect a difference in using POCL or not. Standardised 
instruments such as the visual analogue scale should be used to evaluate the patients’ well-being 
to limit heterogeneity to ensure that outcomes can be pooled. The main outcome focus to detect 
clinical benefit such as decreased insulin resistance and length of stay should be in patients 
receiving major surgery, whereas the main outcome focus in patients receiving minor surgery 
should be well-being. Trials comparing minor versus major surgery will be able to confirm this 
speculation.  
Since POCL is incorporated into the ERAS® concept, it will be difficult to conduct trials with only 
one intervention in future. Therefore, trials should clearly indicate all the ERAS® components used 
to optimise recovery since a combination of elements will have a greater effect than a single 
component. Confounding factors such as medication used prophylactically and postoperative 
feeding regimens should be accounted for when reporting on the outcomes. Incomplete outcome 
data is an important matter that needs to be addressed as well as poor reporting and 
correspondence.  
Industry-sponsored research will always be a limitation in trials on this topic since the POC 
beverage is patented and usually sponsored. A trial on the effect of different POC beverages is a 
possibility but it will be extremely difficult to conduct due to confounding factors and industry 
influence. It is important for all authors to declare their conflict of interest so that the reader can 
interpret data with caution.  
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Appendix 6.1: Eligibility form 
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A single failed eligibility criterion is sufficient for a study to be excluded from the review, and the remaining criteria need not be assessed. 
LANGUAGE 








Go to next question 
Exclude: 
Foreign Language 
TYPE OF STUDY 








Go to next question 
Exclude: 
Study Type 
TYPES OF PARTICIPANTS 








Go to next question 
Exclude: 
Animal Study 








Go to next question 
Exclude: 
Age Restriction 








Go to next question 
Exclude: 
Non-Elective Surgery 








Go to next question 
Exclude: Abnormal 
Glucose Levels 
Stellenbosch University  https://scholar.sun.ac.za













Go to next question 
Exclude: 
Feeding Route 
Did the beverage contain > 12% carbohydrates with an osmolality of 












Did the participants consume at least 400ml of the beverage 90 – 300 








Go to next question 
Exclude: 
Dosage and/or Timing 
OUTCOMES 






















FINAL DECISION INCLUDE EXCLUDE 
 
 
Stellenbosch University  https://scholar.sun.ac.za














REVIEW AUTHOR ID 
 
 
JANINE KRIEL (8603030236080) 
 
 
LAUREN PIETERSEN (8611160177081) 
 
STUDY ID  
 (last name of first author and the year of the primary reference; 








































Stellenbosch University  https://scholar.sun.ac.za

























ETHICS APPROVAL OBTAINED 
 














RISK OF BIAS 
 
 
SEE RISK OF BIAS FORM 
Stellenbosch University  https://scholar.sun.ac.za



































MALE FEMALE MALE FEMALE MALE FEMALE MALE FEMALE 
 
BMI / WEIGHT 
 






GLUCOSE VALUE PRIOR TO SURGERY 
 
    
 
TYPE OF SURGERY 
 
ABDOMINAL OTHER UNCLEAR 
 
TYPE OF ANAESTHESIA 
 




HIGH LOW UNCLEAR 
 
TIME FROM INGESTION TO INDUCTION OF 
ANAESTHESIA 
    
 
TIME FROM INGESTION TO START OF SURGERY 
 
    
 
ERAS PROTOCOL FOLLOWED 
 
YES NO UNCLEAR 
 
Stellenbosch University  https://scholar.sun.ac.za























































       
Stellenbosch University  https://scholar.sun.ac.za





RANDOMIZATION / ALLOCATION 
 
















































Stellenbosch University  https://scholar.sun.ac.za




























































































































































































            
 
 
Stellenbosch University  https://scholar.sun.ac.za


















































































Stellenbosch University  https://scholar.sun.ac.za




















































































































































































































Stellenbosch University  https://scholar.sun.ac.za



















































































































































































































Stellenbosch University  https://scholar.sun.ac.za


















































Stellenbosch University  https://scholar.sun.ac.za







































































Stellenbosch University  https://scholar.sun.ac.za




















































END OF DATA EXTRACTION 
Stellenbosch University  https://scholar.sun.ac.za




Appendix 6.3: Assessment of risk of bias form 
DOMAIN JUDGEMENT DESCRIPTION 
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Adequate Sequence Generation 
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Blinding of Participants 
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Appendix 6.6: Included studies (phase 1) 
STUDY ID 
AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A1 Carli 2015 
Physiological Considerations of Enhanced Recovery After Surgery 
(ERAS) 
A2 Singh 2015 
Evaluation of effects of a Preoperative 2-hour Fast with Glutamine 
and Carbohydrate Rich Drink on Insulin Resistance in Maxillofacial 
Surgery 
A3 Ljunggren 2014 
Insulin Sensitivity and Beta-cell Function after Carbohydrate Oral 
Loading in Hip Replacement Surgery: A Double-blind, Randomised 
Controlled Clinical Trial 
A4 Webster 2014 
Does Preoperative Oral Carbohydrate reduce Hospital Stay? A 
Randomized Trail 
A5 Wijk 2014 
Implementing a Structured Enhanced Recovery after Surgery (ERAS) 
Protocol reduces Length of Stay after Abdominal Hysterectomy 
A6 Canby 2014 
Effects of Preoperative Consumption of High Carbohdyrate Drink 
(Pre-Op®) on Postoperative Metabolic Stress Reaction in Patients 
undergoing Radical Prostatectomy 
A7 Zhao 2014 
Fast-Track Surgery Improves Postoperative Clinical Recovery and 
Reduces Postoperative Insulin Resistance after Esophagectomy for 
Esophageal Cancer 
A8 
De Anguilar – 
Nascimento 2014 
Preoperative Education in Cholecystectomy in the Context of a 
Multimodal Protocol of Perioperative Care: A Randomized, Controlled 
Trial 
A9 Li 2014 
Fast-Tract Improves Post-operative Nutrition and Outcomes of 
Colorectal Surgery: A Single-Centre Prospective Trial in China 
A10 Jones 2013 
Randomized Clinical Trial on Enhanced Recovery versus Standard 
Care following Open Liver Resection 
A11 Pexe-Machado 2013 
Shrinking Preoperative Fast Time with Maltodextrin and Protein 
Hydrolysate in Gastrointestinal Resections due to Cancer 
A12 Suliman 2013 
Pre-Operative Oral Carbohydrate Loading is Safe and Improves 
Patients Satisfaction with Elective Ambulatory Surgery and 
Anesthesia: It’s Time for Change 
A13 Zareba 2013 
Parenteral Nutrition and PreOp Preoperation in Prevention of Post-
operative Insulin Resistance in Gastrointestinal Carcinoma 
A14 Yilmaz 2013 
Preoperative Carbohydrate Nutrition Reduces Postoperative Nausea 
and Vomiting Compared to Preoperative Fasting 
A15 Zelic 2013 
Preoperative Oral Feeding Reduces Stress Response after 
Laparoscopic Cholecystectomy 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A16 Yildiz 2013 
Oral Carbohydrate Supplementation reduces Preoperative 
Discomfort in Laparoscopic Cholecystectomy 
A17 Miller 2013 
An Evidence-Based Approach to Perioperative Nutrition Support in 
the Elective Surgery Patient 
A18 Braga, 2012 
Oral Preoperative Antioxidants in Pancreatic Surgery: A Double-blind, 
Randomized, Clinical Trial 
A19 Ljunggren, 2012 
Oral Nutrition or Water Loading before Hip Replacement Surgery: A 
Randomized Clinical Trial 
A20 Viganò 2012 
Effects of Preoperative Oral Carbohydrate Supplementation on 
Postoperative Metabolic Stress Response of Patients Undergoing 
Elective Abdominal Surgery 
A21 Dock-Nascimento 2012 
Evaluation of the effects of a preoperative 2-hour fast with 
maltodextrine and glutamine on insulin resistance, Acute-phase 
response, nitrogen balance, and serum glutathione after laparoscopic 
cholecystectomy: A controlled randomized trial 
A22 Verheijen  2012 
Feasibility of enhanced recovery programme in various patient 
groups 
A23 Awad 2012 
Metabolic conditioning to attenuate the adverse effects of 
perioperative fasting and improve patient outcomes 
A24 Power  2012 
Reducing preoperative fasting in elective adult surgical patients: a 
case-control study 
A25 Itou  2012 
Safety and efficacy of oral rehydration therapy until 2 h before 
surgery: a multicenter randomized controlled trial 
A26 Wang 2012 
Immunologic Response after Laparoscopic Colon Cancer Operation 
within an Enhanced Recovery Programme 
A27 Yang 2012 
Fast-Track Surgery Improves Postoperative Clinical Recovery and 
Immunity after Elective Surgery for Colorectal Carcinoma: 
Randomized Controlled Clinical Trial 
A28 Huibers 2012 
The Effect of the Introduction of the ERAS Protocol in Laparoscopic 
Total Mesorectal Excision for Rectal Cancer 
A29 Kennedy 2012 
EnROL: A Multicentre Randomised Trial of Conventional versus 
Laparoscopic Surgery for Colorectal Cancer within an Enhanced 
Recovery Programme 
A30 Aarts 2012 
Adoption of Enhanced Recovery After Surgery (ERAS) Strategies for 
Colorectal Surgery at Academic Teaching Hospitals and Impact on 
Total Length of Hospital Stay 
A31 Ren 2012 
Enhanced Recovery After Surgery (ERAS) Program Attenuates 
Stress and Accelerates Recovery in Patients after Radical Resection 
for Colorectal Cancer: A Prospective Randomized Controlled Trial 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A32 Pawa 2012 
Enhanced Recovery Program following Colorectal Resection in the 
Elderly Patient 
A33 Bopp  2011 
A liberal preoperative fasting regimen improves patient comfort and 
satisfaction with anesthesia care in day-stay minor surgery 
A34 Awad  2011 
A randomized crossover study of the effects of glutamine and lipid on 
the gastric emptying time of a preoperative carbohydrate drink 
A35 Awad  2011 
A randomized cross-over study of the metabolic and hormonal 
responses following two preoperative conditioning drinks 
A36 Gustafsson  2011 
Adherence to the Enhanced Recovery after Surgery Protocol and 
Outcomes After Colorectal Cancer Surgery 
A37 Burden  2011 
An unblinded randomised controlled trial of preoperative oral 
supplements in colorectal cancer patients 
A38 Goichon  2011 
Effects of an enteral glucose supply on protein synthesis, proteolytic 
pathways, and proteome in human duodenal mucosa 
A39 Perrone  2011 
Effects of preoperative feeding with a whey protein plus carbohydrate 
drink on the acute phase response and insulin resistance. A 
randomized trial 
A40 Martelli 2011 
Pre-Operative Oral Nutrition Supplementation of Carbohydrates in 
Aortic Surgery: A Randomized Trial of 40 Patients 
A41 Ramirez  2011 Enhanced Recovery in colorectal surgery: a multicentre study 
A42 Vermeulen  2011 
Gastric emptying, glucose metabolism and gut hormones: Evaluation 
of a common preoperative carbohydrate beverage 
A43 Okabayashi  2011 
Oral supplementation with carbohydrate- and branched-chain amino 
acid-enriched nutrients improves postoperative quality of life in 
patients undergoing hepatic resection 
A44 Gustafsson  2011 Perioperative nutritional management in digestive tract surgery 
A45 Manchikanti  2011 
Preoperative fasting before interventional techniques: Is it necessary 
or evidence-based? 
A46 Crenshaw 2011 Preoperative Fasting: Will the evidence ever be put into practice? 
A47 Donatelli 2011 
Preoperative insulin resistance and the impact of feeding on 
postoperative protein balance: A stable isotope study 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A48 Kratzing  2011 Pre-operative nutrition and carbohydrate loading 
A49 Gianotti  2011 
Revising concepts of artificial nutrition in contemporary surgery: from 
energy and nitrogen to immune-metabolic support 
A50 Christensen  2011 
Short hospital stay and low complication rate are possible with a fully 
implemented fast-track model after elective colonic surgery 
A51 Ozdemir  2011 
The Effect of Preoperative Oral Carbohydrate Loading on Stress 
Response in Patients Undergoing Major or Minor Surgery 
A52 Yagmurdur  2011 
The effects of carbohydrate-rich drink on perioperative discomfort, 
insulin response and arterial pressure in spinal aesthesia 
A53 Jones  2011 
The role of carbohydrate drinks in pre-operative nutrition for elective 
colorectal surgery 
A54 Awad  2010 
Cellular mechanisms underlying the protective effects of preoperative 
feeding: A randomized study investigating muscle and liver glycogen 
content, mitochondrial function, gene and protein expression 
A55 
De Aguilar-Nascimento  
2010 
Clinical benefits after the implementation of a multimodal 
perioperative protocol in elderly patients 
A56 Ahmed  2010 
Compliance with enhanced recovery programmes in elective 
colorectal surgery 
A57 Proctic  2010 
Effect of preoperative feeding on gastric emptying following spinal 
anaesthesia: a randomized controlled trial 
A58 Teeuwen 2010 
Enhanced Recovery After Surgery (ERAS) versus conventional 
postoperative care in colorectal surgery 
A59 Liu 2010 
Multimodal optimization of surgical care shows beneficial outcome in 
gastrectomy surgery 
A60 Senesse 2010 
Perioperative nutrition care protocols / Nutrition périopératoire: 
protocols de soins 
A61 Coti-Bertrand 2010 Preoperative Nutritional Support 
A62 Okabayashi 2010 
Preoperative oral supplementation with carbohydrate and branched-
chain amino acid-enriched nutrient improves insulin resistance in 
patients undergoing a hepatectomy: a randomized clinical trial using 
an artificial pancreas 
A63 Hendry 2010 
Randomized clinical trial of laxatives and oral nutritional supplements 
within an enhanced recovery after surgery protocol following liver 
resection 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A64 Wang 2010 
Randomized clinical trial to compare the effects of preoperative oral 
carbohydrate versus placebo on insulin resistance after colorectal 
surgery 
A65 Lassen 2010 
Randomized controlled trial of preoperative oral carbohydrate 
treatment in major abdominal surgery 
A66 Mathur 2010 
Randomized controlled trial of preoperative oral carbohydrate 
treatment in major abdominal surgery 
A67 Awad 2010 
The effects of fasting and refeeding with a 'metabolic preconditioning' 
drink on substrate reserves and mononuclear cell mitochondrial 
function 
A68 Kaška 2010 
The impact and safety of preoperative oral or intravenous 
carbohydrate administration versus fasting in colorectal surgery-a 
randomized controlled trial 
A69 Aronsson 2009 
A carbohydrate rich drink shortly before surgery affected IGF-I 
bioavailability after a total hip replacement: A double-blind placebo 
controlled study on 29 patients 
A70 De Oliveira 2009 
Does abbreviation of preoperative fasting to two hours with 
carbohydrates increase the anesthetic risk? [A abreviação do jejum 
pré-operatório para duas horas com carboidratos aumenta o risco 
anestésico?] 
A71 Helminen 2009 
Effect of preoperative intravenous carbohydrate loading on 
preoperative discomfort in elective surgery patients 
A72 Yang 2009 
Effects of drinking fluid hours before anesthesia on gastric fluid 
volume and pH in patients with colorectal cancer 
A73 Lauwick 2009 
Effects of oral preoperative carbohydrate on early postoperative 
outcome after thyroidectomy 
A74 Tran 2009 
Preoperative Carbohydrae Loading in Patients undergoing Coronary 
Artery Bypass or Spinal Surgery 
A75 Šerclová 2009 
Fast-track in open intestinal surgery: prospective randomized study 
(Clinical Trials Gov Identifier no. NCT00123456) 
A76 Sutanto 2009 
Gastric emptying of oral nutritional supplements assessed by 
ultrasound 
A77 Lobo 2009 
Gastric emptying of three liquid oral preoperative metabolic 
preconditioning regimens measured by magnetic resonance imaging 
in healthy adult volunteers: A randomised double-blind, crossover 
study 
A78 Ljungqvist 2009 
Modulating postoperative insulin resistance by preoperative 
carbohydrate loading 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A79 Roig 2009 
Perioperative care in colorectal surgery: Current practice patterns 
and opinions 
A80 Can 2009 
Preoperative administration of oral carbohydrate-rich solutions: 
comparison of glucometabolic responses and tolerability between 
patients with and without insulin resistance 
A81 Faria 2009 
Preoperative fasting of 2 hours minimizes insulin resistance and 
organic response to trauma after video-cholecystectomy: A 
randomized, controlled, clinical trial 
A82 Taniguchi 2009 
Preoperative fluid and electrolyte management with oral rehydration 
therapy 
A83 Awad 2009 
Short-term starvation and mitochondrial dysfunction–A possible 
mechanism leading to postoperative insulin resistance 
A84 Yagci 2008 
Effects of preoperative carbohydrate loading on glucose metabolism 
and gastric contents in patients undergoing moderate surgery: a 
randomized, controlled trial 
A85 An 2008 
Effects of preoperative carbohydrate loading on the changes in 
serum tumor necrosis factor receptors 1 and 2 and insulin resistance 
in patients of colon carcinoma 
A86 Meisner 2008 
Liberalisation of preoperative fasting guidelines: Effects on patient 
comfort and clinical practicability during elective laparoscopic surgery 
of the lower abdomen [Liberalisierte Präoperative Flüssigkeitskarenz: 
Patientenbefinden und Klinische Praktikabilität bei Elektiven 
Laparoskopischen Eingriffen im Unterbauch] 
A87 Gustafsson 2008 
Pre-operative carbohydrate loading may be used in type 2 diabetes 
patients 
A88 Hendry 2008 
Preoperative conditioning with oral carbohydrate loading and oral 
nutritional supplements can be combined with mechanical bowel 
preparation prior to elective colorectal resection 
A89 Tully 2008 
Pre-operative modification of dietary glycemic index improves pre but 
not post-operative indices of insulin resistance in patients undergoing 
coronary artery bypass graft surgery 
A90 Järvelä 2008 
Pre-operative oral carbohydrate treatment before coronary artery 
bypass surgery 
A91 Deniz 2007 
Oral carbohydrate solution ameliorates endotoxemia-induced 
splanchnic ischemia 
A92 Svanfeldt 2007 
Randomized clinical trial of the effect of preoperative oral 
carbohydrate treatment on postoperative whole-body protein and 
glucose kinetics 
A93 Soop 2007 Stress-induced insulin resistance: recent developments 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A94 Melis 2006 
A carbohydrate-rich beverage prior to surgery prevents surgery-
induced immunodepression: A randomized, controlled, clinical trial 
A95 Soreide 2006 
Modern preoperative fasting guidelines: a summary of the present 
recommendations and remaining questions 
A96 Breuer 2006 
New preoperative fasting guidelines: potential for metabolic 
conditioning. / Reduktion der präoperativen Nahrungskarenz: 
Potenzial zur metabolischen Konditionierung 
A97 Soop 2006 
Optimizing perioperative management of patients undergoing 
colorectal surgery: what is new? 
A98 Waitzberg 2006 
Postsurgical Infections are Reduced with Specialized Nutrition 
Support 
A99 Furrer 2006 
Preoperative fasting times. Patients' perspective [Präoperative 
nüchternzeiten. Sicht der patienten] 
A100 Breuer 2006 
Preoperative oral carbohydrate administration to ASA III-IV patients 
undergoing elective cardiac surgery 
A101 Noblett 2006 
Pre-operative oral carbohydrate loading in colorectal surgery: a 
randomized controlled trial 
A102 Pu 2005 
Effect of preoperative carbohydrate supplementation on insulin 
resistance in patients after scarectomy 
A103 Svanfeldt 2005 
Effect of "preoperative" oral carbohydrate treatment on insulin action-
-a randomised cross-over unblinded study in healthy subjects 
A104 Diks 2005 Preoperative fasting: an outdated concept? 
A105 Hausel  2005 
Randomized clinical trial of the effects of oral preoperative 
carbohydrates on postoperative nausea and vomiting after 
laparoscopic cholecystectomy 
A106 Yuill 2005 
The administration of an oral carbohydrate-containing fluid prior to 
major elective upper-gastrointestinal surgery preserves skeletal 
muscle mass postoperatively--a randomised clinical trial 
A107 Scheepers 2004 
Carbohydrate solution intake during labour just before the start of the 
second stage: A double-blind study on metabolic effects and clinical 
outcome 
A108 Tjandra 2004 
Carboydrate-electrolyte (E-Lyte) solution enhances bowel preparation 
with oral fleet phospsho-soda 
A109 Noblett 2004 
Pre-operative oral carbohydrate loading in colorectal surgery: a 
randomized controlled trial 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A110 Soop 2004 
Preoperative oral carbohydrate treatment attenuates endogenous 
glucose release 3 days after surgery 
A111 Smedley 2004 
Randomized clinical trial of the effects of preoperative and 
postoperative oral nutritional supplements on clinical course and cost 
of care 
A112 Ljungqvist 2004 To fast or not to fast? Metabolic preparation for elective surgery 
A113 Ali 2003 
Effect of supplemental pre-operative fluid on postoperative nausea 
and vomiting 
A114 Henriksen 2003 
Effects of preoperative oral carbohydrates and peptides on 
postoperative endocrine response, mobilization, nutrition and muscle 
function in abdominal surgery 
A115 Bisgaard 2003 
Randomized clinical trial comparing an oral carbohydrate beverage 
with placebo before laparoscopic cholecystectomy 
A116 Anderson 2003 
Randomized clinical trial of multimodal optimization and standard 
perioperative surgical care 
A117 Ljungqvist 2003 Preoperative fasting 
A118 Fearon 2003 
The nutritional management of surgical patients: enhanced recovery 
after surgery 
A119 Scheepers 2002 
A double-blind, randomised, placebo controlled study on the 
influence of carbohydrate solution intake during labour 
A120 Erdem 2002 
The effects of perioperative oral enteral support with glutamine-added 
elemental formulas in patients with gastrointestinal cancers. A 
prospective, randomized, clinical study 
A121 Hausel 2001 
A carbohydrate-rich drink reduces preoperative discomfort in elective 
surgery patients 
A122 Naguib 2001 
Metabolic, hormonal and gastric fluid and pH changes after different 
preoperative feeding regimens 
A123 Ljungqvist 2001 
Preoperative nutrition—elective surgery in the fed or the overnight 
fasted state 
A124 Nygren 2001 Preoperative oral carbohydrate nutrition: an update 
A125 Soop 2001 
Preoperative oral carbohydrate treatment attenuates immediate 
postoperative insulin resistance 





AUTHOR AND YEAR 
(TRIAL IDENTIFIER) 
TITLE 
A126 Nygren 1999 Preoperative oral carbohydrates and postoperative insulin resistance 
A127 Hausel 1999 
Preoperative oral carbohydrates improve well-being after elective 
colorectal surgery 
A128 Nygren 1998 
Preoperative oral carbohydrate administration reduces postoperative 
insulin resistance 
A129 Soop 1997 
Preoperative oral carbohydrate intake attenuates metabolic changes 
immediately after hip replacement 
A130 Nygren 1996 
Safety and patient well-being after preoperative oral intake of 
carbohydrate rich beverage 
A131 Nygren 1995 
Preoperative gastric emptying. Effects of anxiety and oral 
carbohydrate administration 
A132 NCT02330263 
Effect of Preoperative Oral Carbohydrates on Postoperative Insulin 
Resistance in Patients Undergoing OPCAB (Off-Pump Coronary 
Artery Bypass Surgery) 
A133 NCT01844375 
A Trial of Preoperative CHO Drinks on Postoperative Walking 
Capacity in Colorectal Surgery 
A134 NCT02062788 Evaluation of Preoperative Oral Rehydration Solution in Colectomy 
A135 NCT02537262 
Effect of Preoperative Oral Carbohydrates on Quality of Recovery in 
Laparoscopic Colorectal Surgery Patients 
A136 NCT01167387 
Preoperative Oral Carbohydrate Loading: Effects on The Glucose 
Metabolism and Postoperative Infections 
A137 ISRCTN91109766 
Feasibility and Metabolic Effects of Carbohydrate Loading in Patients 
with Fragile Hip Fracture – A Randomised Doulble Blind Pilot Study 
A138 TRC-10001517 
Study of preoperative oral carbohydrate-rich solusion ameliorating 
insulin resistance in postoperative patients of radical gastrectomy 
A139 KCT0000108 
The safety and the effectiveness of the Fast-track recovery system in 
gastric cancer patients who undergo laparoscopy assisted distal 
gastrectomy 
A140 CTRI/2009/091/000070 
The Effect of Preoperative Carbohydrate Loading in Major Colorectal 




Clinical Value of Preoperative Oral Carbohydrate Loading in 
Colorectal Surgery. 









Effects of Oral Carbohydrate Beverage on Glucose Metabolism and 
Preoperative Discomforts in Oral Surgery: A Randomized Controlled 
Trial. 
A143 NCT00538954 
Optimised recovery with accelerated nutrition and GI enhancement (a 
randomised controlled trial optimised surgical recovery: the potential 
synergy between enhanced gastrointestinal motility and oral 
nutritional/metabolic support) 
A144  
Randomised controlled study into pre-operative oral carbohydrate 
loading before resectional colorectal surgery 
A145  
The effect of the preoperative oral carbohydrate attenuating 






























A1 Carli 2015 
Physiological Considerations of Enhanced 
Recovery After Surgery (ERAS) 
Review 
A9 Li 2014 
Fast-Tract Improves Post-operative Nutrition 
and Outcomes of Colorectal Surgery: A Single-
Centre Prospective Trial in China 
Foreign Language: 
Chinese 
A12 Suliman 2013 
Pre-Operative Oral Carbohydrate Loading is 
Safe and Improves Patients Satisfaction with 
Elective Ambulatory Surgery and Anesthesia: 
It’s Time for Change 
Abstract 
A17 Miller 2013 
An Evidence-Based Approach to Perioperative 
Nutrition Support in the Elective Surgery 
Patient 
Comments / Letter / 
Editorial Comments 
A23 Awad 2012 
Metabolic conditioning to attenuate the 
adverse effects of perioperative fasting and 
improve patient outcomes 
Review 
A32 Pawa 2012 
Enhanced Recovery Program following 
Colorectal Resection in the Elderly Patient 
Review 
A36 Gustafsson  2011 
Adherence to the Enhanced Recovery after 
Surgery Protocol and Outcomes After 
Colorectal Cancer Surgery 
Abstract 
A40 Martelli 2011 
Pre-Operative Oral Nutrition Supplementation 
of Carbohydrates in Aortic Surgery: A 
Randomized Trial of 40 Patients 
Comments / Letter / 
Editorial Comments 
A44 Gustafsson  2011 
Perioperative nutritional management in 
digestive tract surgery 
Review 
A46 Crenshaw 2011 
Preoperative Fasting: Will the evidence ever 
be put into practice? 
Comments / Letter / 
Editorial Comments 
A48 Kratzing  2011 
Pre-operative nutrition and carbohydrate 
loading 
Review 
A49 Gianotti  2011 
Revising concepts of artificial nutrition in 
contemporary surgery: from energy and 
nitrogen to immune-metabolic support 
Review 
A51 Ozdemir  2011 
The Effect of Preoperative Oral Carbohydrate 
Loading on Stress Response in Patients 
Undergoing Major or Minor Surgery 
Foreign Language: 
Turkish 
A53 Jones  2011 
The role of carbohydrate drinks in pre-
operative nutrition for elective colorectal 
surgery 
Review 
A60 Senesse 2010 
Perioperative nutrition care protocols / Nutrition 
périopératoire: protocols de soins 
Foreign Language: 
French 










A61 Coti-Bertrand 2010 Preoperative Nutritional Support Review 
A65 Lassen 2010 
Randomized controlled trial of preoperative 
oral carbohydrate treatment in major 
abdominal surgery 
Comments / Letter / 
Editorial Comments 
A70 De Oliveira 2009 
Does abbreviation of preoperative fasting to 
two hours with carbohydrates increase the 
anesthetic risk? [A abreviação do jejum pré-
operatório para duas horas com carboidratos 
aumenta o risco anestésico?] 
Foreign Language: 
Portuguese 
A72 Yang 2009 
Effects of drinking fluid hours before 
anesthesia on gastric fluid volume and pH in 
patients with colorectal cancer 
Foreign Language: 
Chinese 
A76 Sutanto 2009 
Gastric emptying of oral nutritional 
supplements assessed by ultrasound 
Abstract 
A78 Ljungqvist 2009 
Modulating postoperative insulin resistance by 
preoperative carbohydrate loading 
Comments / Letter / 
Editorial Comments 
A83 Awad 2009 
Short-term starvation and mitochondrial 
dysfunction–A possible mechanism leading to 
postoperative insulin resistance 
Review 
A85 An 2008 
Effects of preoperative carbohydrate loading 
on the changes in serum tumor necrosis factor 
receptors 1 and 2 and insulin resistance in 
patients of colon carcinoma 
Foreign Language: 
Chinese 
A86 Meisner 2008 
Liberalisation of preoperative fasting 
guidelines: Effects on patient comfort and 
clinical practicability during elective 
laparoscopic surgery of the lower abdomen 
[Liberalisierte Präoperative Flüssigkeitskarenz: 
Patientenbefinden und Klinische Praktikabilität 




A89 Tully 2008 
Pre-operative modification of dietary glycemic 
index improves pre but not post-operative 
indices of insulin resistance in patients 
undergoing coronary artery bypass graft 
surgery 
Abstract 
A91 Deniz 2007 
Oral carbohydrate solution ameliorates 
endotoxemia-induced splanchnic ischemia 
Animal Study 
A93 Soop 2007 
Stress-induced insulin resistance: recent 
developments 
Review 
A95 Soreide 2006 
Modern preoperative fasting guidelines: a 
summary of the present recommendations and 
remaining questions 
Practice Guidelines 
A96 Breuer 2006 
New preoperative fasting guidelines: potential 
for metabolic conditioning. / Reduktion der 














A97 Soop 2006 
Optimizing perioperative management of 
patients undergoing colorectal surgery: what is 
new? 
Review 
A98 Waitzberg 2006 
Postsurgical Infections are Reduced with 
Specialized Nutrition Support 
Review 
A99 Furrer 2006 
Preoperative fasting times. Patients' 
perspective [Präoperative nüchternzeiten. 
Sicht der patienten] 
Foreign Language: 
German 
A102 Pu 2005 
Effect of preoperative carbohydrate 
supplementation on insulin resistance in 
patients after scarectomy 
Foreign Language: 
Chinese 
A104 Diks 2005 Preoperative fasting: an outdated concept? 
Comments / Letter / 
Editorial Comments 
A108 Tjandra 2004 
Carboydrate-electrolyte (E-Lyte) solution 
enhances bowel preparation with oral fleet 
phospsho-soda 
Abstract 
A109 Noblett 2004 
Pre-operative oral carbohydrate loading in 
colorectal surgery: a randomized controlled 
trial 
Multiple Publication 
A112 Ljungqvist 2004 
To fast or not to fast? Metabolic preparation for 
elective surgery 
Comments / Letter / 
Editorial Comments 
A117 Ljungqvist 2003 Preoperative fasting Review 
A118 Fearon 2003 
The nutritional management of surgical 
patients: enhanced recovery after surgery 
Review 
A123 Ljungqvist 2001 
Preoperative nutrition—elective surgery in the 
fed or the overnight fasted state 
Comments / Letter / 
Editorial Comments 
A124 Nygren 2001 
Preoperative oral carbohydrate nutrition: an 
update 
Review 
A126 Nygren 1999 
Preoperative oral carbohydrates and 
postoperative insulin resistance 
Review 
A127 Hausel 1999 
Preoperative oral carbohydrates improve well-
being after elective colorectal surgery 
Abstract 
A129 Soop 1997 
Preoperative oral carbohydrate intake 
attenuates metabolic changes immediately 
after hip replacement 
Abstract 
A130 Nygren 1996 
Safety and patient well-being after 
preoperative oral intake of carbohydrate rich 
beverage 
Abstract 











Effect of Preoperative Oral Carbohydrates on 
Postoperative Insulin Resistance in Patients 
Undergoing OPCAB (Off-Pump Coronary 
Artery Bypass Surgery) 
Ongoing Trial 
A133 NCT01844375 
A Trial of Preoperative CHO Drinks on 




Evaluation of Preoperative Oral Rehydration 
Solution in Colectomy 
Ongoing Trial 
A135 NCT02537262 
Effect of Preoperative Oral Carbohydrates on 




Preoperative Oral Carbohydrate Loading: 




Feasibility and Metabolic Effects of 
Carbohydrate Loading in Patients with Fragile 




Study of preoperative oral carbohydrate-rich 
solution ameliorating insulin resistance in 
postoperative patients of radical gastrectomy 
Ongoing Trial 
A139 KCT0000108 
The safety and the effectiveness of the Fast-
track recovery system in gastric cancer 






The Effect of Preoperative Carbohydrate 
Loading in Major Colorectal Resections: A 





Clinical Value of Preoperative Oral 





Effects of Oral Carbohydrate Beverage on 
Glucose Metabolism and Preoperative 




Optimised recovery with accelerated nutrition 
and GI enhancement (a randomised controlled 
trial optimised surgical recovery: the potential 
synergy between enhanced gastrointestinal 
motility and oral nutritional/metabolic support) 
Multiple Publication 
A144  
Randomised controlled study into pre-
operative oral carbohydrate loading before 
resectional colorectal surgery 
Multiple Publication 
A145  
The effect of the preoperative oral 
carbohydrate attenuating immediate 
postoperative insulin resistance on PI3K 








Appendix 6.8: Study eligibility phase 3 
Study ID 










































































































































   
   















   
   
   
   











   
   
   
   






























A2        x  x    x 
A3               
A4          x    x 
A5  x    ? ? ? ? ? ?   x 
A6               
A7        x ? ?    x 
A8          x    x 
A10      x        x 
A11          x    x 
A13  ?           x x 
A14               
A15               
A16               
A18      x  ? ? ?    x 
A19               
A20  x            x 
A21          x    x 
A22  x    ?  ? ? ? ?   x 
A24  x    ?  x ? ?    x 
A25      ?  x  x    x 
A26      ?       x x 
A27        x ? x    x 
A28  x    ?  ? ? ?    x 
A29  ?    ?    x    x 
A30  x    ?  ? ? ?    x 
A31          x    x 
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A33      ?    x    x 
A34  x   x ?        x 
A35  x   x         x 
A37      ?   ?  x   x 
A38     x ? x ? ?  x   x 
A39         ? x    x 
A41  x            x 
A41  x   x         x 
A43      x  x ? ? x   x 
A45  x    ?  ? x x x   x 
A47  x    X  ? ? ? x   x 
A50  x    ? ? ? ? ? ? x  x 
A52               
A54         ? x    x 
A55  x    ?   ? x    x 
A56  x    ?  ? ? ?    x 
A57      ?   ? x    x 
A58  x    ?  ? ?     x 
A59  ?    ? x x ? ?    x 
A62      x  x ? ? x   x 
A63      x        x 
A64               
A66               
A67  x   x ?   ? ?    x 
A68               
A69          x    x 
A71               
A73         x     x 
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A74               
A75               
A77  x   x ?        x 
A79  x    ? ? ? ? ? ? ?  x 
A80  ?    x        x 
A81      ?    x    x 
A82        x   ?   x 
A84               
A87  ?   x x        x 
A88  x            x 
A90               
A92             x x 
A94               
A100      x        x 
A101               
A103  x   x         x 
A105               
A106               
A107     x    ? ? x   x 
A110               
A111      ?  x ? ? x   x 
A113      ? x ? ? x x   x 
A114         ?  x   x 
A115               
A116         x     x 
A119     x     ? x   x 
A120      ? x  x x x   x 
A121               
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A122        x ? ?    x 
A125               
A128  x            x 
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A2 Singh 2015 
Evaluation of effects of a Preoperative 2-hour Fast with 
Glutamine and Carbohydrate Rich Drink on Insulin 
Resistance in Maxillofacial Surgery 
Concentration: 
<12% CHO 
A4 Webster 2014 
Does Preoperative Oral Carbohydrate reduce Hospital 
Stay? A Randomized Trail 
Dosage: 200ml 
A5 Wijk 2014 
Implementing a Structured Enhanced Recovery after 




A7 Zhao 2014 
Fast-Track Surgery Improves Postoperative Clinical 
Recovery and Reduces Postoperative Insulin 





De Anguilar – 
Nascimento 
2014 
Preoperative Education in Cholecystectomy in the 
Context of a Multimodal Protocol of Perioperative 
Care: A Randomized, Controlled Trial 
Dosage: 200ml 
A10 Jones 2013 
Randomized Clinical Trial on Enhanced Recovery 






Shrinking Preoperative Fast Time with Maltodextrin 
and Protein Hydrolysate in Gastrointestinal Resections 
due to Cancer 
Dosage: 200ml 
A13 Zareba 2013 
Parenteral Nutrition and PreOp Preoperation in 
Prevention of Post-operative Insulin Resistance in 
Gastrointestinal Carcinoma 
>1 Active Control 
A18 Braga, 2012 
Oral Preoperative Antioxidants in Pancreatic Surgery: 
A Double-blind, Randomized, Clinical Trial 
Abnormal 
Glucose Value 
A20 Viganò 2012 
Effects of Preoperative Oral Carbohydrate 
Supplementation on Postoperative Metabolic Stress 








Evaluation of the effects of a preoperative 2-hour fast 
with maltodextrine and glutamine on insulin resistance, 
Acute-phase response, nitrogen balance, and serum 
glutathione after laparoscopic cholecystectomy: A 









A24 Power  2012 
Reducing preoperative fasting in elective adult surgical 
patients: a case-control study 
Study Design: 
Non-Randomized 
A25 Itou  2012 
Safety and efficacy of oral rehydration therapy until 2 h 
before surgery: a multicenter randomized controlled 
trial 
Concentration:    
< 12% CHO 










A26 Wang 2012 
Immunologic Response after Laparoscopic Colon 
Cancer Operation within an Enhanced Recovery 
Programme 
>1 Active Control 
A27 Yang 2012 
Fast-Track Surgery Improves Postoperative Clinical 
Recovery and Immunity after Elective Surgery for 




A28 Huibers 2012 
The Effect of the Introduction of the ERAS Protocol in 




A29 Kennedy 2012 
EnROL: A Multicentre Randomised Trial of 
Conventional versus Laparoscopic Surgery for 
Colorectal Cancer within an Enhanced Recovery 
Programme 
Dosage: 200ml 
A30 Aarts 2012 
Adoption of Enhanced Recovery After Surgery (ERAS) 
Strategies for Colorectal Surgery at Academic 




A31 Ren 2012 
Enhanced Recovery After Surgery (ERAS) Program 
Attenuates Stress and Accelerates Recovery in 
Patients after Radical Resection for Colorectal Cancer: 
A Prospective Randomized Controlled Trial 
Dosage: 200ml 
A33 Bopp  2011 
A liberal preoperative fasting regimen improves patient 
comfort and satisfaction with anesthesia care in day-
stay minor surgery 
Dosage: 200ml 
A34 Awad  2011 
A randomized crossover study of the effects of 
glutamine and lipid on the gastric emptying time of a 
preoperative carbohydrate drink 
Study Design: 
Cross-over Study 
A35 Awad  2011 
A randomized cross-over study of the metabolic and 




A37 Burden  2011 
An unblinded randomised controlled trial of 
preoperative oral supplements in colorectal cancer 
patients 
Timing: > 300min 
preoperative 
A38 Goichon  2011 
Effects of an enteral glucose supply on protein 
synthesis, proteolytic pathways, and proteome in 
human duodenal mucosa 
No Surgery 
A39 Perrone  2011 
Effects of preoperative feeding with a whey protein 
plus carbohydrate drink on the acute phase response 
and insulin resistance. A randomized trial 
Dosage: < 400ml 
A41 Ramirez  2011 








Gastric emptying, glucose metabolism and gut 







Oral supplementation with carbohydrate- and 
branched-chain amino acid-enriched nutrients 
improves postoperative quality of life in patients 
undergoing hepatic resection 
Abnormal Glucose 
Values 













Preoperative fasting before interventional techniques: 




A47 Donatelli 2011 
Preoperative insulin resistance and the impact of 








Short hospital stay and low complication rate are 
possible with a fully implemented fast-track model after 




A54 Awad  2010 
Cellular mechanisms underlying the protective effects 
of preoperative feeding: A randomized study 
investigating muscle and liver glycogen content, 
mitochondrial function, gene and protein expression 





Clinical benefits after the implementation of a 
multimodal perioperative protocol in elderly patients 
Study Design: 
Cohort Study 
A56 Ahmed  2010 
Compliance with enhanced recovery programmes in 
elective colorectal surgery 
Study Design: Case 
Note Review 
A57 Proctic  2010 
Effect of preoperative feeding on gastric emptying 
following spinal anaesthesia: a randomized controlled 
trial 
Dosage: < 400ml 
A58 Teeuwen 2010 
Enhanced Recovery After Surgery (ERAS) versus 
conventional postoperative care in colorectal surgery 
Study Design: 
Cohort Study 
A59 Liu 2010 
Multimodal optimization of surgical care shows 





Preoperative oral supplementation with carbohydrate 
and branched-chain amino acid-enriched nutrient 
improves insulin resistance in patients undergoing a 




A63 Hendry 2010 
Randomized clinical trial of laxatives and oral 
nutritional supplements within an enhanced recovery 
after surgery protocol following liver resection 
Abnormal Glucose 
Values 
A67 Awad 2010 
The effects of fasting and refeeding with a 'metabolic 
preconditioning' drink on substrate reserves and 







A carbohydrate rich drink shortly before surgery 
affected IGF-I bioavailability after a total hip 
replacement: A double-blind placebo controlled study 
on 29 patients 
Dosage: < 400ml 
A73 Lauwick 2009 
Effects of oral preoperative carbohydrate on early 
postoperative outcome after thyroidectomy 
Osmolality:          
> 300mOsm 
A77 Lobo 2009 
Gastric emptying of three liquid oral preoperative 
metabolic preconditioning regimens measured by 
magnetic resonance imaging in healthy adult 
volunteers: a randomised double-blind crossover study 
Study Design: 
Cross-over Study 










A79 Roig 2009 
Perioperative care in colorectal surgery: Current 
practice patterns and opinions 
Study Design: 
Cross-over Study 
A80 Can 2009 
Preoperative administration of oral carbohydrate-rich 
solutions: comparison of glucometabolic responses 




A81 Faria 2009 
Preoperative fasting of 2 hours minimizes insulin 
resistance and organic response to trauma after video-
cholecystectomy: A randomized, controlled, clinical 
trial 




Preoperative fluid and electrolyte management with 
oral rehydration therapy 
Concentration:    




Pre-operative carbohydrate loading may be used in 
type 2 diabetes patients 
No Surgery 
A88 Hendry 2008 
Preoperative conditioning with oral carbohydrate 
loading and oral nutritional supplements can be 
combined with mechanical bowel preparation prior to 
elective colorectal resection 
Study Design: Non-
Randomized 
A92 Svanfeldt 2007 
Randomized clinical trial of the effect of preoperative 
oral carbohydrate treatment on postoperative whole-
body protein and glucose kinetics 
Other: > 1 Active 
Control 
A100 Breuer 2006 
Preoperative oral carbohydrate administration to ASA 
III-IV patients undergoing elective cardiac surgery 
Abnormal Glucose 
Values 
A103 Svanfeldt 2005 
Effect of "preoperative" oral carbohydrate treatment on 
insulin action--a randomised cross-over unblinded 






Carbohydrate solution intake during labour just before 
the start of the second stage: A double-blind study on 
metabolic effects and clinical outcome 
No Surgery 
A111 Smedley 2004 
Randomized clinical trial of the effects of preoperative 
and postoperative oral nutritional supplements on 
clinical course and cost of care 
Concentration:    
< 12% CHO 
A113 Ali 2003 
Effect of supplemental pre-operative fluid on 





Effects of preoperative oral carbohydrates and 
peptides on postoperative endocrine response, 
mobilization, nutrition and muscle function in 
abdominal surgery 





Randomized clinical trial of multimodal optimization 
and standard perioperative surgical care 





A double-blind, randomised, placebo controlled study 
on the influence of carbohydrate solution intake during 
labour 
No Surgery 










A120 Erdem 2002 
The effects of perioperative oral enteral support with 
glutamine-added elemental formulas in patients with 




A122 Naguib 2001 
Metabolic, hormonal and gastric fluid and pH changes 
after different preoperative feeding regimens 
Concentration:    
< 12% CHO 
(unknown) 
A128 Nygren 1998 
Preoperative oral carbohydrate administration reduces 






























Appendix 6.10: Information of included studies 
 
NAME STUDY ID AUTHOR, YEAR TITLE 
1 A3 Ljunggren, 2014 
Insulin sensitivity and beta-cell function after carbohydrate 
oral loading in hip replacement surgery: a double-blind, 
randomised trial 
2 A6 Canby, 2014 
Effect of preoperative consumption of high carbohydrate 
drink (Pre-op®) on postoperative metabolic stress reaction in 
patients undergoing radical prostatectomy 
3 A14 Yilmaz, 2013 
Preoperative carbohydrate nutrition reduces postoperative 
nausea and vomiting compared to preoperative fasting 
4 A15 Zelic, 2013 
Preoperative oral feeding reduces stress response after 
laparoscopic cholecystectomy 
5 A16 Yildiz, 2013 
Oral carbohydrate supplementation reduces preoperative 
discomfort in laparoscopic cholecystectomy  
6 A19 Ljunggren, 2012 
Oral nutrition or water loading before hip replacement 
surgery; a randomized clinical trial 
7 A52 Yagmurdur, 2011 
The effects of carbohydrate-rich drink on perioperative 
discomfort, insulin response and arterial pressure in spinal 
aesthesia 
8 A64 Wang, 2010 
Randomized clinical trial to compare the effects of 
preoperative oral carbohydrate versus placebo on insulin 
resistance after colorectal surgery 
9 A66 Mathur, 2010 
Randomized controlled trial of preoperative oral 
carbohydrate treatment in major abdominal surgery 
10 A68 Kaska, 2010 
The impact and safety of preoperative oral or intravenous 
carbohydrate administration versus fasting in colorectal 




Effect of preoperative intravenous carbohydrate loading on 
preoperative discomfort in elective surgery patients 
12 A74 Tran, 2009 
Preoperative carbohydrate loading in patients undergoing 




Fast-track in open intestinal surgery: prospective 
randomized study 




Effects of preoperative carbohydrate loading on glucose 
metabolism and gastric contents in patients undergoing 
moderate surgery: a randomized, controlled trial 








Pre-operative oral carbohydrate treatment before coronary 




A carbohydrate-rich beverage prior to surgery prevents 
surgery induced immunodepression: a randomized, 




Pre-operative oral carbohydrate loading in colorectal 
surgery: a randomized controlled trial 
18 A105 Hausel, 2005 
Randomized clinical trial of the effects of oral preoperative 





The administration of an oral carbohydrate-containing fluid 
prior to major elective upper-gastrointestinal surgery 
preserves skeletal muscle mass postoperatively – a 




Preoperative oral carbohydrate treatment attenuates 




Randomized clinical trial comparing an oral carbohydrate 
beverage with placebo before laparoscopic cholecystectomy 
22 A121 Hausel, 2001 
A carbohydrate-rich drink reduces preoperative discomfort in 
elective surgery patients 
23 A125 Soop, 2001 
Preoperative oral carbohydrate treatment attenuates 
immediate postoperative insulin resistance 
24 A131 Nygren, 1995 



















Appendix 6.11: Characteristics of included studies (part A) 
















10 / 12 3:7 / 4:8 
66 (57 – 75) / 
68 (57 – 76) 
27.1 ± 3.3 / 
27.8 ± 4.4 







25 / 25 unknown 
60.00 ± 10.37 / 
58.36 ± 11.19 







20 / 20 unknown 
42.57 ± 14.42 / 
45.73 ± 10.39 







35 / 35 15:20 / 16:19 48.2 / 52.1  unknown 
 
 







30 / 30 5:25 / 8:22 
47.63 ± 8.83 / 
43.56 ± 9.82 







19 / 20 unknown 
65.2 ± 8 / 
68.5 ± 9.6 







22 / 22 12:10 / 14:8 
45 ± 7 / 
43 ± 8 
25 ± 2 / 
24 ± 3 








16 / 16 / 16 11:5 / 9:7 / 8:8 
66 (48 – 74) / 
63 (37 – 74) / 
62 (48 – 74) 
21 (19 – 24) / 
23 (20 – 25) / 
23 (18 – 26) 







69 / 73 29:40 / 44:29 
60 (27 – 80) / 
65 (22 – 81)  
26 (19 – 45) / 
25 (17 – 37) 








63 / 66 / 65 unknown 
excluded: age 
< 35 years and 
>75 years 
excluded: BMI < 20 
kg/m
2












70 / 73 / 67 26:44 / 22:51 / 25:42 
60 ± 15 / 58 ± 4 
/ 61 ± 16 
27 ± 5 /  
27 ± 5 / 
26 ± 4 
I - III 
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19 / 19 15:4 / 9:10 
59 (50;67) / 
59 (52; 64) 
26.9 (24.4; 30.1) / 
25.6 (23.5;29.3) 







53 / 52 20:33 / 32:20 
35.1 ± 11 / 
37.6 ± 12.5 
23.5 ± 4.7 / 
23.3 ± 4.4 







34 / 36 14:20 / 15:21 
49.59 ± 15.2 / 
43.00 ± 11.0 
26.82 ± 4.77 / 
25.54 ± 4.4 







50 / 51 39:11 / 45:6 
64 ± 8.6 / 
66.8 ± 11.4 
27.6 ± 4.2 / 
27.1 ± 3.5 







10 / 9 6:4 / 2:7 
59 ± 9 / 
56 ± 13 
24 ± 1 / 









12 / 12 / 11 unknown 
58 (30 – 77) / 
55 (21 – 79) / 
59 (32 – 71) 












48.3 ± 14.6 / 
48.0 ± 14.9 / 
46.8 ± 14.9 
 
24.2 ± 3 / 
25.2 ± 2.8 / 
23.8 ± 2.9 







31 / 34 
20:11 / 
19:15 
52.8 ± 2.5 / 
52.1 ± 2.4 
25.2 ± 1.2 / 








8 / 6 
3:5 / 
6:0 
59 ± 3 / 
66 ± 2 
26 ± 1 / 
26 ± 0 







43 / 43 6:37 / 9:34 
42 (24 – 69) / 
44 (18 – 65) 
27 (19 – 42) / 
26 (19 – 39) 
I – II  
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80 / 86 / 86 24:56 / 26:60 / 34:52 
Chole: 
49 (36 – 58) / 
48 (37 – 59) / 
52 (34 – 58) 
Colorectal: 
56 (50 – 67) / 
52 (34 – 66) / 
56 (46 – 69) 
Chole: 
24 (22 – 26) / 
25 (23 – 26) / 
24 (22 – 26) 
Colorectal: 
25 (21 – 27) / 
25 (23 – 27) / 
24 (21 – 26) 







8 / 7  1:7 / 3:4 
66 ± 3 / 
58 ± 3 
25 ± 1 / 








6 / 6 3:3 / 4: 2 
46 ± 3 / 
47 ± 7 
25.8 ± 1.6 / 
27.1 ± 1.7 
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Appendix 6.12: Characteristics of included studies (part B) 
STUDY 
ADMINISTERED DOSE AND 

























800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
800ml Placebo evening before + 
400ml Placebo 2 hour before 
anaesthesia / No food from 00:00 




100 ± 21 / 
102 ± 15 
Combination 





800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
Standard Fasting / No food after 









800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 








800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
Standard Fasting (no oral intake 




Unknown Unknown No 
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ADMINISTERED DOSE AND 

























800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 








800ml CHO evening before + 400ml 
CHO at least 90minutes before 




99 ± 21 / 






800ml CHO evening before + 400ml 
CHO at least 90minutes before 
anaesthesia / Standard Fasting 
Unknown Unknown Abdominal 






Low Residue Diet evening before + 
400ml CHO 3 hours before 
anaesthesia / Standard Fasting / 
Low Residue Diet evening before + 





98 (70 – 190) / 
115 (75 – 180) / 
103 (65 – 160) 
General No 
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ADMINISTERED DOSE AND 

























800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
800ml evening before + 400ml 
Placebo 2 hours before anaesthesia 
154 (87 – 566) / 
144 (85 – 202) 
213 (125 – 618) / 





154 (43 – 409) / 








400ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 









No restrictions evening before + 
400ml CHO 2 hours before 
anaesthesia / Standard Fasting / 
NPO + IV CHO 
3.8 ± 1.7 /  
4.3 ± 1.8 / 




and General Surgery) 
100 /  







800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
Standard Fasting (no intake after 




Bypass and Spinal 
Surgery) 
Unknown Combination No 
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ADMINISTERED DOSE AND 

























Light dinner evening before + 400-
800ml CHO 2-4 hours before 
surgery / Standard Fasting 
3.6 (±1.7) /  














800ml CHO evening before + 400ml 












No restrictions evening before + 
400ml CHO 2 hours before 










Light diet evening before + 400ml 






124 (45) /  
155 (74) 
Combination 
(General n = 18; 
Spinal n = 8; 
Epidural n = 7) 
No 
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ADMINISTERED DOSE AND 

























800ml CHO evening before + 400ml 
CHO 3 hours before anaesthesia / 
Standard Fasting / 800ml Placebo 
evening before + 400ml Placebo 3 









800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
Standard Fasting / 800ml Placebo 
evening before + 400ml Placebo 2 





69 (36) /  






800ml CHO evening before + 400ml 
CHO 2-3 hours before anaesthesia / 
800ml Placebo evening before + 










800ml CHO evening before + 400ml 
2.5 hours before surgery / 800ml 
Placebo evening before + 400ml 
Placebo 2.5 hours before surgery 
Unknown 





84 (9) /  
86 (5)  
Epidural No 
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ADMINISTERED DOSE AND 

























800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
800ml Placebo evening before + 
400ml Placebo 2 hours before 
anaesthesia 
145 (110 – 200) 
/ 145 (90 – 245) 
162 (100 – 260) / 




56 (25 – 130) / 








800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
Standard Fasting / 800ml Placebo 
evening before + 400ml Placebo 2 
hours before anaesthesia 
















800ml CHO evening before + 400ml 
CHO 2 hours before anaesthesia / 
800ml Placebo evening before + 












400ml CHO 4 hours before 
anaesthesia / 400ml Placebo 4 






Unknown Combination No 
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LOW UNCLEAR UNCLEAR UNCLEAR UNCLEAR UNCLEAR UNCLEAR UNCLEAR LOW 
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HIGH 
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Unclear Blinded Blinded Yes  Unclear  Yes   Yes  Yes; Unclear Unclear Unclear 
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Appendix 6.15: Measured outcomes per trial 
Study 
















































































































































































n 915 620 270 45 142 406 140 885 1891 932 862 1139 574 902 1081 288 589 573 584 
A3 * *                  
A6                    
A14                    
A15                    
A16                    
A19                    
A52                    
A64                    
A66                    
A68                    
A71                    
A74                    
A75                    
A84                    
A90                    
A94                    
A101                    
A105                    
A106                    
A110 * *                  
A115                    
A121                    
A125 * *                  
A131                    
*glucose and insulin as indicated during a hyperinsulinaemic euglycaemic state when measuring insulin resistance with the hyperinsulinaemic-euglycaemic clamp method 
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Appendix 6.16: Results versus discussion representation 
 
The results of the primary outcomes will be presented per comparison in Chapter 3 but will be 
discussed per time interval in Chapter 4.  
 
Primary Outcomes: Results (Chapter 3) versus Discussion (Chapter 4) [e.g. glucose] 
Chapter 3: Results Chapter 4: Discussion 
Comparison 1: Oral CHO versus Inactive Control 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 2: Oral CHO versus Fasting 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 3: Oral CHO versus Placebo 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Comparison 4: Oral CHO versus Active Control 
 Baseline 
 Before anaesthesia 
 Day 0 post-surgery 
 Day 1 post-surgery 
Baseline 
 Oral CHO versus Inactive Control 
 Oral CHO versus Fasting 
 Oral CHO versus Placebo 
 Oral CHO versus Active Control 
Before Anaesthesia 
 Oral CHO versus Inactive Control 
 Oral CHO versus Fasting 
 Oral CHO versus Placebo 
 Oral CHO versus Active Control 
Day 0 Post-Surgery 
 Oral CHO versus Inactive Control 
 Oral CHO versus Fasting 
 Oral CHO versus Placebo 
 Oral CHO versus Active Control 
Day 1 Post-Surgery 
 Oral CHO versus Inactive Control 
 Oral CHO versus Fasting 
 Oral CHO versus Placebo 















Appendix 6.17: Median (interquartile range) for some characteristics 
Outcome Trial 
Median (Interquartile Range) 
Oral CHO Fasting Placebo IV CHO 
Glucose at Baseline (mmol/l) 





5.2 (4.9;5.5) 5.0 (4.7;5.2)   
Glucose at Day 0 post-op (mmol/l) 







6.1 (5.4;6.9) 6.6 (6.0;8.1)   
Glucose at Day 1 post-op (mmol/l) Kaska 2010 6.4 (5.4-7.5) 6.65 (5.63-7.8) 
 
6.5 (5.7-7.7) 
Insulin at Baseline (mU/l) 






 10 (6;12) 9 (4;19)   




Insulin at Day 0 post-op (mU/l) Tran 2009
3
 7 (6;9) 6 (4;10)   




Insulin Resistance at Baseline (HOMA-IR) Tran 2009
3 2.2 (1.5;2.9) 1.7 (1.2;2.0)   
Insulin Resistance at Day 0 post-op (HOMA-IR) Tran 2009
3 2.5 (1.1;5.9) 1.8 (1.2;3.1)   
C-Reactive Protein at Baseline (mg/dl) 
Kaska 2010 4 (2-11.5) 5 (2.23-12.3) 
 
2.4 (1.15-8.5) 




C-Reactive Protein before Anaesthesia (mg/dl) 
Kaska 2010 4.5 (2-16) 6 (3.25-19.7) 
 
2 (1.53-8) 








C-Reactive Protein at Day 3 post-op (mg/dl) 
Kaska 2010 101 (74.8-150) 125 (76.8-147) 
 
108 (82-157) 
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Median (Interquartile Range) 
Oral CHO Fasting Placebo IV CHO 
C-Reactive Protein at Day 7 post-op (mg/dl) 
Kaska 2010 21.5 (14.5-59) 24 (12.5-41.5) 
 
29 (16-55) 




Return of Stool (days)
2
 Noblett 2006 2 3 3 
 
Return of Bowel movement (days)
2
 Noblett 2006 2 3.5 5 
 
Length of Hospital Stay (days) 















 4.0 (4.0;5.0) 5.0 (5.0;8.0)
1
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Appendix 6.18: Glucose analyses per comparison 
 
COMPARISON 1: ORAL CHO VERSUS INACTIVE CONTROL (FASTING + PLACEBO) 
Analysis 1.1: Glucose (HOMA-IR + QUICKI) at Baseline 
 
 
Analysis 1.2: Glucose (HOMA-IR + QUICKI) before Anaesthesia 
 
  
Analysis 1.3: Glucose (HOMA-IR + QUICKI) at Day 0 Postoperative 
 
 
Analysis 1.4: Glucose (HOMA-IR + QUICKI) at Day 1 Postoperative 
 




COMPARISON 2: ORAL CHO VERSUS FASTING 
 
Analysis 2.1: Glucose (HOMA-IR + QUICKI) at Baseline 
 
 
Analysis 2.2: Glucose (HOMA-IR + QUICKI) before Anaesthesia 
 
 













COMPARISON 3: ORAL CHO VERSUS PLACEBO 
Analysis 3.1: Glucose (HOMA-IR + QUICKI) at Baseline 
 
Analysis 3.2: Glucose (HOMA-IR + QUICKI) before Anaesthesia 
 
Analysis 3.3: Glucose (HOMA-IR + QUICKI) at Day 1 Postoperative 
 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 
Analysis 4.1: Glucose (HOMA-IR + QUICKI) at Baseline 
 
Analysis 4.2: Glucose (HOMA-IR + QUICKI) before Anaesthesia 
 




Appendix 6.19: Insulin analyses per comparison 
 
COMPARISON 1: ORAL CHO VERSUS INACTIVE CONTROL (FASTING + PLACEBO) 
Analysis 1.1: Insulin (HOMA-IR + QUICKI) at Baseline 
 
Analysis 1.2: Insulin (HOMA-IR + QUICKI) before Anaesthesia 
 
Analysis 1.3: Insulin (HOMA-IR + QUICKI) at Day 1 Postoperative 
 
 
COMPARISON 2: ORAL CHO VERSUS FASTING 
Analysis 2.1: Insulin (HOMA-IR + QUICKI) at Baseline 
 




Analysis 2.2: Insulin (HOMA-IR + QUICKI) before Anaesthesia
 
 
COMPARISON 3: ORAL CHO VERSUS PLACEBO 
Analysis 3.1: Insulin (HOMA-IR + QUICKI) at Baseline 
 
Analysis 3.2: Insulin (HOMA-IR + QUICKI) at Day 1 Postoperative 
 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 
Analysis 4.1: Insulin (HOMA-IR + QUICKI) at Baseline 
 
Analysis 4.2: Insulin (HOMA-IR + QUICKI) before Anaesthesia 
 




Appendix 6.20: Insulin resistance analyses per comparison 
 
COMPARISON 1: ORAL CHO VERSUS INACTIVE CONTROL (FASTING + PLACEBO) 
Analysis 1.1: Insulin Resistance (HOMA-IR) at Baseline 
 
Analysis 1.2: Insulin Resistance (HOMA-IR) before Anaesthesia 
 
Analysis 1.3: Insulin Resistance (HOMA-IR) at Day 1 Postoperative 
 
 
COMPARISON 2: ORAL CHO VERSUS FASTING 
No analyses for this comparison. 
 
COMPARISON 3: ORAL CHO VERSUS PLACEBO 
Analysis 3.1: Insulin Resistance (HOMA-IR) at Baseline 
 




Analysis 3.2: Insulin Resistance (HOMA-IR) before Anaesthesia 
 
Analysis 3.3: Insulin Resistance (HOMA-IR) at Day 1 Postoperative 
 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 



















Appendix 6.21: Total body protein analyses per comparison 
 
COMPARISON 1: ORAL CHO VERSUS INACTIVE CONTROL (FASTING + PLACEBO) 
Analysis 1.1: Total Body Protein at Baseline 
 
Analysis 1.2: Total Body Protein at Day 3 Postoperative 
 
Analysis 1.3: Total Body Protein at Day 7 Postoperative 
 
Analysis 1.4: Total Body Protein at Day 28 Postoperative 
 
 
COMPARISON 2: ORAL CHO VERSUS FASTING 









COMPARISON 3: ORAL CHO VERSUS PLACEBO 
Analysis 3.1: Total Body Protein at Baseline 
 
Analysis 3.2: Total Body Protein at Day 3 Postoperative 
 
Analysis 3.3: Total Body Protein at Day 7 Postoperative 
 




COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 
No analyses for this comparison. 
 
 





Appendix 6.22: Muscle strength analyses per comparison 
 
COMPARISON 1: ORAL CHO VERSUS INACTIVE CONTROL (FASTING + PLACEBO) 
Analysis 1.1: Muscle Strength at Day 1 
 
Analysis 1.2: Muscle Strength at Day 3 
 
Analysis 1.3: Muscle Strength at Day 7 
 




COMPARISON 2: ORAL CHO VERSUS FASTING 
No analyses for this comparison. 
 
 





COMPARISON 3: ORAL CHO VERSUS PLACEBO 
Analysis 3.1: Muscle Strength at Day 1 
 
Analysis 3.2: Muscle Strength at Day 3 
 
Analysis 3.3: Muscle Strength at Day 7 
 





COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 
No analyses for this comparison. 
 




Appendix 6.23: CRP analyses per comparison 
 
COMPARISON 1: ORAL CHO VERSUS INACTIVE CONTROL (FASTING + PLACEBO) 
Analysis 1.1: CRP at Baseline 
No analysis for this time interval. 
Analysis 1.2: CRP before Anaesthesia 
No analysis for this time interval. 
Analysis 1.3: CRP at Day 1 
 
Analysis 1.4: CRP at Day 3 
No analysis for this time interval. 
Analysis 1.5: CRP at Day 7 
No analysis for this time interval. 
COMPARISON 2: ORAL CHO VERSUS FASTING 
Analysis 2.1: CRP at Baseline 
No analysis for this time interval. 
Analysis 2.2: CRP before Anaesthesia 
No analysis for this time interval. 
Analysis 2.3: CRP at Day 1 
 




Analysis 2.4: CRP at Day 3 
No analysis for this time interval. 
Analysis 2.5: CRP at Day 7 
No analysis for this time interval. 
 
 
COMPARISON 3: ORAL CHO VERSUS PLACEBO 
No analyses for this comparison. 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 



















Appendix 6.24: Stool/flatus analysis per comparison 
 








COMPARISON 3: ORAL CHO VERSUS PLACEBO 
No analyses for this comparison. 
 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 











Appendix 6.25: Bowel movement analyses per comparison 
 








COMPARISON 3: ORAL CHO VERSUS PLACEBO 
No analyses for this comparison. 
 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 











Appendix 6.26: Length of ICU stay analyses per comparison 
 








COMPARISON 3: ORAL CHO VERSUS PLACEBO 
No analyses for this comparison. 
 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 













Appendix 6.27: Length of hospital stay analyses per comparison 
 








COMPARISON 3: ORAL CHO VERSUS PLACEBO 
 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 









Appendix 6.28: Fit for discharge analyses per comparison 
 
COMPARISON 1: ORAL CHO VERSUS INACTIVE CONTROL (FASTING + PLACEBO) 
No analyses for this comparison. 
 
COMPARISON 2: ORAL CHO VERSUS FASTING 
No analyses for this comparison. 
 
COMPARISON 3: ORAL CHO VERSUS PLACEBO 
No analyses for this comparison. 
 
COMPARISON 4: ORAL CHO VERSUS ACTIVE CONTROL (IV CHO) 

















Appendix 6.29: Results of trials assessing thirst 
 
INTRAGROUP COMPARISON INTERGROUP COMPARISON 












1 – 2 hours 
before 
surgery 
CHO group less thirsty < 0.05 A6 
Baseline (i.e. 
day before 
surgery) to 1 
– 2 hours 
before 
surgery 
CHO group less thirsty than fasting 
group 
< 0.05 
Fasting group more thirsty  > 0.05 A16 




CHO group no change in thirst 0.921 A52 
CHO group less thirsty than fasting 
group 
< 0.05 
Fasting group more thirsty 0.001 
A64 
Difference in thirst between oral CHO, 
fasting and placebo group 
0.005 
Placebo more thirsty 0.015 
No difference in thirst between CHO 
and placebo groups 
0.970 
A71 
CHO group less thirsty < 0.05 A74 
CHO group less thirsty than fasting 
group 
0.01 
Fasting group more thirsty < 0.05 A94 
CHO group less thirsty than other 
groups 
? 
IV group more thirsty < 0.05 A121 




CHO group less thirsty ? 
  
Fasting group more thirsty < 0.001 
Placebo no consistent trend ? 
A131 
CHO group less thirsty for 60 minutes < 0.01 










 None of the trials assessed this comparison. 
A15 Day 2  









No difference between CHO and 












No difference in thirst between CHO 
and placebo groups 
> 0.05 
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Appendix 6.30: Results of trials assessing hunger 
 
INTERGROUP COMPARISON INTRAGROUP COMPARISON 












1 – 2 hours 
before 
surgery 
CHO group less hungry < 0.05 A6 
Baseline (i.e. 
day before 
surgery) to 1 
– 2 hours 
before 
surgery 
CHO group less hungry than fasting 
group 
< 0.05 
Fasting group more hungry  > 0.05 A16 




CHO group no change in hunger 0.147 A52 
CHO group less hungry than fasting 
group 
< 0.05 
Fasting group more hungry 0.006 
A64 
Difference in hunger between oral 
CHO, fasting and placebo group 
0.041 
Placebo no change in hunger 0.291 
No difference in hunger between CHO 
and placebo groups 
0.146 
A71 
CHO group less hungry < 0.05 A74 
CHO group less hungry than fasting 
group 
0.04 
Fasting group more hungry < 0.05 A94 
CHO group less hungry than other 
groups 
? 
IV group no change in hunger > 0.05 A121 




CHO group less hungry ? 
  
Fasting group more hungry < 0.05 
Placebo no consistent trend ? 
A131 
CHO group no change in hunger 0.10 










  A16 
2 hours 




No difference in hunger between CHO 












No difference in hunger between CHO 
and placebo groups 
> 0.05 
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INTERGROUP COMPARISON INTRAGROUP COMPARISON 











surgery) to 1 
– 2 hours 
before 
surgery 
CHO group no change in nausea 0.139 A52 
Baseline (i.e. 
day before 
surgery) to 1 
– 2 hours 
before 
surgery 
No difference in nausea between 
CHO and fasting groups 
> 0.05 
Fasting group no change in nausea  0.116 A64 
No difference in nausea between 
CHO fasting and placebo groups 
> 0.05 
Placebo group no change in nausea 0.135 A94 




CHO group no change in nausea > 0.05 
  Fasting group no change in nausea > 0.05 








 None of the trials assessed this comparison 
A14 Day 1 
CHO group less nauseous than 
fasting group 
< 0.001 
A15 Day 2 
CHO group less nauseous than 
fasting group 
> 0.05 
A115 Day 1 
No difference between CHO and 
















No difference in nausea between 
CHO and fasting groups 
> 0.05 
Placebo group more nauseous < 0.001 A66 
No difference in nausea between 
CHO and placebo groups 
> 0.05 
  A105 
No difference in nausea between 
CHO, fasting and placebo groups 
> 0.05 
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IN GROUP COMPARISON BETWEEN GROUP COMPARISON 



















CHO less nausea < 0.001 A15 
Number of 
episodes 
CHO group less nauseous  than 
fasting group 
> 0.05 
Fasting no difference 0.067 A75 
Number of 
patients 
Fewer patients nauseous in CHO 
group than in fasting group (on day 2 
to 4) 
< 0.05 
Placebo less nausea 0.006 A90 
Number of 
patients 
More patients nauseous in CHO group 






No difference between CHO, fasting 





No difference between CHO and 
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INTRAGROUP COMPARISON INTERGROUP COMPARISON 
















None of the trials assessed this comparison 
A14 Day 1 
CHO group less vomiting than fasting 
group 
< 0.001 
A15 Day 2 
CHO group less vomiting than fasting 
group 
> 0.05 
A115 Day 1 
No difference between CHO and 








None of the trials assessed this comparison None of the trials assessed this comparison 
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IN GROUP COMPARISON BETWEEN GROUP COMPARISON 



















CHO less vomiting < 0.001 A15 
Number of 
episodes 
CHO group less vomiting  than fasting 
group 
> 0.05 
Fasting no difference 0.067 A75 
Number of 
patients 
Less patients vomiting in CHO group 
than in fasting group (on day 2) 
< 0.05 
Placebo less vomiting 0.006 A90 
Number of 
patients 
No difference between CHO and 






No difference between CHO, fasting 





No difference between CHO and 
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Appendix 6.33: Results of trials assessing anxiety 
 
INTRAGROUP COMPARISON INTERGROUP COMPARISON 












1 – 2 hours 
before 
surgery 
CHO group decrease in anxiety < 0.05 A14 
Baseline (i.e. 
day before 
surgery) to 1 
– 2 hours 
before 
surgery 




CHO group no change in anxiety 0.080 A16 
No difference between CHO and 
fasting groups 
> 0.05 
Fasting group no change in anxiety 0.278 A52 
CHO group less anxious than fasting 
group 
< 0.05 
Placebo group no change in anxiety 0.712 
A64 
Difference in thirst between oral CHO, 
fasting and placebo groups 
0.104 
A71 
CHO group no change in anxiety > 0.05 
No difference in anxiety between CHO 
and placebo groups 
0.940 
Fasting group increase in anxiety < 0.05 A74 
CHO group less anxious than fasting 
group 
0.01 
IV group increase in anxiety < 0.05 A94 




Fasting group no change in anxiety > 0.05 A121 
CHO group less anxious than fasting 
group 
< 0.001 
Placebo group no change in anxiety > 0.05 
  
A131 
CHO group no change in anxiety for 
90minutes 
0.11 






















No difference in anxiety between CHO 
and fasting groups 
> 0.05 
A66 
No difference in anxiety between CHO 
and placebo groups 
> 0.05 
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Appendix 6.34: Results of trials assessing pain 
 
INTRAGROUP COMPARISON INTERGROUP COMPARISON 












1 – 2 hours 
before 
surgery 
CHO group no change in pain > 0.05 A52 
Baseline (i.e. 
day before 
surgery) to 1 
– 2 hours 
before 
surgery 
No difference in pain between CHO 
and fasting groups 
> 0.05 
Fasting group no change in pain  > 0.05 A71 
No difference in pain between CHO, 
fasting and IV groups 
> 0.05 








 None of the trials assessed this comparison. 
A15 Day 2  
CHO group less pain than fasting 
group 
> 0.05 
A75 Day 0 - 5 














No difference in pain between CHO 
and placebo groups 
> 0.05 
A105 
No difference in pain between CHO, 
fasting and placebo groups 
> 0.05 
A115 
No difference in pain between CHO 
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Appendix 6.35: Results of trials assessing fatique 
 
INTRAGROUP COMPARISON INTERGROUP COMPARISON 







 None of the trials assessed this comparison A16 
Baseline (i.e. 
day before 
surgery) to 1 – 
2 hours before 
surgery 










 None of the trials assessed this comparison. A16 Day 1 
No difference in fatigue between CHO 
















No difference in fatigue between CHO 
and placebo groups 
> 0.05 
Placebo group increase in fatigue < 0.05 A115 
No difference in fatigue between CHO 
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Appendix 6.36: Results of trials assessing weakness 
 
INTRAGROUP COMPARISON INTERGROUP COMPARISON 










surgery) to 1 
– 2 hours 
before 
surgery 
CHO group no change in weakness 0.198 A16 
Baseline (i.e. 
day before 
surgery) to 1 – 
2 hours before 
surgery 
CHO group less weak than fasting 
group 
< 0.05 




No difference in weakness between 
CHO, fasting and placebo groups 
0.832 
Placebo group no change in 
weakness 
0.868 
No difference in weakness between 
CHO and placebo groups 
0.584 
A71 
CHO group no change in weakness > 0.05 A94 
CHO group less weak than other 
groups 
? 
Fasting group increase in weakness < 0.05 
  
IV group no change in weakness > 0.05 
A121 
CHO group no change in weakness > 0.05 
Fasting group increase in weakness < 0.05 

















 None of the trials assessed this comparison  None of the trials assessed this comparison. 
 
Stellenbosch University  https://scholar.sun.ac.za




Appendix 6.37: Results of trials assessing tiredness 
 
INTRAGROUP COMPARISON INTERGROUP COMPARISON 










surgery) to 1 
– 2 hours 
before 
surgery 
CHO group no change in tiredness 0.150 A52 
Baseline (i.e. 
day before 
surgery) to 1 – 
2 hours before 
surgery 
No difference in tiredness between 
CHO and fasting groups 
> 0.05 




No difference in tiredness between 
CHO, fasting and placebo groups 
0.615 
Placebo group no change in 
tiredness 
0.223 
No difference in tiredness between 
CHO and placebo groups 
0.509 
A71 
CHO group no change in tiredness > 0.05 A94 
CHO group less tired than other 
groups 
? 
Fasting group increase in tiredness < 0.05 
  
IV group no change in tiredness > 0.05 
A121 
CHO group no change in tiredness > 0.05 
Fasting group increase in tiredness < 0.0001 















 None of the trials assessed this comparison.  None of the trials assessed this comparison. 
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Appendix 6.38: Results of trials assessing malaise 
 
INTRAGROUP COMPARISON INTERGROUP COMPARISON 







A52 Baseline (i.e. 
day before 
surgery) to 1 
– 2 hours 
before 
surgery 
CHO decrease in malaise < 0.05 A16 
Baseline (i.e. 
day before 
surgery) to 1 – 
2 hours before 
surgery 
No difference in malaise between CHO 
and fasting groups 
> 0.05 
A121 
Fasting group no change in malaise > 0.05 A52 
CHO group experienced less malaise 
than fasting group  
< 0,.05 
Placebo group decrease in malaise < 0.01 A66 
No difference in malaise between CHO 
and placebo groups 
> 0.05 
  A121 
CHO group experienced less malaise 









 None of the trials assessed this comparison. A16 Day 1 
CHO group experienced less malaise 
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